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Summary 
The low selectivity of chemotherapy is an ongoing problem in the treatment 
of cancer. Prodrugs that are activated in vivo provide a therapeutic advantage for 
selective cytotoxicity. Here we have designed redox-active compounds that are 
electrochemically reduced in hypoxic (poorly oxygenated) tissue, resulting in release 
of a nitrogen mustard cytotoxin. This thesis describes the synthesis of novel 
macrocyclic N-mustard drugs and the development of their Cu(II) complexes as 
hypoxia-selective prodrugs. 
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The (2-trimethylsilyl)ethanesulfonyl (SES) protecting group is very versatile. 
It is removed under mild conditions using fluoride. The published synthesis of the 
sulfonyl chloride A gave variable yield and purity, but we have improved the 
conditions to give consistently pure material in high yield (70-86% overall) (Scheme 
1). 
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Triamines with carbon bridges longer than three are difficult to prepare, often 
requiring multistep ~yntheses. A route was developed to synthesize linear triamines, 
using the SES-amide B. This route produces these triamines in relatively high yields 
(60-80% overall), via simple reactions with little purification necessary (Scheme 2). 
A variation on the Richman-Atkins synthesis has been exploited to reach 
known and. novel triaz~acrocyclic compounds D (Scheme 3), in order to explore 
their structure-activity relationship as N-mustard drugs E (made as shown in Scheme 
4). Eight novel macrocyclic N-mustards E were found to be potent DNA cross-
linking agents (nM range) by Prof. John Hartley at University College London. 
Three of the novel triazamacrocycles' b were assessed in vitro for anti-parasitic 
activity by Dr. Michael Barrett at the University of Glasgow. They showed 
moderate activity against Leishmania mexicana and Trypanosoma brucei. 
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Scheme 4 
Water soluble Cu(II) complexes of cytotoxic macrocyclic nitrogen mustards 
have been prepared and their structures have been determined using X-ray 
crystallography by Dr. Louis Farrugia in this department. The redox behaviour and 
reduction potentials (Cu[II] to Cu[lD of the complexes in phosphate buffer were 
assessed using cyclic voltammetry. The thermodynamic stabilities of the Cu(II) 
complexes in aqueous solution were analysed qualitatively using UV-Vis 
spectroscopy: The mustard complexes F and G showed irreversible redox behaviour 
and low thermodynamic stability, and were not hypoxia-selective but behaved as 
typical mustard drugs. The cyclen-based mustard complex H showed reversible 
redox behaviour and had high thermodynamic stability under aqueous conditions. H 
exhibited excellent hypoxia selectivity (the best so far in the lung tumour cell line 
tested) and is an attractive lead compound for further development or" this novel 
approach to cancer chemotherapy. 
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Chapter 1 
1. Introduction 
1.1. Cancer 
Cancer is the second most frequent cause of death in the western world. One 
in three people contract cancer at some point in their lives. Roughly two-thirds of 
those people die as a result of their cancer, bringing the total death toll by cancer to 
one in four people. 1 For decades we have been searching for 'the cure;' but it became 
apparent long ago that things were not going to be that simple. 
A wealth of data exists describing the biological and environmental origins 
and characteristics of cancer. The post-genomic era provides a new environment in 
which to seek out and understand the genetic basis for tumour development. As we 
r 
come to grips with the biological mechanisms inherent in cancer development, new 
strategies in the fight against it emerge. Better aims in tissue targeting, fewer side 
effects and improved length and quality of life for cancer sufferers bring us closer to 
the holy grail of complete treatment and control. However, like a mathematical 
asymptote, we will probably never reach that ultimate goal; cellular evolution will 
always be one step ahead of us. 
.. 
1.1.1. Biology of cancer development 
The biological irregularities that eventually lead to cancer are extremely 
complex. Many steps are involved, beginning with genetic changes and culminating 
in regulatory defects that allow the uncontrolled proliferation of cells. . The/ process 
has been compared to Darwinian evolution: genetic mutations allowing a better 
chance for survival and thus being carried on to further generations? Advanced 
tumours are almost perfect examples of 'the surVival of the fittest.' Cancer cells have 
forgotten they are an integral part of an .organism. With an adequate supply of 
nutrients, they can continue to grow and reproduce virtually indefinitely, even being 
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termed 'immortal.' One of the first samples of human tumour cells, the Hela cell line 
isolated in 1951, is still alive and growing today. 
Cells have built-in obstacles that must be overcome in order for them to 
become cancerous. Hanahan and Weinberg3 describe the six major traits that must be 
acquired to begin tumour development: self-sufficiency in growth signals; 
insensitivity to growth-inhibitory signals; evasion of apoptosis (programmed cell 
death); limitless replicative potential; sustained angiogenesis (blood vessel growth); 
and tissue invasion and metastasis (aggressive spread of cancer via release and 
migration of tumour tissue to other tissues). 
Cell growth is regulated by countless pathways within the cell, but also 
importantly by the cell's external environment. For example, cells in normal tissue 
are mostly instructed to replicate or cease replication by contact with their 
neighbours.3 Some tumours are able to co-opt their neighbouring normal cells into 
abnormal growth.4 Ignoring growth-inhibitory signals also involves a combination of 
inter- and intra-cellular factors. Normally the tissue environment tells its cells to stop 
mUltiplying. The commands are carried out via signalling pathways within the cell. 
Unrestricted growth requires circumvention of those pathways. Essentially, 
cancerous cells stop responding to the messages telling them not to replicate. 
Evasion of apoptosis is a hallmark of almost every type of cancer. Tumour 
cell populations explode because far more cells are being produced than destroyed. 
Apoptosis . usually occurs in old and abnormal C'ells via a cascade of proteases called 
caspases.5 Caspases cause cell death by taking apart the genome and various 
organelles and sub-c~llular struc,tures. Cancer cells acquire resistance to apoptosis 
through genetic mutations, losing genes for key apoptosis-inducing responses. 
Limitless replicative potential goes beyond the combined abilities to ignore 
cell-growth messaging and to avoid self-degradation. Normal cells have built-in 
restrictions ~n their replic'ative potential: Each.cell cycle results in the shortening of 
telomeres (protective sequences of DNA at the ends of the chromosomes). Eventually 
the' telomeres have been shortened to a ·critical length, causing disadvantageous 
chromosomal fusion, disarray and widespread cell death (the 'crisis' state). However, 
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those cells that have adapted to maintain the length of their telomeres survive past the 
crisis state and become 'immortalised' ,6 replicating indefinitely. 
Another requirement for cancer development is the ability to sustain 
continuous angiogenesis to supply the tumour tissue with blood. Regulation of 
angiogenesis is carried out through an array of homeostatic pathways. Vascular 
endothelial growth factor (VGEF) is closely involved in the stimulation of 
angiogenesis. These relationships have been demonstrated using anti-VGEF 
antibodies to impair the growth of implanted tumours in mice.7 Integrins (cell-surface 
proteins that participate in cellular adhesion and intercellular communication) are also 
essential to the process of angiogenesis and interfering with their signalling pathways 
can have an inhibitory effect. Many proteases are also involved in controlling the 
levels of various activating and inhibiting factors in the angiogenic response. 
Lastly, 90% of lethal cancers develop the ability to invade and colonise other 
tissues.s This activity, called metastasis, is the culmination of the tumour's progress 
towards 'survival of the fittest.' Its enhanced speed of growth and facility to use 
nutrients gives it an advantage over the normal tissues it invades. In order to begin 
metastasis, tumour cells must be able to release themselves from their extracellular 
matrix and eventually create entrances into new tissue. These processes involve the 
impairment of integrins and other cell-adhesion proteins, as well as stimulation of 
extracellular proteases to degrade the matrix. Without metastasis, the tumour would 
eventually use all the nutrients in its immediate area and its growth would be halted. 
With this process, it can keep its progeny cells alive by sending them to distant 
territories with plentiful resources; that is, until the cancer completely overwhelms the 
organism it has invaded and destroys its own environment. 
Since all of the above processes are highly complex and no one instigator for 
any of them can be identified, it is important to maintain a holistic mindset when 
developing ~ancer treat~ent.3 The disciplines of biochemistry, immunology, 
genetics, molecular biology, pharmacology and synthetic chemistry all need to be 
considered in a comprehensive cancer treatment strategy. This thesis discusses our 
.. . 
synthetic chemistry approach to drug design in the struggle against cancer. 
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1.1.2. Cancer therapy 
Classical cancer therapy takes on a number of forms. Sometimes various 
therapies are applied concurrently. When the cancer takes the form of a solid tumour, 
physical removal of the tumour is common. However, when tumours are difficult to 
access surgically or have already begun to metastasise, chemical or radiotherapies are 
employed. Radiotherapy takes advantage of the damaging hydroxyl radicals 
produced following the exposure of water to ionising radiation (Scheme 1.1.2.1). 
Unfortunately the damage is difficult to localise, resulting in damage to healthy 
tissues and highly unpleasant side effects. Occasionally radiotherapy induces 
secondary cancers, especially in children. Chemotherapy uses toxic chemicals to kill 
the tumour cells, often focusing on rapidly proliferating cells by targeting the cell 
cycle.9 Recent chemotherapy advances have exploited the cytotoxic effects of a 
number of natural products, e.g. daunorubicin1o and taxol. ll Other strategies employ 
toxic analogues of cellular components, such as 5-fluorouracil.12, 13 Again, toxicity is 
often unselective, resulting in side effects especially to fast-growing cells like hair 
,., 
follicles and bone marrow. 
Scheme 1.1.2.1 
H20 + ionising energy 
----... ~ + H+. 
! 
DNA damage 
Cellular hypoxia (lowered intracellular oxygen concentration) is common in 
solid tumours.14-16 The rapid proliferation of cancer cells and the resulting 
insufficient growth of supporting vasculature creates an environment in which the 
cells adapt to survive under anaerobic conditio.ns. This often results in resistance to 
normal chemo- and radio-therapy. However, it advantageously provides a key 
difference between cancer cells and normal cells, offering opportunities for more 
directed targeting of tumour. cells, as well as allowing for therapeutic differentiation 
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between types of cancers via the specific enzyme profiles of the various cell typeS.17 
The targeting of hypoxic cells with bioreducible alkylating agents, through the 
exploitation of tumour hypoxia, is the principal aim of this project. Therefore, the 
discussion of cancer therapies herein will focus on the use of these drugs. 
1.2. Bioreductive drugs 
1.2.1. Hypoxia 
Tumour hypoxia is highly heterogeneous; changing with tumour size, stage of 
development, extent of necrosis and histological environment.18. 19 Almost all solid 
murine tumours (commonly used for in vivo drug studies) contain large proportions of 
hypoxic cells. 20 There is also a large body of experimental evidence for the existence 
of hypoxia in human tumour cells.14-16 Hypoxic environments have been found in 
cervical cancer, squamous cell carcinoma of the head and neck, melanoma, breast 
cancer, prostate cancer and brain tumours. Lactate levels give an indication of the 
degree of anaerobic metabolism present and thus the degree of oxygenation of tissue, 
but are less quantitative for determination of hypoxia.21-24 Oxygen levels can be 
detected quantitatively by electrode methods, although electrodes are unable to 
distinguish between cell viabilities and cell types.23.2S Chemical marker methods are 
more reliable, such as radiolabelled or fluorescently labelled nitroimidazoles, which 
bind to ~ypoxic cells in vitro and in vivo.26-28 In addition, bis(thiosemicarbazone) 
ligands (e.g. 1) act as vectors for bioreducible C~u(II) isotopes which are deposited in 
hypoxic cells upon reduction to Cu(l).29 
Tumour hypoxia has been linked tQ the unsuccessful outcome of therapeutic 
treatments, especially radiotherapy. The dose of radiation required to kill hypoxic 
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cells is three times that necessary to kill well-oxygenated cells; therefore at safe levels 
of radiation for treatment, most hypoxic cells survive. Chemotherapy is often 
inhibited in hypoxic cells due to the requirement for molecular oxygen in the toxicity 
of many anti-cancer agents (e.g. bleomycin). In addition, cell proliferation is greatly 
reduced as a result of lowered oxygen concentration, so agents that specifically target 
the mechanism of fast proliferation are less toxic in hypoxic cells. Lastly, since 
hypoxia often occurs as a result of insufficient vasculature and oxygen delivery, drug 
delivery through these same channels is also affected and can result in lower effective 
doses to the hypoxic regions.30 
Aside from contributing to treatment resistance, hypoxia also contributes to 
adverse malignant effects within the tumour microenvironment by promoting 
metastasis and angiogenesis. Metastasis is promoted through the increased expression 
of matrix metalloproteinases (MMPs) under hypoxic conditions.31. 32 MMPs are 
essential to the metastasis process.33. 34 They degrade the basement membrane and 
extracellular matrix to facilitate the release of migrating tumour cells. There is some 
evidence that hypoxia contributes to cell adhesion processes required for metastasis, 
by reducing the levels of cell surface integrins and allowing the migration of cells 
from their originallocation?5. 36 Hypoxia also increases the levels of interleukin-8, an 
inflammatory factor associated with tumourigenicity, angiogenesis and metastasis in 
many types of tumours. The same processes (MMP production, cell adhesion 
changes) are important in the beginning of angiogenesis. Angiogenesis begins when 
the cells 'respond to the initiation of production of VEGF and its receptors (mediated 
by hypoxia inducible factor [HIP-I] which is des~ribed later).3o 
Clinically, hypoxia in known to affect adversely the average success of 
treatment for a population, specifically resulting in lower levels of two-year local 
control of the cancer, disease-free survival and survival.3o.37 Because hypoxia opens 
up numerous avenues for the promotion of tumour malignancy, there is a need to 
target hypoxJa both as ~ cellular process and as an opportunity to differentiate 
between normal healthy cells and cancer cells?o. 
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1.2.2. Exploiting tumour hypoxia 
Gene therapy approach38 
The adaptation of cells to hypoxic conditions is dependent upon the induction 
of key genes that regulate for glucose transporters, glycolytic enzymes, production of 
red blood cells and stimulation of angiogenesis. The products of these genes all 
participate in the viability of anaerobic metabolism either directly (glycolysis 
participants) or indirectly (by increasing oxygen delivery). Hypoxia inducible factor-
I (HIF-I) is the primary activator protein for transcription in one of the key genes 
involved in the hypoxic response.39-41 The protein is a heterodimer comprised of a 
novel subunit, HIF-Ia, and a previously identified subunit, HIF-I~, identical to a 
protein involved in the xenobiotic response.42 Under oxic conditions, the proline-564 
residue in HIF-Ia is normally hydroxylated by a prolyl hydroxylase enzyme with an 
absolute requirement for oxygen and iron, enabling its binding to the product of the 
Von Hippel Lindau (VHL) tumour suppressor gene which targets the HIF-I protein 
r 
for proteolysis.43 Thus, in the presence of normal oxygen levels, induction of the 
hypoxia response genes is inhibited via the breakdown of their activator, HIF-I. If 
oxygen levels are lowered, the prolyl hydroxylase protein is unable to perform its 
crucial proline-564 hydroxylation; HIF-I will no longer bind to the VHL protein; and 
HIP-I is able to accumulate in sufficient quantities to activate the hypoxic response. 
Hlf-1 synthesis 
prolyl 
hydroxylase I O2 
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IDF-l is a target for cancer therapies in its own right. Without activation of 
the hypoxic response, cells without sufficient oxygen for aerobic metabolism cannot 
survive. Some strategies have been proposed such as blocking of IDF-la production 
through anti-sense and have met with moderate success.44,45 
Another way to exploit the IDF-l response involves placing a gene for a 
therapeutic protein under the transcriptional regulation of IDF-l. Following the 
hypoxia-specific production of IDF-l, the therapeutic enzyme will be expressed. The 
enzyme could be therapeutic in itself, or it could be used to activate a prodrug. In the 
case of the expressed enzyme being a prodrug activator, the process is called gene 
directed enzyme prodrug therapy (GDEPT).38, 46 Although promising, the classic 
problems of gene therapy arise in the development of suitable gene delivery vectors. 
A related but possibly less problematic approach involves the use of antibodies as 
therapeutic enzyme delivery systems (called antibody directed enzyme prodrug 
therapy [ADEPT]).17, 38, 47 In ADEPT, the therapeutic enzyme is attached to an 
antibody that can bind to a cell-surface protein expressed during hypoxia (e.g. 
,. 
angiogenic proteins such as flk_l).48 The prodrug would only be activated in the 
immediate vicinity of the targeted cell, with the aim of diffusion of the active drug 
into the desired location. 
Bioreductive drug approach 
Bioreductive drug activation operates on the principle that hypoxic cells 
provide an environment in which reductive electron transfer can· occur in one 
direction, without subsequent back oxidation by molecular oxygen. . The electron 
affinity of radiosensiti,sing drugs allows them to act as substitutes for the molecular 
oxygen required for the production of the hydroxyl radical (key to the toxicity of 
ionising radiation). Other hypoxia selective cytotoxins employ prodrug sqategies to 
mask their effects until reductase enzymes in the hypoxic tissue can activate them. 
The optimum_ redox poten~al for cellular reduction has been suggested to be between 
-200 and -400 mV vs. the normal hydrogen electrode (NHE),49 but many bioreductive 
drugs with different potentials still have useful clinical activity.50 
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Various problems appear in the bioreductive approach to prodrug design. 
Because of the heterogeneous nature of tumour hypoxia, important activation factors, 
such as pH, level of oxygen concentration, blood flow and enzyme levels, can differ 
even between neighbouring hypoxic cells within a tumour.47 Additionally, it can be 
very difficult to predict the efficiency of bioreductive activation in human cells, as 
they often exhibit much slower rates of bioreduction than rodent cells?8 Even when 
some human cell lines show appropriate levels of bioreduction, in vivo reduction 
behaviour for individual patients could be completely different due to the inherent 
genetic polymorphism in enzyme expression displayed between different people.51 
Even in the best-case scenario of hypoxia selective drug activation, the aerobic back-
oxidation may provide unwanted side effects through the production of superoxide 
radicals (Scheme 1.2.2.1).38 However, in life-threatening diseases such as cancer, 
some chances can be taken and the practical goal is to minimise side effects rather 
than completely eliminate them. 
Scheme 1.2.2.1 
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There are two possibilities for bioreductive drug delivery. systems: 
a) designing the prodrug as a release system, whi9h masks the activity <?f a drug that is 
released under the bioreductive conditions; or b) designing the prodrug as an inactive 
form of a drug, which can be converted directly into an active form. For either type 
of delivery system, Denny and Wilson propose a three-component design involving 
trigger (deactivating functionality) and effector (active drug) units joined by a linker 
(method for activation, either conceptual or chemical).s2 Their terminology will be 
used in this review. 
Release systems 
The release systems (termed 'self-inactivating' delivery systems by 
Naughtoni3 involve attaching the effector by a molecular linker to a separate trigger 
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molecule, which masks the drug's activity. This method often avoids some of the 
unwanted side effects of cytotoxicity in the intermediates of the bioreductive process. 
There are three main types of self-inactivating delivery systems: the quinone 
lactonisation system; the self-alkylating bioreductives; and vitamin E analogues. 
Quinone lactonisation systems contain a quinone moiety attached to a 
propionic acid linker, which is easy to attach to alcohol or amine functionality on the 
desired drug.53 Reduction of the quinone triggers lactonisation of the masked acid, 
resulting in release of the drug. Gem-dimethyl substitution on the propionic acid 
chain, along with a methyl substituent on the quinone ring (called a 'trimethyllock'), 
imparts a Thorpe-Ingold-type effect on the drug-linked ester or amide, encouraging 
lactonisation (Scheme 1.2.2.2).53 Generally, the lability of quinone delivery systems 
is not well controlled under biological conditions and they require further 
development in order to be clinically usefu1.53 
Scheme 1.2.2.2 
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Most bioreductive agents form alkylating intermediates which can react with 
DNA and other biological macI'9molecules, which is not advantageous in diseases 
where the hypoxic tissue is to be preserved (e.g. arthritic tissue) rather than destroyed 
(as for tumour tissue). The self-alkylating bioreductives are simil~ to the 
'deactivated drug' -type prodrugs, but are designed to undergo intramolecular 
alkylation up~m reduction~ to avoid the generation of cytotoxic intermediates. One 
such system uses the active drug as a leaving group, linking it to a nitroaniline that 
releases the drug upon reduction of the nitro group to a dianiline and cyclisation to a 
be~zopiperazine (Scheme 1.2.2.3).38 
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Vitamin E analogues exploit the propensity of vitamin E to undergo reductive 
cyclisation to a hydroquinone derivative. The hydroxyl group is ejected as a result of 
the cyclisation, offering the opportunity to attach and mask a drug moiety to oxidised 
vitamin E analogues (Scheme 1.2.2.4). Trolox®, in which a water-soluble vitamin E 
analogue has been oxidised and conjugated to aspirin, shows effective release of 
aspirin in chemical model systems.54 
Scheme 1.2.2.4 
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Direct sctlvstlon systems 
When limiting damage to the hypoxic tissue is not an issue, the delivery 
system can ignore or even exploit the formation of toxic intermediates upon 
bioreduction. For this type of targeting, the direct conversion of the molecule from 
trigger-deactivated prodrug into activated effector is usually employed. The linkers 
are usually conceptual, for example intramolecular electron release to change electron 
density within the molecule, or intramolecplar fragmentation to generate more than 
one cytotoxic product. The prodrugs can be activated by endogenous enzymes in the 
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tumour environment, by enzymes introduced or exploited using ADEPT or GDEPT, 
or by radiotherapy utilising the reducing species produced from water in the presence 
of ionising radiation and absence of oxygen. DNA affinic agents and alkylating 
agents (quinone methides, cyclopropyldienone precursors and nitrogen mustards) are 
the most commonly employed effectors.52 
Effectors 
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DNA affinic agents such as AQ4 (2) are excellent DNA intercalators, binding 
tightly to DNA and inhibiting topoisomerase II. Usually this type of compound has 
, 
little effect on non-cycling cells, as topoisomerase II activity is specific to the cell 
cycle. However, in the case of AQ4, although the binding capability is activated 
under hypoxic conditions, the effector binds tightly enough to be retained by the DNA 
for a long time, until the cells are reoxygenated and recommence their normal cycle 
and topoisomerase II resumes activity.55 
Cyclopropyldienone precursors deliver highly potent DNA alkylating agents 
upon bioreduction, with IC50 values in the pico~olar range.56. 57 They are based on 
the cyclopropylpyrroloindoles, e.g. CPI (cyclopropylpyrroloindoloquinol1e [3]), which 
react solely with the N-3 of adenine in the minor groove of double stranded DNA.58 
They do not react with proteins, RNA, or single-stranded DNA; therefore their 
selectivity is easier to control. Upon reduction, the cyclopropyl moiety opens and 
alkylates DNA. The active effector in carzelesin (another cyclopropylpyrroloindole 
drug) reacts too quickly, preventing useful absorption into tissues. The cyclopropyl 
group is masked as a chloromethyl substituent, which is hydrolysed to the 
hydroxymethyl followed by cyclisation to the cyclopropyl ring. 57 This allows the 
" . 
drug to be adequately distributed throughout tumour tissues before conversion into the 
active cyclopropyl analogue and subsequent alkylation. One disadvantage is that the 
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trigger is not very tumour-specific, with activation occurring under most cellular 
conditions. 57 
Scheme 1.2.2.5 
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Quinone methides are reactive intermediates generated from the reduction of 
quinones. They are activated via an elimination ~- to the quinone, usually of a 
hydroxyl group. The activated species (4) of mitomycin C, formed after nucleophilic 
attack of a nucleophile (nucleophilic sites in DNA or proteins) on an .aziridinium ion, 
i~ a quinone methide. It can bond covalently with nucleophiles (Scheme 1.2.2.5), 
e.g. N-7 of guanine in DNA or thiol-containing proteins.59 
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Nitrogen mustards, such as mechloretha.J}1ine (5) and chlotam~ucil (6) have 
historically-proven clinical effectiveness. They were developed from the analogous 
sulfur mustard gas after World War IT and present a number of advantages for 
therapeutic use. Their cytotoxicify is fairly indiscriminate, giving them the ability to 
kill almost all types of tumour cells, both cycling and non-cycling. Without prodrug 
deactivation, this can be a disadvantage, as they generally exhibit cytotoxicity in 
normal cells as well. The mechanism of action of nitrogen mustards via aziridinium 
ion intermediates is shown in Scheme 1.2.2.6.60 • The reactivity of these compounds is 
almost completely dependent on the electron density on the nitrogen. This allows for 
versatile and stable deactivation through the..manipulation of the electronic properties 
of the molecule around the central nitrogen. The traditional nitrogen mustard 
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effectors present challenges, since they generally exhibit lower potency when 
activated; but design of more potent nitrogen mustards would allow for further 
clinical investigation of these compounds. These compounds will be discussed 
further in a later section. 
Scheme 1.2.2.6 
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Triggers 
A variety of trigger functionality has been used for the activation of the 
common effectors. Previously studied triggers include nitroaromatics (as 
functionality within the parent drug compound and also as quaternary nitrobenzyl 
salts of active amines), N-oxides (aromatic and aliphatic), quinones and transition 
metal complexes.52• 61. 62 Nitroaromatics have been extensively studied as 
"I 
bioreductive drugs, mostly due to their potential as radiosensitisers.· Numerous 
nitroimidazole, nitrothiophene and nitrofuran derivatives (such as misonidazole [7], 
and others [8 and 9]) have shown promising radiosensitisation activity in vitro, but 
7 
9 
18 
solubilities and systemic toxicities have slowed their development as clinical 
agents.63, 64 Other nitrofuran and nitroimidazole derivatives can be used as release 
systems (Scheme 1.2.2.7).65,66 Nitroaromatic nitrogen mustards, such as nitroaniline 
and nitrobenzamide derivatives,62 have reduced electron density on the central 
nitrogen atom, affecting the formation of the active aziridinium ion and thus the 
activity. Reduction of the nitro group to the amino group shifts the electron density 
back onto the mustard nitrogen, re-establishing its potential for alkylation. Nitroaryl 
quaternary salts of tertiary nitrogen mustards take advantage of the propensity of the 
nitroaryl functionality to fragment upon one-electron reduction of the nitro group.67 
These prodrugs have high hypoxia selectivity in vitro (up to 10,000 fold),68 but 
exhibit unpredictable cytotoxicity in vivo. Nitrobenzyl salts have low activities,68 and 
other nitro aryl salts show non-specific toxicity to normal cells.69 
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~DRUG 
02N 0 
bioreduction 
• 
{?-~DRUG H~ 0 V 
OH 
proton 
transfer 
• N~ I 
OH + 
I DRUG I 
N-Oxides provide three types of prodrug trigger. The tirapazamine prodrug 10 
can undergo 9xygen-reve~sible fragmen~ation upon reduction, generating reactive 
drug species and hydroxyl radicals under hypoxic conditions, causing DNA damage. 
70 DNA affinic agents, such as AQ4, can be masked as their N-oxides (e.g. 11) to 
.c 
prevent DNA binding until they reach hypoxic tissues. N-Oxides of nitrogen 
mustards also have their activity masked by changing the electron density of the 
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central nitrogen, as previously described for nitroaromatic mustards.7} So far, only 
tirapazamine derivatives are being investigated for clinical use.70 
10 11 
Transition metal ions are common components of anticancer drugs, 
e.g. cis-platin 12. However, their use as trigger agents has only emerged within the 
past 13 years. Some metal ions can be reduced from stable complexes (e.g. Co[llI]) 
to less stable ones (Co [liD by reductase enzymes.72 Molecular oxygen should reverse 
this process, as with other hypoxia selective drugs. However, if the reduced complex 
is too labile, the active agent may be released before reoxidation of the complex and 
th.is may reduce the selectivity.52 Thermodynamic lability of the oxidised form of the 
complex may also cause problems. This is discussed in more depth in Chapter 4. 
NHs 
I 
HsN-lt- C' 
CI 
CI CI~S 
N O'\~ I ,~ 
t;-CQ'-' 0 0"'1 .. N02 
12 13 
One of the first nitrogen mustard metal complexes 13 was designed as a 
radiosensitiser, not as a masked alkylating agent. It showed mild hypoxic activity 
(although it was actually more active in oxygenated cells) and evidence of alkylating 
activity as compared to a similar non-alkylating complex.73 Soon after, Denny, 
Wilson and Ware published a series of Co(lll) complexes of bifunctional alkylating 
agents. Their use of ethylenediamine mustards as chelating ligands increased the 
stability of the reduced Co(lI) complex sufficiently to provide the first transition metal 
complex with bioreducible. hypoxia selectivity (-six-fold).74 Originally, a 
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one-electron mechanism was suggested for the hypoxic activation of these complexes 
(Scheme 1.2.2.8). 
Scheme 1.2.2.8 
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These promising results were followed by a rapid succession of further 
characterisation studies of similar Co(m) complexes. Correlations were found 
between ligand structure, redox potential and activity. Hypoxia selectivity was 
increased to approximately 20-fold with SN 24771 (14). It was subjected to more 
detailed investigations into the oxygen dependence of its cytotoxicity.61 The released 
mustard showed extensive killing in multi-cellular spheroids, demonstrating'its ability 
to diffuse into surrounding tissue. Pulse radiolysis studies to determine the kinetics of 
reduction revealed an unexpected result: the activation mechanism did not appear to 
follow the one-electron pathway, common to other hypoxia selective drugs (as in 
Scheme 1.2.2.8).75 Instead, it appears that 14 may compete with 02 for available 
reductants, with low oxygen concentrations freeing those reductants to activate the 
Co(m) complex. Since this result in 1996, there have been few reports of these 
complexes in. the literaturl? Problems with their aqueous solubility and selectivity 
(compared to some other N-oxides etc.) could be the reason for the lack of 
de,,-~lopment. 
21 
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Cu(ll) complexes of bis(thiosemicarbazone) ligands have also shown hypoxia 
selectivity.76 Their redox potentials are easily tuned by changing the ligand 
substituents and the complexes with the lowest reduction potentials are the most 
selective." These complexes have cytotoxic properties, but so far have been 
primarily employed as vectors for Cu(ll) radionucleotides for hypoxia-targeted 
radiotherapy. Radiolabelled 60Cu_ and 62CU_ ATSM (e.g. 15) are used in the imaging 
of hypoxic tissue.'8-80 Macrocyclic Cu(ll) complexes of cyclen and cyclam 
derivatives (e.g. 16) have also been shown to release 64CU into tumour tissue, 
s~ggesting lower stability of the bioreduced complex.81 All of these Cu(ll) complexes 
are water-soluble and bioreducible, as shown clinically. Generally, the bioreduction 
of Cu(ll) to Cu(I) shows great versatility, practicality and promise for new 
bioreductive drug development. 
1.2.3. Enzymology of bioreduction 
A ntlmber of enzymes have been implicated in the activation of bioreductive 
drugs, including cytochrome p450, cytochrome p450 reductase, NQOl and xanthine 
oxidase.82 The activation generally proceeds via a one-electron reduction, with the 
exception of NQOl, which can also utilise an aerobic two-electron reduction pathway 
in the reduction of quinones, causing possible loss of selectivity.82 'Within key 
enzymatic pathways, different enzymes activate particular drugs to various extents. 
For example, _mitomycin <; and other quinone drugs are often activated by NQOl 
(albeit sometimes in the presence of oxygen), while cytochrome p450 reductase and 
cytochrome p450 isozymes dominate in the hypoxia selective activation of 
.. . 
nitroimidazoles.49 Although the relationships between drug activation and 
enzymology are highly complex, they do offer some useful opportunities for drug 
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development. Occasionally, bioreductive drugs can be targeted specifically to 
different types of cancer by combining knowledge of the role of a specific enzyme in 
the activation of a particular drug with an understanding of tumour cell lines that 
express elevated levels of that enzyme.83 
NQOl has been extensively studied, due to its overexpression in many 
cancers.84-87 However its behaviour is widely variable depending on the tumour type 
and cell line. Diaphorases such as NQOl, called "coenzyme factors," catalyse 
electron transfer between reduced pyridine nucleotides and redox indicators. NQOl 
is a two- or four-electron reductase flavoprotein (using FAD as a cofactor) that is 
unique in its ability to use both NADH and NADPH as cofactors as well.88,89 Given 
its propensity to activate bioreducible drugs under oxic as well as hypoxic conditions 
and the complexity of its in vivo behaviour, NQO 1 can be a difficult enzyme to target 
in predictive bioreducible drug design. The one-electron reductases, such as xanthine 
oxidase and cytochrome p450 reductase, perform much more predictably and 
correlations can be made between reduction potentials and rates of 
r~ductionlactivation of drugs.82 However, NQOl activity still needs to be considered 
in any screening regime, as it is commonly overexpressed in tumours.49 
The enzyme profile of hypoxia, along with computerised databases of tumour 
enzyme expression and enzymatic drug activation,90 provide a unique opportunity to 
target tumours without extensive toxicity to healthy cells. 
1.2.4. Electrochemiatry of bioreductlon50 
Thorough inv~stigation of electrochemical properties can be useful in 
predicting the activity of bioreductive drugs. Many factors influence the fate and 
mode of action of such drugs in vivo, so it is dangerous to base assumptions on in 
vitro electrochemical data. Hdwever, techniques such as cyclic voltammetry (CV) 
can provide information on important parameters such as ionisation potentials, 
electrcm affinity and redox potentials. The conditions and standards used for analysis 
must be carefully considered in order to obtain biologically relevant information. As 
yet;' there are no standardised procedures for assaying bioelectrochemical data, but 
common sense and reference.to previous studies can be used to develop possibilities 
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for suggestive, if not predictive, ways of modelling biological electrochemical 
activity. 
In addition to the parameters listed above, cyclic voltammetry can be used to 
study the reactivity of reduced chemical species by monitoring the reversibility of the 
system. Reversible systems indicate that the reduced species is thermodynamically 
stable and doesn't change chemically before in vivo reoxidation under oxic 
conditions. This positively affects the selectivity of the release of cytotoxin, as well 
as contributing to bystander effect diffusion into the surrounding tissue before 
reaction with biomolecules. It is important to evaluate the redox potential in both 
aqueous and non-protic conditions, as at least one essential reductase enzyme, 
cytochrome p450, has domains in both the lipophilic cell membrane and the aqueous 
cytoplasm.91 Although the redox potential provides a possible starting point for 
prediction of activity, it is not prudent to use their values as a screening method, since 
the technique can be less accurate for slower electron transfer reactions and is highly 
dependent on pH and other unpredictable effects such as in vivo metabolism. so 
" 
The aforementioned ionisation potential and electron affinity provide useful 
information about the drug's ability to exchange protons and accept electrons, 
respectively. The pH of hypoxic cells is generally lower than in normal tissues, thus 
the ionisation potential can be of greater significance to its interaction with 
biomolecules as well as inter- and intra-cellular transport. so An optimum electron 
affinity can' also be important, as molecules that accept electrons too readily will be 
quickly metabolised and excreted, while those with lower affinities risk poor levels of 
activation by reductase enzymes. 
The most relevant information that can be obtained from reduction potentials 
is the comparison of reduction rates under hypoxic and oxic conditions, as it c.an give 
a good indication of the selectivity of cytotoxicity based on whether or not it is 
possible to gene!ate the reactive species under oxic conditions.so So although it is not 
possible to correlate electrochemical behaviour with bioactivity directly, it is useful to 
consider electrochemical characterisation when performing a full exploration of in 
vitro bioreductive drug activity. Additionally, knowledge of optimum redox 
potentials for enzymatic reduction can contribute to directed bioreductive drug design. 
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1.2.5. Bioreductive drug design 
Many aspects of the cellular environment contribute to the efficacy of 
bioreductive drugs, including the enzymes present, the level of hypoxia and the rate of 
metabolism of the prodrug and activated drug.92 Additionally, the reduction potential 
of the prodrug and the stability of the activated drug can be significant for the drug's 
selectivity. It is thought that the reduction potential should fall within an appropriate 
range for reduction by one of the common enzymatic activation pathways (ca. -200 to 
-400 mV vs. NHE).50 The reduced compound must be stable enough to allow for 
reoxidation in the presence of oxygen in order to prevent activation under aerobic 
conditions. 
There are many approaches available for design. The affinity of drugs for 
reductase enzymes can be assessed experimentally or by computer modelling of the 
compounds in the enzyme active sites. The reduction potentials can be estimated 
using Hammett calculations (based on certain constants for substituents). Metal 
complexes provide a particularly attractive avenue for bioreducible drug design. 
Their potential as hypoxia selective agents has only been touched on so far: their 
redox potentials are easily tuned by changing the metal ion or the ligand substituents; 
and a wealth of data already exists describing their synthesis and complexation 
properties. 93-99 Accordingly, the development of cytotoxic ligands for bioreductive 
release from a redox metal trigger has been the primary focus of the work described 
herein. 
1.3. Nitrogen mustard alkylating agents 
1.3.1. Biological effects 
Nitrogen mustard alkylating agents can interact covalently with many cellular 
components, especially enzymes and DNA. As. detailed in Scheme 1.2.2.6, the 
reactive aziridinium ions formed can alkyl ate nuc1eophiles such as histidine (17) and 
cystei~e (18) residues of proteins,lOO or guanine residues (19) of DNA.IOI Binding to 
enzyme backbone peptides can cause conformational changes of the active site and 
25 
9° ~y\ N ° ((I HN Jl)y\ ~sj 0 
N-7~Ni:° (( I NH 
N ~ 1 N NH, 
17 18 19 
these can result in deactivation of the enzyme. Such is the case for the vesicant 
(blistering) effect of mustard compounds on skin and mucous membranes. lOO 
The primary toxicity of mustards upon inhalation or skin contact arises from 
their vesicant effect. Mustard exposure causes epithelial cells to change shape, detach 
from each other and form blisters. The mustard agents alkyl ate muscarinic 
acetylcholine receptors (mAChRs) in epithelial cells. These receptors control cell 
adhesion together with acetylcholine (20, an important cellular transmitter). Their 
interaction with mAChR proteins may be enhanced by the similarity of aziridinium 
ions to the trimethylammonium group of acetylcholine. 100 
20 
Some lipophilic nitrogen mustards (e.g. 21) are able to cross the blood-brain 
barrier to bind to neural muscarinic receptors, resulting in cholinergic effects (such as 
seizures). 102 These compounds bind irreversibly JO mAChRs, targeting them for 
protease degradation. However, the use of reversible cholinergic drugs can moderate 
the adverse effects of mustards on the cholinergic systems by occupying the active 
sites of the enzymes a~d reducing the conformational changes induced by the 
alkylation. Thus, drugs such as atropine (22, the racemate of hyoscyamine) can 
'diminish the adverse vesicant effects of mustard drugs. IOO 
cTB0 
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Bifunctional nitrogen mustards are known to form DNA cross-links. 103, 104 
When guanines on different strands of DNA are cross-linked, DNA unwinding is 
obstructed, triggering apoptosis (23). Resistance can develop through the up-
regulation of DNA repair pathways. IDS However, the cytotoxic effects of DNA cross-
linking can be enhanced with the concurrent use of DNA repair inhibitors or via 
inactivation of other repair pathways. IDS, 106 Similarly, DNA-rep air-deficient mutant 
cell lines (e.g. UV4) are more sensitive to alkylating agents than cells with normal 
repair mechanisms. Other pathways of cytotoxicity may arise from the linking of 
DNA to proteins. 107 Generally, the cytotoxicity of mustard drugs is non-specific and 
potent (IC50 values around 10-6 M), which is useful in the design of anti-cancer agents. 
Specificity of drug action encourages the development of resistance to the treatment.47 
Non-specific action ensures a multiplicity of pathways for drug activity, all of which 
must be overcome before resistance will succeed. 
1.3.2. Previous developments in mustard drugs 
Nitrogen mustard alkylating agents provided an entry into the previously 
unknown world of cancer chemotherapeutics. One of the first anti-cancer drugs 
developed was the N-mustard mechlorethamine (5). During World War II, medical 
technicians noticed that exposure to mustard gas dramatically lowered the white blood 
cell counts of survivors (among other toxic effects). Dr. Cornelius Rl10ad~, who 
treated many patients poisoned by mustard gas, postulated that similar drugs might be 
used to inhibit leukaemia, as it involves the cancerous overproduction of white blood 
cells. !Os Louis Goodman and Alfred Gilman pioneered the clinical trials of 
mechlorethamine in the first attempts at chemotherapy in the 1940s.109 Although the 
initial trials were not successful, they represented the birth of medical oncology and 
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mechlorethamine is still used today for the treatment of Hodgkin's disease and other 
lymphomas. Modifications of mechlorethamine to improve stability, membrane 
transport and solubility led to the development of analogues such as chlorambucil (6). 
Chlorambucil had its first clinical trials in the 1950s and is currently used in the 
treatment of lymphomas and leukaemia. Its analogue melphalan (24) is used to treat 
mUltiple myeloma and ovarian carcinomaYo, 111 
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Although mustard drugs have experienced some success in cancer treatment, 
theirr side effects can be severe and dangerous. Seizures, reduced immunity, blistering 
of mucous membranes and instigation of new cancers are unpleasant and potentially 
life threatening. Therefore, it was a priority to develop prodrugs of these compounds 
in order to improve their selectivity and minimise the adverse effects to normal 
tissues. Cyclophosphamide (25) was one of the first of these prodrugs.112 Developed 
in 1958, it was designed for activation by phosphoramidase enzymes in vivo, cleaving 
the mustard moiety from the phosphoramide.1l2 Unexpectedly, cyclophosphamide is 
actually activated via hydroxylation by cytochrome p450 and breakdown into 
,) 
phosphoramide mustard (26) and acrolein (27) (Scheme 1.3.2.1). The production of 
acrolein is unfortunate, as it causes cystitis and other bladder problems. However, 
overall the side effects are less severe than with naked mustard drugs. Accordingly, 
cyclophosphamide is the most commonly used alkylating agent. 112 
28 
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Extensive research has been conducted in the drive to improve the selectivity 
of alkylating agents and only the most recent developments will be discussed here. 
Studies on the kinetics of chlorambucil hydrolysis in biological model systems have 
yielded useful information about the reactivity of mustard drugs. For example, the 
rates of reaction of mustards at physiological pH with various biologically available 
nucleophiles proceeded in the following order: water « phosphate < imidazole « 
thio1.6o This suggests that mustard drugs may have some selectivity towards thiol-
containing proteins. Conjugates of chlorambucil with polyamines have been 
studied60• 113 in an attempt to exploit the increased uptake of polyamines by tumour 
cells. Indeed, a chlorambucil-spermidine conjugate (28) exhibited a 104 increase in 
potency over chlorambuci1.6o It was not clear whether the increase was due to an 
intrinsic enhancement of the mustard's reactivity, Qr an increased association of the 
. , 
conjugate with DNA via the affinity of polyamines for DNA. If the increase was due 
to increased DNA interaction, it w~ non-sequence specific.114 
Other nitrogen mustard conjugates have been investigated, including poly-
"arylamide (29) and distamycin-type compounds (30).115-117 Like polypyrrole 
antibiotics (e.g. distamycin), these compounds have planar conformations that are 
complementary-to the minor· groove of DNA. Th~se mustards are bifunctional, with 
the alkylating groups on the same nitrogen or on different nitrogens separated by a 
spacer. The polyamide backbones confer rigidity on the spacer between mustard 
moieties, allowing for control of the distance between the nitrogens. 
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In vitro tests of these compounds showed enhanced DNA-crosslinking activity 
and IC50 values in the micro- to nano-molar ranges against human cancer cell 
lines. 115-117 A hairpin polyamide-chlorambucil conjugate was particularly effective 
against leukaemia, with an IC50 value of 2.2 nM.116 Its polyamide sequence targeted a 
specific sequence of DNA. Distamycin mustard conjugates (e.g. 30) were also 
" 
effective against human leukaemia cells in vitro, with ICso values in the sub-
micromolar range. In vivo tests of the polyamide mustard 29 showed a 37% increased 
lifespan in tumour-bearing animals, which was equal to the activity of 
chlorambucil. 115 
Our group began working with alkylating agents in the mid 1990s. In order to 
prepare N-oxide prodrugs, Nicola Henderson first synthesised a series of bifunctional 
mustards based on piperidine (31) during her PhD research.us It was hoped that the 
conformational restriction inherent in cyclic nitrogen mustard analogues would 
temper the reactivity in .setting up ·the necessary conformation for aziridinium ion 
formation. The best of these compounds showed good cytotoxicity against human 
.colon carcinoma cell lines (-8 fAM).119 However, their N-oxide derivativ~s were 
inactive under both oxic and hypoxic conditions. Their reduction potentials were 
probably not within an appropriate range for cellular reduction. 
M 
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Rather than concentrating on improving the potential for prodrug activation, 
Henderson focused on· further increasing the selectivity of the alkylation. She 
extended her work to a series of bispiperidine derivatives, e.g. 32. They showed 
improved selectivity for N-7 of guanine over melphalan and were cytotoxic in three 
cisplatin-resistant cell lines.120 Although these compounds cross-linked DNA at 
lower concentrations than melphalan, their IC50 values showed they were not as 
potent. A relationship began to emerge between the linker chain length and the 
reactivity. Compound 32, with an ethylene linker, was twice as reactive as its longer-
chain analogues. This suggested that there might be an optimum distance between 
nitrogens for cross-linking activity. 
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During her PhD research, Fiona Anderson carried out further investigations 
int~ this issue. 121 She synthesised a series of homochiral bispyrrolidine mustard 
derivatives (33) and a number of alkyl cyclic and linear mustards (34 and 35).122 The 
bispyrrolidine compounds showed a relationship between linker length and alkylating 
activity, with the 2-, 5- and 6- carbon linkers giving the best alkylation. Surprisingly, 
the 3- and 4- carbon linkers resulted in no DNA cross-linking activity. Also, in 
contrast to conventional mustard drugs, there was no clear correlation between 
alkylating ability and cytotoxicity. None of the linear or cyclic mustards showed 
cytotoxicity within a useful range « 100 JAM). The reasons for the lack of activity 
were not apparent. Perhaps cells did not take up the inactive compounds efficiently, 
or they may have been more reaytive with other cellular components (e.g. thiol-
containing proteins). 
In order to expand the previous work, macrocyclic polyamines provided an 
attractive aven~e to compounds with multiple alkylating moieties, variable carbon 
chain lengths and the possibility for metal ion .chelation to generate bioreducible 
prodrugs. Macrocyclic polyamines (e.g. cyclen 36) are well known in the field of 
inorganic chemistry as ligands for chelation.97, 98, 123-125 They offer a range of 
n 
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possibilities for variation of structure, including multiple substituents at carbons and 
nitrogens, as well as variation in the size of the macrocycle. They also have the 
biological advantage of being natural polyamine analogues, e.g. cyclic spennidine 
(37). Linear polyamines show a range of interesting biological activities, including 
anti-malarial and anti-cancer and will be discussed in a later section. 
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During his work with the Robins group, Dr. Stephen Lacy synthesized the 
cyclen derivative 38, which had phenomenal DNA cross-linking activity (100% cross-
linked DNA at 0.1 JAM) and higher cytotoxicity (ICso = 22 JAM) than chlorambucil 
, 
(ICso = 45 JlM) against a human colon carcinoma cell line. 126 Fiona Anderson 
followed up this line of work and synthesised a series of polY-2-chloroethylated 
macrocyclic polyamines such as 39.42, from commercially available starting 
materials. Some had very promising biological activity (Table 1.3.2.1) and she 
extended her work to vary ring size, carbon chain length between nitrogens and 
number of nitrogens in the ring. However, she encountered difficulties in the 
synthesis of many of these compounds, such that she was unable to reach her targets. 
As a result, the primary synthetic aims of this project have been to develop a flexible, 
reliable method to obtain azamacrocycles of variable ring size with different carbon 
chain lengths between the nitrogen atoms. 
Table 1.3.2.1. DNA cross-linking and cytotoxicity data for previously tested 
macrocycllc N-mustards 
% crosslinked DNAa 
Compound 
- 0.01fJ.M 0.1fJ,M 1fJ,M 10fJ,M 
38 100 .-
39 64 100 
40 16.4 93.7 100 
"41 77 100 
42 30 100 
• details of testing procedures published previously121 
IC50a 
(fJ,M) 
22 
10 
7.5 
9 
13 
32 
1.4. Synthesis of macrocyclic polyamines 
1.4.1. Cyclisation 
Polyazamacrocyc1es are notoriously difficult to synthesise. As is the case for 
other types of cyclisation, the reaction conditions must be designed to ensure 
intramolecular cyclisation as opposed to intermolecular oligomerisation. This can be 
achieved in a number of ways: using high dilution conditions; templating the starting 
polyamine with a metal ion or carbon-based backbone; or using sulfonamides for 
preorganisation in the Richman-Atkins-type synthesis.127 The details of these 
methods, particularly the Richman-Atkins synthesis, will be discussed in this mini-
review. 
High dilution cycllsations 
Up until the 1970s, polyazamacrocyc1es were typically isolated in low yields 
from complex mixtures of oligomers formed in simple amine-substitution· 
reactions.128-130 Amines protected as sulfonamides were first used by Stetter and Roos 
in the 1950s131, 132 and by Stetter and Mayer in the 1960S133 with limited success-
yields were still very low «15% overall) and reactions required high dilution to 
prevent oligomerization. High dilution conditions are usually characterised by 
maintaining a concentration of less than 0.1 M reactant, under the assumption that 
fewer collisions will take place between reactants, ~nd thus an intermediate will have 
time to react with itself in a cyclisation before meeting another reactant molecule. 
This effect can be achieved either by using a large excess of solvent or by slow 
addition of reactants (e.g. with a syringe pump). The main disadvantages of this 
technique are the large volumes of solvent required and the long reaction times 
.. necessary. Even on a small scale (0.5-1 g), high dilution cyclisations can take longer 
than two weeks to reach completion. Still, these conditions often result in high yields 
and can involve fewer protection-deprotection steps than some other methods. 
- The 'crab-like' cyclisation is one e)5.ample of very effective high dilution 
synthesis of selectively N-substituted cyc1am derivatives (Scheme 1.4.1.1). A wide 
variety of cyc1am derivatives were produced in just three steps giving ca. 80% yield 
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in the cyclisation.134 This method still results in the formation of 2:2 and 3:3 
cyclisation byproducts; however they are easily separated by filtration through a short 
silica gel column. The drawback is that the efficiency of the cyclisation is highly 
dependent on the ring size formed, so it is not very effective for the production of 
macrocycles other than cyclam. Also, the reduction of the diamide precludes the 
incorporation of reduction-sensitive functionality. 
Scheme 1.4.1.1 
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Similar diamide cyclisations have analogous problems. Diester-triamine 
condensations give very low yields «13%) and require long reaction times (>5 days), 
135, 136 however they do allow the potential for selective alkylation (Scheme 1.4.1.2). 
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OEt 
0=\ . reflux 
O=< EtOH 
OEt 
j reduction 
selectively 
substituted 
macrocycle 
34 
In general, diamide formation is useful in certain situations, especially when 
selective N-substitution is desired. However, it can be lengthy and low yielding and is 
dependent on the ring size formed so it is not a good general method for producing a 
range of polyazamacrocycles. 
Templated cycllsations 
Metal ion templates 
One way to reduce the need for high dilution is to template the polyamine in 
some way in order to preorganise it for cyclisation. The complexation of amines with 
metal ions has been exploited for this purpose.137-140 The first of these methods used a 
diamine-Ni(II) complex which was condensed with acetone (Scheme 1.4.1.3) to 
produce two structural isomers of a cyclam derivative (43 and 44). The resulting 
diimine complex must be reduced to the alkylazamacrocycle.137 
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Another classic example of this type of m.acrocycle synthesis is the Ni(II)-
templated synthesis of cyclam (Scheme 1.4.1.4). This method starts from the readily 
available, low-cost 1,2-bis(3-amin~propyl)-1,2-ethanediamine and gives good yields 
.. 
of cyclam. However, the Ni(1I) must be removed via displacement of the cyclam 
ligand with cyanide, so this method is not suitable for industrial production of 
"' macrocycles.138 
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Carbon templates 
Carbon-based templates can also be employed for macrocyclic polyamine 
synthesis. These strategies are also high-yielding and the template is usually removed 
by simple hydrolysis, avoiding the toxic reagents required for metal-template 
removal. 
Triazamacrocyc1es can be synthesised using bicyc1ic guanidine 
templates,141-144 as in Scheme 1.4.1.5. This allows for reasonably large-scale 
synthesis of a number of triazamacrocyc1es (-3 g macrocyc1e obtained), but the 
bicyclic guanidines are not commercially available and must be made beforehand. 
Also, the intermediate tricyclic guanidinium salts can be difficult to purify, as their 
crystallinity varies with ring size. 
Scheme 1.4.1.5 
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Tetraamines can also be templated using carbon-based structures. Cyc1en (36) 
can be synthesised from a tricyclic b~samidine precursor via reductive ring expansion 
(Scheme 1.4.1.6).145 This method· produces cyclen in high yields with minimal 
purification necessary. However the synthesis of the bisamidine precursor produces 
'stoichiometric amounts of ethanethiol, which reduces the industrial viability of this 
procedure. 
36 
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Other similar syntheses using glyoxal as the template, forming the bisaminal, 
are mostly useful for producing N-substituted macrocycles (e.g. Scheme 1.4.1.7) due 
to the difficulties in removing the template from the unsubstituted tetracycle at the 
end. 146, 147 
Scheme 1.4.1.7 
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More recently, two very simple carbon-templated tetraazamacrocycle 
syntheses have appeared in the literature. The first uses butanedione as the template, 
fOrming a rigid tricyclic bisaminal. Once cyclised t~ the protected macrocycle, the C-
substituted bisaminal is much easier to remove than the aforementioned glyoxal 
derivative and the acid salt of the tetraazamacrocycle can be obtained in good yield by 
simple hydrolysis (Sche~e 1.4.1.8).148 
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Unfortunately, the success of the cyclisation to the tetracyclic bisamidine is 
highly dependent on the conformation of the tricyclic compound. The 3,2,3-
tetraamine 45 forms two conformational isomers of the tricyclic guanidine (46 and 
47), neither of which allows the cyclisation of the final six-membered ring (Scheme 
1.4.1.9).148 The 2,3,2-tetraamine does provide access to cyclam, but it is much more 
expensive than the 3,2,3-tetraamine. 
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The second recent method uses a bisimidazoline to form cyclen through a 
diaminocarbene intermediate (Scheme 1.4.1.10).149, 150 This route uses cheap starting 
materials and gives good overall yield of cyclen (36). The diaminocarbene 
dimerisation mechanism was confirmed by using ethylene carbonate (48) as the 
electrophile, giving the product 49: Unfortunately, this route was found not to be 
suitable for the production of other tetraazamacrocycles. This observation is 
. discussed further in Chapter 2. 
.. 
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Template methods can provide good yields and convenient access to 
polyazamacrocycles, but all are highly dependent on the ring size and the 
conformation of the templated intermediates. This restricts the range of carbon 
bridges available to two and three carbons. Although those bridge lengths were useful 
for some of the macrocycles desired for this project, this restriction was not 
satisfactory for the production of all of the nitrogen mustard alkylating agents we 
wished to produce. Thus it was important to investigate other strategies as well. 
Richman-Atkins cyclisation of sulfonamides 
Sulfonamide cyclisation has emerged as the most flexible synthesis of 
polyazamacrocycles. Variations in type of sulfonamide, base and deprotection 
strategy have allowed for the production of a wide range of ring sizes and structural 
features. One disadvantage of the p-toluenesulfonamides traditionally used is the 
harsh conditions required for their deprotection. Usually hydrolysis in H2S04 or 
HBr/AcOH is necessary, but reductive removal, e.g. with sodium or lithium in 
, 
ammonia can sometimes be effective. More recent variations have used sulfonamides 
that are removed under milder conditions, such as the (2-trimethylsilyl)ethanesulfonyl 
(SES)151 and 2- and 4-nitrobenzenesulfonyl (2- and 4_Ns)152, 153 groups. 
p-To/uenesu/fonam/de eye/Isatlon 
The first efficient cyclisation of sulfonamides was developed in the 1970s by 
Richman and Atkins.127 The initial conditions in' the Richman-Atkins. cyclisation 
combined the pre-formed disodium salt of a p-toluenesulfonamide in DMF with a diol 
ditosylate or dihaloalkane, heating a~ 100°C for 2 hours, followed by detosylation in 
conc. sulfuric over two days (Scheme 1.4.1.11). This process did not require high 
dilution and gave very high yields for the synthesis of cyclen (36) and other 
- . 
macrocycles including triazamacrocycles (e.g. tacn [53]) and dioxodiazamacrocycles 
(e.g. [54]). 
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A number of notable observations were reported in this paper. Importantly, 
ditosylates (or dimesylates) were found to give the best yields in the cyc1isation. The 
rates of reaction were measured for different leaving groups -X (1, Br, OTs, OMs and 
CI) and found to give second-order kinetics for the disappearance of sulphonamide 
(suggesting an sN2 mechanism); however only the dimesylate gave a clean second-
order plot. Curvature in the plots for the dihalo-compounds indicated competing 
pro~esses e.g. elimination and/or oligomerization. Also, Richman and Atkins found 
that the high yield was not due to a template effect on the cyclisation by the sodium 
ion. Replacing the sodium with a tetramethylammonium cation did not significantly 
decrease the yield. However subsequent groups have reported a dependence on the 
cation suggesting some degree of template effect.154. 155 Synthesis of cyc10phanes 
with the modified Richman-Atkins conditions also indicates that there is not a 
template effect and so it is best to assume that some combination of factors applies. 
~s_ 
~<.. CoTs Ts N'~ I N~ bulky groups are forced apart, \. ~0N0 movlngll1e ends closer together 
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Although the reasons for the improved intramolecular reaction were not immediately 
clear, it was later suggested that the sulfonami3e groups contributed to the success of 
the cyclisation in two ways:151 they rendered the amine hydrogens sufficiently acidic 
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for facile deprotonation; and the steric bulk of the p-toluenesulfonyl groups 
conferred a Thorpe-Ingold-type effect on the intennediate 55, encouraging 
intramolecular reaction. 
Soon after it was found that the sulfonamide salt could be fonned in situ 
using CS2C03156 or K2C03.154 The yields were still good and the reaction no longer 
required high temperatures (although the reaction time was increased to -24 h). 
Using K2C03 gave better yields for smaller rings, allowing improved access to 
triazamacrocycles. Some cyc10phanes (e.g. 56) were also fonned and deprotected 
with sodium-mercury amalgam. These 'modified Richman-Atkins conditions' using 
CS2C03 or K2C03 are now regarded as the most effective for the fonnation of most 
polyazamacrocyc1es. However the yield was still somewhat dependent on the ring 
size being fonned and the deprotection of the alkylazamacrocyc1es was still difficult 
with typical hydrolysis procedures. 
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It was apparent that although thi~ method was much more general than 
template methods and more convenient than high dilution syntheses, there were still 
problems with inconsistencies in cyclisation and deprotection yields. Numerous 
.) 
adaptations of the Richman-Atkins synthesis have appeared over the years, each 
providing its own advantages. Although none stands out as the definitive ideal 
method, a few do proVide distirtct improvements in protection strategy or 
practicality. 
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For example, use of phase-transfer conditions (Scheme 1.4.1.12) improved 
the cyclisation yields for some ring sizes. 155 Presumably this is because it allows for 
the use of NaOH, a stronger base, which is also kept separate from the ditosylate 
(preventing possible elimination of the tosylate groups and loss of this starting 
material). Another interesting use of the tosyl group involves the synthesis of 
triazamacrocycles by closing 57 with tosylamide (Scheme 1.4.1.13).157,158 With the 
right solvent and base, this reaction is quantitative for certain ring sizes (e.g. [2,2,2]). 
This route is amenable to laboratory scale production of some triazamacrocycles. 
However, this route encounters the same problems with deprotection of the 
tosylamide macrocycles as for traditional Richman-Atkins synthesis. 
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Some alternative sulfonamides have been used in attempts to simplify the 
. 
deprotection. Each has advantages and disadvantages, however they do provide 
higher yieldS of some azamacrocycles. 
Using trifluoromethylsulfonamides (triflamides) allows for dilution-specific 
control over the cyclisation process, giving either 1: 1 or 2:2 cyclisation products 
(Scheme 1.4.1.14).159 Reactant concentrations of 0.02 M give predOminantly the 1: 1 
.~yclised product, whereas concentrations -0.5 M result in the 2:2 'dim~rised' 
macrocycle. The process still avoids oligomerisation, so it can be used to prepare 
certain ring siz~s ([3,3,3]; [3,3,4]; [3,3,3,3,3,3]; and [3,3,4,3,3,4]) in a reliable 
manner. The deprotection is achieved using' lithium in ammonia and the 
macro~ycles are obtained as their hydrochloride salts after ion-exchange 
chromatography. 
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Scheme 1.4.1.14 
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The 2- or 4-nitrobenzenesulfonyl (nosyl, Ns) group has also been used. It 
most specifically provides an advantage in the synthesis of 
cyclophanes-pyridinophanes, naphthalenophanes and anthracenophanes.152, 153 The 
deprotection is mild enough for the N-benzylic functionality to survive. The 
(2-trimethylsilyl)ethanesulfonyl group is also removed under mild conditions and is 
also useful for the synthesis of the aforementioned cyclophanes as well as for 
alky)triazamacrocycles. The synthesis of polyazamacrocycles using these protecting 
groups is discussed in more detail in Chapter 2. 
Overall, the Richman-Atkins route provides the most flexible, generally 
applicable synthesis of polyazamacrocycles. It is not as sensitive to ring size and 
intermediate conformation as the template routes and does not require high dilution 
and extended reaction times as do diamide condensations. This route was chosen for 
this project as.· the primary method with which to prepare a series of 
triazamacrocycles of various carbon-bridge lengths aild ring sizes. 
1.5. Other biological ,considerations 
Polyazamacrocycles have numerous interesting biological activities in 
addition to their potential use as bioreductive prodrugs. As analogues of natural 
polyamines, they may show- anti-fungal and anti-parasitic activity. N-Substituted 
polyazamacrocycles have a range of activities, such as anti-tumour and 
anti_IDV.160-163 As complexes with transitioQ metals, they are useful as magnetic 
resonance imaging (MRI) contrast agents. They can also act as catalysts and mimics 
of various enzymes including ribonucleases and proteases. In order to understand 
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fully the biological characteristics of the novel polyazamacrocycles and complexes 
produced in this project, it is important to investigate these alternatives for biological 
activity. 
1.5.1. Polyamine analogues 
Polyamines are present in all living systems, playing a key role in the 
replication and proliferation of cells. 164, 165 Introduction of unnatural polyamines 
into the natural pathway can have a therapeutically useful impact on stopping the 
proliferation of cells such as cancer cells, which usually show elevated levels of 
polyamine activity.166 
Four key aspects of polyamines could be exploited in the treatment of 
disease. 167 Firstly, the uptake and transport systems are not highly specific. They 
will transport polyamine analogues with diverse functionality and structure. Indeed, 
it is, possible to 'tag' compounds with polyamines in order to exploit the transport 
system for their uptake. 168 Second, certain tissues have increased levels of 
polyamine transport, including tumours and prostate tissues (as shown by 
radiolabelling studies). They can be targeted with strategies involving unnatural 
polyamine analogues. Third, intracellular polyamines can be depleted with drugs 
such as (+1-) 2-(difluoromethyl)ornithine ~DFMO, 58), further increasing the uptake 
of artificiaily introduced analogues by polyamine-dependent cells. DFMO is 
especially active in tumour cells versus normal cells in vivo. Last, polycationic 
•. 
polyamines such as spermidine (59) and spermine (60) have a high affinity for DNA. 
Drugs based on these structures that are transported by the polyamine system will 
collect in the nucleus, in high local concentrations near DNA. 
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Unnatural polyamine analogues (e.g. with unusual chain lengths or 
substitution) can act in a number of ways: by inhibiting polyamine transport systems 
and preventing uptake of extra-cellular polyamines; by being incorporated into the 
cell via polyamine transport systems and inhibiting the biosynthetic and metabolic 
pathway of polyamines (as does DFMO); and by acting as vectors for cytotoxic and 
imaging agents.167 Polyamines are essential for cell reproduction, so disrupting these 
h
r 
11 d th 169 170 U all . . . pat ways can cause ce ea.' su y It IS necessary to combme drugs with 
complementary effects on the polyamine system to ensure maximum therapeutic 
viability, e.g. depleting cellular polyamine levels with DFMO combined with a 
polyamine transport inhibitor disabling the uptake system, preventing extracellular 
replenishing of polyamine levels. 
Bergeron et ai. showed that even small variations in structure, such as length 
of carbon bridges between nitrogen atoms, h3:ve drastic effects on the. biological 
activity. 169 Polyamine analogues have also shown useful anti-parasitic activity 
against trypanosomes, le.ishmania ~d malaria, as well as anti-fungal activity.171-173 
Polyamine levels and metabolism in these organisms are also susceptible to 
disruption by unnatural substrate analogues. N-Benzyl analogues appear to be 
especially active, perhaps due to their increased lipophilicity. This would imply that 
their uptake is 1'!0t through polyamine transport systems, but instead due to increased 
ability to cross cell membranes.167 N-Aryl substituted polyamines also function well 
as anti-cancer agents, probably by interacting with DNA via both ionic effects and 
hydrophobic intercalation.174 However, if lipophilicity is increased too much the 
compounds lose some of the selectivity of their cytotoxicity. 167 
45 
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N-Substituted polyazamacrocycles have shown a variety of biological 
activities, including anti-tumour (61)160 and anti-malarial (e.g. 62).173 They are also 
used commercially for their anti-microbial and anti-fungal properties. 175 
There is scope for the use of new polyazamacrocycles as polyamine 
analogues. It is of interest to consider the polyamine transport system as a target for 
polyazamacrocyclic drug delivery.168 It is also important to keep in mind the 
possible polyamine analogue activity of polyazamacrocyclic drugs targeted towards 
,. 
other systems, in the light of possible side effects or potentiation of cytotoxicity. 
1.5.2. Catalysts and enzyme mimics 
Metal ions, either alone or complexed to various ligands, are well known as 
catalysts. They are also essential components of many enzyme active sites. 
Complexation with peptides holds the metal in place and nearly always contributes 
to the reactivity of the metal for the desired enzymatic catalysis. Accordingly, small 
molecule metal complexes can act as artificial enzymes. Polyazamacrocycle 
complexes have a range. of catalytic activities. Manganese complexes of cross-
bridged cyclams (e.g. 63) are peroxide oxidation catalysts used in laundry 
.detergents.176 Complexes of tetra- and triazamacrocycles with various meta!s can 
catalyse the hydrolysis of carboxyesters, phosphate esters and peptide bonds. 
63 
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Carboxyesters 
Experimental evidence from Kimura et al. shows zinc to be the best metal ion 
for hydrolysis of carboxyesters by polyazamacrocycle complexes. 177 Zinc 
complexes readily bind water molecules. The nature of the ligand can lower the pKa 
of the bound water, facilitating ionisation at neutral pH. For optimum activity, the 
ligand should have alcohol functionality that can also be deprotonated in order to 
participate in an initial transesterification reaction. This is followed by hydrolysis of 
the newly formed ester (Scheme 1.5.2.1) by the bound hydroxyl ion.178 Dinuclear 
Zn(ll) complexes provide two reactive centres, increasing rate constants by 
approximately 2.4. 179 These complexes provide useful model systems for 
elucidating the mechanism of zinc enzyme-catalysed ester hydrolysis. 177-179 
Scheme 1.5.2.1 
Phosphate esters 
-O-R 
) ~ 
The phosphate esters that make up the DNA and RNA backbones are 
.' incredibly stable to hydrolysis. With half-lives (under physiological conditions) 
estimated at 106 and 103 years, respectively, RNA is relatively less stable'to 
hydrolysis than DNA.180 H~wever, they are both essentially inert to hydrolysis 
within biological systems without the catalysis of nuclease enzymes. The anionic 
charge of the backbone hinders the approach bf nucleophiles, so nuclease enzymes 
often utilise cationic metal centres to neutralise the charge. The complexed metal 
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can also serve to activate water molecules for deprotonation to hydroxide ions, 
facilitating the hydrolysis. 
In order to be useful, a catalyst needs to increase the rate of DNA hydrolysis 
by at least 1014.180 The efficiency of the catalysis is dependent on a number of 
factors, such as the attraction of the catalyst to DNA, the strength of the substrate 
binding and the pKa of the bound water. These properties are all adjusted by 
changing the nature of the active site. Metal complexes of organic ligands are used 
as model systems, allowing for broad variation in the active site components and 
correlation of the behaviour with structure. 
Metal complexes of polyazamacrocycles can have artificial nuclease 
activity,181-18s although so far only limited success has been achieved (increasing 
hydrolysis rates by up to 7 orders of magnitude). Usually a large excess of complex 
relative to DNA substrate is required to effect even minimal cleavage. The 
mecl)anism is similar to that for carboxyester hydrolysis, however the need for large 
'catalyst' excess implies that the cycle may often stop at transesterification. The 
activity is highly dependent on the substitution around the ligand macrocycle and the 
metal involved. Lanthanide complexes of substituted cyclen increase the rate of 
RNA hydrolysis to -0.65 M-Is-I. Peptide and peptide-nucleic acid functionality can 
improve the interaction of the complex . with oligonucleotides. For example, a 
hexapeptide derivatised with two Zn(ll) triazacyclononane complexes lowered the 
pKa of the water bound to zinc to -7.7, which increased the hydrolysis of DNA by 
about 107•180 
These are only the more promising of a wide range of results from 
polyazamacrocycle complex catalysis of phosphate ester hydrolysis. There is still 
.extensive scope for further development in this area, especially given the 
improvement in macrocycle synthesis and substitution methods. Also, Cu(ll) 
complexes usually need to be reductively activated to Cu(I) in order to function in 
~ this way. Thus, it is feasible they could provide another mode of hypoxia selective 
action .. increasing cytotoxicity to tumours w~ile remaining unreactive in normal 
cells. 
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Peptide bonds 
Amides are also very stable to hydrolysis under physiological conditions. 
Peptide linkages normally have half-lives between 500 and 1000 years. Free metal 
ions can catalyse the hydrolysis of amides, but only if the substrate contains a 
proximal metal binding site.186 However, metal complexes are more useful, as they 
usually avoid the problem of metal hydroxide precipitation (which makes 
mechanistic studies difficult). Incorporating substrate binding moieties in the ligand 
can improve the efficiency of amide hydrolysis. 
H 
Nf(NH2 
+NH~ 1 ° 
/ 
-On ~N)lR 
° H 
. too randomly distributed 
for short peptides to reach 
catalytic metal centre 
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The Cu(II) complex of cyclen was randomly attached to polystyrene (64), 
along with guanidinium ions to attract negatively charged protein components 
(e.g. carboxylate groups of aspartate resid~es and C-termini of peptide chains). The 
guanidinium ion made the catalyst a mimic of carboxypeptidase A.187 The polymer-
supported catalyst improved hydrolysis rates by up to 2 X 108 (from normal 
..l 
physiological conditions).188 However, the active site of the catalyst was too large to 
bind small peptides for hydrolysis. The guanidinium ions and the metal complex 
were distributed too widely to bring bound small peptides sufficiently close to the 
1 
catalytic centre. The catalyst was improved by attaching the guanidinium ion 
directly to the metal complexing component of the polymer, in order to ensure 
binding of peptides in close proximity to the active moiety (65). This is the first 
example of a general artificial ~peptidase. 
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A selective artificial peptidase has been prepared by attaching cyclen 
complexes to peptide nucleic acid (PNA) chains. A combinatorial selection strategy 
found PNA sequences that selectively bound myoglobin over bovine serum albumin, 
y-globulin, elongation factor P and gelatins A and B. When the sequences were 
ligated to cyclen complexes, they did selectively cleave myoglobin. The authors 
claim that this provides a paradigm for the design of drugs to cleave specific disease-
related proteins. However, optimisation of catalytic centres and binding sequences 
for those specific proteins would be necessary in order for this to be practiCal. l89, 190 
Artificial peptidases are biochemically and pharmaceutically interesting. 
Very few examples of artificial peptidases based on polyazamacrocyles have been 
published. As yet, work has focused on the use of commercially available 
compounds such as cyclen and tacn. A non-specific, high-turnover artificial catalyst 
to hydrolyse proteins to their component-amino acids for analysis would be very 
useful and S0 far is not forthcoming. Perhaps new macrocycle synthesis strategies 
will allow detailed structure-activity investigations, leading to catalysts that are more 
effective. Very few groups are concentrating work in this area, thus it offers scope 
for extensive development. 
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Chapter 2 
2. Synthesis of parent macrocycles 
2.1. Initial strategy using the mesitylenesulfonyl protecting 
group 
In her PhD project, Fiona Anderson used amines protected with 
p-toluenesulfonyl (tosyl) groups in the Richman-Atkins polyazamacrocycle 
synthesis. 121 Her difficulties in the deprotection step indicated that a different 
protecting group was necessary. . Our initial approach involved the use of 
mesitylenesulfonamides in place of tosylamides (Scheme 2.1.1). The deprotection 
of mesitylenesulfonamides is reported to occur under milder conditions than for 
tosylamides, e.g. stirring at room temperature with conc. HBr/glacial acetic acid.191 
A series of tris-N-(mesitylenesulfonyl) (Mts) triazamacrocycles was prepared via a 
modified Richman-Atkins cyclisation, using the required triamines and diol 
ditosylates. The triamines 66 and 67 were protected under phase transfer conditions 
using triethyl-benzylammonium chloride (TEBACI) according to Scheme 2.1.2 
giving the Mts-amides 68 and 69 in moderate to good yield (41% and 75%, 
respectively). Attempts to cyclise 68 aJways resulted in a complex mixture of 
oligomers. The yields for cyclisation and deprotection of triazamacrocycles using 69 
are listed in Table 2.1.1. For simplicity, macrocysle 'ring size' will be described 
either according to the abbreviations previously listed in this thesis (e.g. 53 = tacn, 
36 = cyclen), or by the convention [nbnl,n3 etc.], where nl etc. indicates the length 
of carbon chain between nitrogens (see 53 and 37 below for examples). 
53 
[2,2,2] 
4 
n 
·CNH.HJN 
3 ~ 3 
. 37 
[3,3,4] 
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Scheme 2.1.1 
Scheme 2.1.2 
A2 
OTs OTs 
66: n = 0 
67: n = 1 
.. 
TEBACI 
NaOH 
Mts Mts 
I I 
NH HN 
• (~~J)n 
R 
68: n =0, R=H 
69: n = 1, R = Mts 
Unfortunately, the deprotection of mesitylenesulfonyl-protected 
triazamacrocycles proved to be just as difficult as for tosylamides. Only one 
compound, the 3,3,3 macrocycle 71, was successfully deprotected under hydrolysis 
conditions to give 73 and then only after 14 days of reflux and 14 days of standing at 
room temperature. Although the yield was good, the unpredictable behaviour and 
still harsh hydrolysis conditions for the deprotection, were undesirable. 
Table 2.1.1 
K2 ~ Mts .. Mts 
'N N"": NH HN . 3HBr (4.:-~J )n, (4;~J)n1 
1 Mts 
n1,n2 ring size cycllsation deprotectlon 
yield (%) yield (%) 
1,0 [3,3,2] 70:'8 nfa 
1,1 [3,3,3] 71: 15 73:84 
1,2 [3,3,4] '72:39 n/a 
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A route was necessary that would provide reliable synthesis of a range of 
polyazamacrocycles. The route also needed to be flexible enough to accommodate 
various types of functionality within the ring. It was clear that it was crucial to find a 
protecting group that could be removed dependably and under milder conditions. It 
was also desirable to stay within the Richman-Atkins-type cyclisation of 
sulfonamides, as it offered the required flexibility in ring size construction. 
2.2. Alternative protecting group strategies 
A number of alternative sulfonamide protecting groups were available. The 
2- and 4-nitrobenzenesulfonyl (nosyl, 74) and (2-trimethylsilyl)ethanesulfonyl (SES, 
75) protecting groups have been used for the synthesis of polyazamacrocycles. Both 
were attractive: the nosyl group was reported to give good yields for the cyclisation 
and mild deprotection could be carried out using a thiol; 152, 153 and the SES group 
provided high yields in the cyclisation and mild deprotection was accomplished 
using fluoride. 151, 192 
QQ, 
0=8=0 
I 
'V\IV" 
74 75 
Initially both groups were investigated; ho\\,)ever the use of the nosyl group 
proved to be more difficult than expected. Preliminary attempts at the protection of 
triamines with 2- or 4-nitrobenzenesulfonyl chloride under phase transfer conditions 
. " 
using TEBACI (Scheme 2.2.1) were complicated by the low solubility of the 
N:N"'-bis-nosylated material in diethyl ether and the steric hindrance at the 
"secondary amine. This was particularly a problem in the protection of 
diethylenetriamine (66). 
, . 
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Scheme 2.2.1 
N02 (}1 Y+ 
0==8==0 
I 
CI 66: n = 0 
67: n = 1 
TEBACI 
NaOH 
.. NS'N~N~N .. NS 
H n I n H 
Ns 
76: n = 0 
77: n = 1 
Following the initial protection of the primary amine functionality, some of 
the bis-protected material precipitated from solution. This resulted in a mixture of 
bis- and tris-protected triamines that was difficult to separate and gave low yields of 
the desired tris-nosylated triamine. This primary amine selectivity has been reported 
previously and with the right conditions can provide an advantage for orthogonal 
protection.193 However, this did not suit the purposes of our project. Changing the 
solvent to dichloromethane or N,N-dimethylformamide reduced the precipitation, but 
still gave a mixture of products. Column chromatography could be used to achieve 
-90% purity but the yield was unsatisfactory (29%). 
Scheme 2.2.2 
NS'N~N~N .. NS 
H n I n H Ns 
DMF 
NS,(),NS 
(C~J\ 
Ns 
.. 
78: n = 0, m = 2; >95% crude yield 
79: n", = 1, m = 0; 94% crude yield 
Additionally, the cyclisation and deprotection of nosyl-amides was not 
straightforward. The cyclisation of two nosylated triamines was attempted with 
moderate success, giving the products 78 and 79 (Scheme 2.2.2). The crude 
.. macrocyclic sulfonamides were not purified, as TLC and IH NMR spectra s~owed 
complex mixtures although they contained mostly the desired material. Attempts to 
deprotect the compounds w~re unsuccessful. The deprotection of nosylamides is 
reported to occur as in Scheme 2.2.3.194 The product then needs to be separated 
from ~l1e byproducts either by chromatography or by aqueous extraction. 
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Scheme 2.2.3 
. . ,..... .. 
- ·0· l,fO 
• ....N-::. • . .
~ .~~SR' 
:0==5==0. . 
• I • 
N 
R" 'R 
- :O~N~O: 
. . Q • 
SR' 
A one-pot cyclisationldeprotection strategy for nosylated polyazamacrocyc1es 
has been previously reported. However the primary advantage lay in the synthesis of 
polyaza[n]naphthalenophanes and polyaza[n]anthracenophanes, e.g. 80 and 81.152 
n((r;NH 
d~ 
l$NH 
n 
80 
n(ICNH 
a\~ ~ 7f // 
(~NH 
n 
81 
The purification of the deprotected material was not described in detail, but it is 
likely that the increased hydrophobicity of the cyc10phanes allowed them to be 
purified by column chromatography or by extraction from aqueous solution. This 
, was not possible with the highly water-soluble alkyl triazamacrocycles. Thus it was 
difficult to separate the free amines from the byproducts of the deprotection. 3-
Mercaptopropionic acid (82) was used as the thiol, in the hope that the carboxylic 
acid byproduct 83 could, be separated from the triazamacrocyc1es using acidlbase 
extraction techniques. It was possible to precipitate the bulk of 83 upon acidification 
of the solution. However, it was too difficult to separate the desired material from 
- . 
the resulting crude mixture. During this time the SES-protecting group was showing 
promise, so the 110syl route was abandoned. 
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The method of Hoye et al. 151 was used for the synthesis, cyc1isation and 
deprotection of SES-amides according to Scheme 2.2.4. 2-(Trimethylsilyl)-
ethane sulfonyl chloride (SES-CI, 85) is not commercially available, so it was 
synthesised according to the procedure -of Weinreb et al. from the corresponding 
sulfonate salt 84 (either purchased from Aldrich or synthesised from 
vinyltrimethylsilane) as in Scheme 2.3.1.195 
Scheme 2.2.4 
o RI 
\ II -SI'~~'C' + H N/'I... .ANi.... ...v""-.NH 2 \~/nl \~/n2 2 / 0 .. 
~s I CS2C03 
r 1 DMF 
OTs OTs r.t. 
.. ,k-,)...,ns 
r - -1 CsF 
CN~HJN • DMF ( N ) 100°C n nl 2 
2.3. Synthesis of (2-trlmethylsilyl)ethanesulfonyl chloride 
The formation of the sulfonyl chlpride (Scheme 2.3.1) was variable. The 
first attempt, gave a high yield of pure material, but subsequent attempts resulted in 
low conversion arid significant amounts of anhydri~,e byproduct 86 (as observed by 
1H and 13C NMR spectroscopy). The conditions were kept under strict c'ontrol: the 
sulfonate salt was thoroughly dried before use; glassware was oven-dried and argon-
cooled; and the thionyl chloride (SOCh) was predistilled. However, after mUltiple 
attempts the yield of 85 was consistently lower than 30%. 
Scheme 2.3.1 
NaHSO; 
.. ~SI/ PhC03t-!3u 
, ............ MaOH/H20 cat. DMF 
84 ' 
e'~lt 
85 86 
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The variation of factors such as dryness of 84, brand of SOCh used and 
length of reaction time had no consistent effect on yield. Over the course of 30-40 
repetitions the only recognisable differences were obtained by ensuring efficient 
dispersion of 84 during the addition of SOCh (by crushing 84 to a fine powder 
before use and using twice the amount of SOCh). However, even that provided only 
a marginal increase in reliability of the reaction. The resulting mixture of 85 and 86 
required separation by distillation. Even under high vacuum the heat necessary for 
the distillation caused significant decomposition of 85 to 86 and HC!. Finally it was 
found that increasing the amount of DMF from 0.04 eq. to 0.4 eq. ensured the 
production of 85 exclusively. It was then possible to produce pure 85 consistently in 
high yield (70-86% overall from vinyltrimethylsilane) without the need for 
distillation. Representative IH NMR spectra are shown in Figs. 2A and 2B to 
illustrate the purity achieved with 0.4 eq. DMF (2A), compared with the crude 
material when only 0.04 eq. DMF was used (2B). 
2.4,. SES-triamines 
Practical difficulties were also encountered in the protection of the 
commercially available triamines (Scheme 2.2.4). Again, yields and purities were 
inconsistent even after repetitions of the same reaction. Reaction times of less than 
16 hours resulted in lower yields. Reactio.n temperatures above 5-10 °c resulted in a 
brown odor~)Us byproduct and reduced yield. The best yields were obtained by 
adding the SES-CI sufficiently slowly to keep ,~e temperature below 10°C; 
monitoring the temperature of the reaction with an internal thermometer; and using 
an immersion cooler to keep the reaction below 5 °c while stirring overnight. The 
compounds 87·89 were obtained in 46, 71 and 87% yield, respectively. 
SES .... N~N~N ... SES 
H "1 SES "2 H 
87: n1,2 = 0 
88: n1,2 = 1 
89: n1 = 1; n2 = 2 
In some cases, triamines with the desired carbon bridge lengths were not 
commercially available. For access to macrocycles with these bridge lengths, a route 
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was developed from primary sulfonamides and the corresponding haloalkanenitriles 
to give the bisalkanenitrile sulfonamides. The nitriles could be reduced to the 
primary amines and subsequently protected as sulfonamides for cyclisation to 
macrocycles. The initial strategy used nosylsulfonamide 90 (Scheme 2.4.1). The 
alkylation of the sulfonamide and reduction of the resulting bis-alkanenitrile to the 
diamine were straightforward, giving the products 91 and 92 in 67 and 78% yields, 
respectively. However, the nosyl group rendered the diamine 92 difficult to purify 
and it was not possible to separate the byproduct of nosyl deprotection 83 (as 
described by Scheme 2.2.3) from the desired triamine 93. 
Scheme 2.4.1 
+ Br~N • 
90 
j BHaTHF THF . 
HN~NH2"'·_~_M_PA_F __ NS2'~NH2 
93 NH2) 92 NH2 83 
'---------y 
inseparable 
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Fig. 2A. SES-CI (crude) when 0.4 eq. DMF was used 
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Fig. 2B. Mixture of SES-CI and SES-anhydride when 0.04 eq. DMF was used 
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With ease of deprotection in mind, the protecting group was changed to SES 
(Scheme 2.4.2). 94 was obtained in good yield from SES-CI and gaseous ammonia 
(generated by warming stirred conc. aqueous NH3). 
Scheme 2.4.2 
94 n = 1-3 
95: n = 1 
96: n = 2 
97: n = 3 
DMF 
BH3THF 
.. 
THF 
98: n = 1 
99: n = 2 
100: n = 3 
The mono-N-SES-triamines 98·100 were acquired in good overall yield 
( .... 70% from 94) with little or no purification required. The selective protection of 
f' 
the secondary amine provides the opportunity for orthogonal protection of the 
subsequent triazamacrocycles. Also, the SES group can be removed in good yield 
(to achieve 50-60% yield overall from 94), offering better yields than previously 
published for the synthesis of the biologically interesting 
triamines 101.103.191.196.197 Yields for building triamines are given in Table 2.4.1 . 
. 
The mono-N-SES-triamines 98·100 were also tris-protected to give the tris-SES-
triamines 104.106, which were cyclised as in Scheme 2.2.4. 
Table 2.4.1 
n 
l' 
2 
3 
R=CN 
95: 96% 
96: 76% 
97: 73% 
H2N~~~NH2 
101: n = 0 
102: n = 1 
103: n = 2 
R = CHaNHa deprotected trlamine 
98: 96% 101: 84% 
99: 95% 102: 84% 
100: 97% 103: 46% 
over three 
steps 
77% 
61% 
32% 
Trls-SES-
trlamlne 
104: 52% 
105: 62% 
106: 65% 
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2.5. Cyclisation and deprotection 
Scheme 2.5.1 
TsCI + K pyridine • OH OH K OTs OTs 
107: n = 0 
108: n = 1 
109: n = 2 
110: n = 3 
Ditosylate formation (Scheme 2.5.1) was straightforward and high-yielding. 
The cyclisation (Scheme 2.2.4) generally proceeded smoothly at room temperature. 
The reaction could be monitored for disappearance of ditosylate by TLC of 
evaporated aliquots. Little or no oligomerization was observed for the larger ring 
sizes (e.g. n > 0) and the macrocyclic sulfonamides 111-121 could usually be 
purified by crystallisation from MeOH or 2-PrOH. The only combination of 
r, 
sulfonamide and ditosylate to produce significant quantities of oligomer was 87 and 
109, which gave the dimer 122. The production of 122 was concentration dependent 
and could be minimised by increasing the dilution (from 0.08 M to 0.03 M 
sulfonamide/ditosylate in DMF). The dimerisation was not immediately recognised, 
as the two compounds co-eluted during column chromatography and the mixture 
gives a IH NMR spectrum that can be rationalised as representing the triaza-[2,2,4] 
compound '112 (Fig. 2C). The dimer was eventually identified from mass 
spectrometry and analytically pure material was obtained from multiple columns. 
The spectroscopic identification of these two compounds is illustrated in Figs. 2D, 
2E and 2F. Yields for cyclisation and deprotection are given in Table 2.5.1. 
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Table 2.5.1 
~3 ~n3 
SES'N N"SES CsF (?) (C~J )" • DMF 100°C ( N )n 1 SES n1 2 
n1, n2, n3 ring size cyclisation yield (%) deprotection yield (%) 
0,0,1 [2,2,3] 111: 53 123:55 
0,0,2 [2,2,4] 112:29 124: 521 
1,1,0 [3,3,2] 113:45 125: 442 
1,1,1 [3,3,3] 114:48 126:58 
1,1,2 [3,3,4] 115: 64 37: 392 
1,1,3 [3,3,5] 116:54 127:622 
2,2,1 [4,4,3] 117: 41 128: 332 
1,2,3 [3,4,5] 118:47 129: 342 
2,2,2 [4,4,4] 119: 29 130: 672 
3,3,2 [5,5,4] 120:29 131: 332 
r 4,4,2 [6,6,4] 121:21 132: 31 2 
(0,0,2)2 [2,2,4]2 122:51 133: 282 
hexaaza 
1 deprotected using TBAFj reported as apparent yield after distillation relative to 
TBAOH (deduced from 1H NMR spectroscopy) 
2 purified by Kugelrohr distillation 
The deprotection of SES-amides proceeded according to Scheme 2.5.2,192 
using caesi~m fluoride. Although IH and l3e NMR spectra of aliquots showed when 
.) 
the material was fully deprotected and there was no significant amount of byproduct, 
only relatively low yields of deprotected material were isolated. No water was used 
in the workup, which might have reduced recovery of the highly water-soluble 
amines and the parent macrocycles are not volatile under normal solvent evaporation 
.. pressures. Some possible reasons for this lower yield are discussed in the next 
section. 
Scheme 2.5.2 
.. 
Si(Me)gF 
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Fig. 2C. Crude SES-[2,2,4] (112 and 122) 
iii iii Iii iii i iii iii Iii iii iii iii iii Iii 
J~5 J.O 2.5 2.0 1.5 1.0 0.5 ppm 
l~(l5( I~I ~~( 
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Fig. 20. 1H NMR spectra of 122 (top) and 112 (bottom) 
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Fig.2E. 13C NMR spectra of 122 (top) and 112 (bottom) 
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Flg.2F. Mass spectra of 122 (top) and 112 (bottom) 
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2.6. Purification of parent macrocycles 
Most of the free triazamacrocycles were purified by Kugelrohr distillation. 
The compounds that were not distilled were produced during an earlier stage of the 
project and time did not allow their syntheses to be repeated. Consequently, only the 
distilled macrocyc1es were successfully converted into mustard drugs. Their high 
purity facilitated this process. Previous work in the group had encountered 
difficulties with the purities of the parent macrocyc1es. The purity can be judged 
from the definition of the peaks in the IH NMR spectra, which are broad and less 
distinguishable from each other in the crude material (Fig. 2G). Upon Kugelrohr 
distillation, some pure amine was obtained as a clear oil, but a significant amount of 
yellow oil remained in the original flask. It was not possible to distill this material 
even at temperatures exceeding 250°C and pressures below 0.1 mmHg. IH NMR 
spectroscopy of the yellow material showed it contained mostly the macrocyclic 
amine. However, slight chemical shift changes indicated that the free amine may 
have complexed to residual Cs+ ions (Fig. 2H). Small macrocyclic heterocycles are 
known to chelate to alkali metal ions, e.g. 18-crown-6 forms a strong complex with 
K+. Also, a 'perfect fit' between ion size and macrocycle cavity is not necessary for 
complexation to occur. 198 Attempts to free the parent amine using EDTA, or 
forming the HCI salt, were not successful. 
2.7. Alternative fluoride sources 
To circumvent the problem of metal ion chelation, alternative fluoride 
sources were investigated. Althoug~ tetraalkylammonium fluorides will successfully 
.. , 
remove the SES-groups, their byproducts are very difficult to remove from the 
desired amines. Separation by Kugelrohr distillation was repeatedly unsuccessful. 
.. The tetraalkylammonium compounds distilled together with the product. Although 
they should decompose to their corresponding triamines with heat, this was not seen 
in practice. -Other fluoride sources were u!lsuccessful at deprotecting the 
sulfonamides. The results are given in Table 2.7.1. The success of the deprotection 
was "assessed by IH NMR spectroscopy af evaporated aliquots, looking for 
disappearance of peaks corresponding to the SES group. 
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Table 2.7.1 
fluoride solvent conditions result 
deprotected, but 
TBAF THF reflux byproducts wouldn't 
separate 
100°C 
deprotected, but 
TBAF on alumina DMF byproducts wouldn't 
separate 
tetraethylammonium 100°C 
deprotected, but 
DMF byproducts wouldn't fluoride (TEAF) 
separate 
incomplete 
tetramethylammonium DMF 100°C deprotection, fluoride (TMAF) byproducts difficult to 
separate 
polymer-supported 10-20 eq. THF reflux no reaction fluoride (Aldrich) 3 days 
polymer-supported 10-20 eq. DMF 100°C no reaction fluoride (Aldrich) 5 days 
<, 
ammonium difluoride DMSO-d6 100°C no reaction 
ammonium fluoride DMF Overnight 100°C no reaction 
Microwave 
ammonium fluoride DMF 110°C no reaction 
15min 
some deprotection, 
KF/18-crown-6 DMF 10 eq .. , but no product 100°C isolated from 
residual 18-crown-6 
sonication 
HF/pyridine DMF' 35°C no reaction 
overnight 
Sonication 
.' 40% aq. HF DMF 35°C no reaction 
overnight 
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Fig. 2G. 1H NMR spectra of distilled (top) and crude (bottom) 37. 
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2.8. Synthesis of triazacyclophanes 
As a secondary synthetic goal, it was desirable to demonstrate the utility of the 
SES-group for synthesising macrocycles with sensitive functionality. CYclophanes 
(e.g. general structure 134) were good candidates for this, since their benzyl linkages 
are more susceptible to hydrolysis under the harsh conditions usually employed in 
the Richman-Atkins synthesis. Indeed, Hoye et al. 151 showed that the SES 
deprotection was mild enough for the synthesis of the (naphthaleno )phanes 135 and 
80 and the (anthraceno)phanes 136 and 81. 
134 
n(/tNH 
cl~ If (~NH 
n 
135: n = 0 
80: n = 1 
n(ICNH 
a~\~ ~ 7f ~ 
(~NH 
n 
136: n = 0 
81: n = 1 
MacrocYcles with anthraquinone (137) and quinoline (138) linkers were chosen 
as targets, as their cyclophanes have not been reported previously. The naphthalene 
linker was also chosen. All three of ~ese groups have previously exhibited the 
ability to intercalate with DNA.199 Mustards with intercalation ability show 
enhanced cytotoxicity,200 and the addition of aromatic functionality within the ring 
,) 
would increase the lipophilicity of the resulting macrocycles. 
o 
137 
\ 
i 
138 
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Scheme 2.8.1 
NBS 
139 140 
Neither the bis(bromomethyl) nor the bis(hydroxymethyl) derivatives of 
naphthalene, anthraquinone and quinoline are commercially available. It was 
therefore necessary to synthesise the bis(bromomethyl) compounds from their 
dimethyl derivatives with N-bromosuccinimide in CC4.201 The regiochemistry of 
the bromomethyl groups was restricted to the corresponding commercially available 
dimethyl compounds. l,4-Bis(bromomethyl)naphthalene 140 was prepared in 53% 
yield and purified by crystallisation from MeCNlhexane (Scheme 2.8.1). Similarly, 
2,3-dimethylanthraquinone 141 was reacted to give 142 in 37% yield and was 
purified by recrystallisation from ethanol (Scheme 2.8.2). 
( 
Scheme 2.8.2 
0 
NBS 
.. Br 
CCI4 Br 
hv 
0 0 
.' 141 142 
Attempts to form the 2,7 -bis(bromomethyl)quinoline in this way were 
unsuccessful due to over-bromination on the aromatic ring, even when only two 
equivalents of NBS were used. The resulting mixture did not contain a significant 
amount of the desired material and it could not be separated by column 
.. chromatography. Also unfortunately, the preliminary attempt at cyclisation of 
2,3-bis(bromomethyl)anthraquinone with tris-SES-spermidine was unsuccessful. It 
produced a complex mixture "that could not be separated by column chromatography. 
Similar halide substitution reactions with this compound are known,202.203 so it may 
still be possible to synthesise the macrocycle. . 
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The bis(bromomethyl)naphthalene compounds were cyclised with tris-SES-
spermidine according to Scheme 2.8.3 [the 1,8-bis(bromomethyl)naphthalene was 
formerly available from Aldrich but has since been discontinued]. 
Scheme 2.8.3 
5 4 rBr 
X= 6~~3 7~vJ2 
a 1 LBr 
140: 1 ,4-substituted 
143: 1 ,a-substituted 
H 
SES'N~N~N'SES 
H SES 
89 
• DMF 
144: X = (1,4-naphth) 
145: X = (1 ,a-naphth) 
As would be expected, the yield for the cyclisation of the sterically-hindered 
([1,8]naphthaleno)phane 145 was relatively low at only 18%. The deprotection 
proceeded in variable but sufficient yield (146 [1,4] and 147 [1,8], respectively, 25% 
and 93%). However the compounds decompose upon distillation so they cannot be 
purified in the same way as the alkyltriazamacrocycles. 
The synthesis of the (naphthaleno)phanes only marginally improves the 
demonstration of utility of the SES-group (with respect to the article by Hoye et 
al. ISI ). It is likely, however, that farther optimisation of the synthesis of additional 
bis(bromomethyl) aromatic compounds and also of the cyclisation of SES-amides 
., with sensitive linkers is possible. Unfortunately, this strategy was taken up near the 
end of the project and it was not possible to carry it on. 
2.9. Alternative routes to polyazamacrocycles 
The use of SES-protecting groups in the modified Richman-Atkins synthesis of 
polyazamacrocycles is flexible 'and allows access to a range of compounds for drug 
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discovery. However, it is not very convenient or cost-efficient. Carbon-template 
methods were investigated in the interest of finding more efficient routes to 
polyazamacrocycles. The primary targets were the tetraazamacrocycles that were 
less efficiently obtained using the SES route. Unfortunately, not all of these attempts 
met with success. 
Scheme 2.9.1 
K n (l (:l Br Br (:l i. HCI (aq) (l K2C03 EtOH 
CNH HNj c:t) MeOH c:t) ii. NaOH (HHN) .. .. II NH2 NH2 MeCN NH HN 
H H L....J LJ 
148 149 150 151 
As described in section 1.4.1 of this thesis, the [2,2,2,3] tetraazamacrocycle 151 
was synthesised from the aminal-templated linear tetraamine 149 (Scheme 2.9.1). 
The yields were not as high as reported in the literature (only 12% overall yield of 
r' 
the free base as opposed to 77% reported for the HCI salt148) but they were sufficient 
to provide a useful amount of parent macrocycle for the synthesis of the nitrogen 
mustard derivatives. The low yield was probably due to low purity of the 
1,4-butanedione-it may be necessary to distill it before use. 
Cyclen (36) was prepared in only 8% overall yield from 153 (Scheme 2.9.3) 
according to the bis-imidazoline diamino-carbene method (Scheme 1.4.1.10, section 
1.4.1).149 Again, the yields were not as good as published (52% overall from 
triethylenetetraamine) but a sufficient amount of material was produced so the route 
was not optimised. It was desirable to apply this short method to the synthesis of 
cyclam and other tetraazamacrocycles from cheap starting amines, 
e.g. bis(3-aminopropyl)ethane-l,2-diamine (Scheme 2.9.3). Accordingly, 153 and 
two bis-tetrahydropyrimidines (154 and 155) were synthesised by condensing the 
tetraamines with N,N-dimeth:ylformamide dimethyl acetal (152). Their cyclisation to 
tricyclic bromide salts (and subsequent hydrolysis' to the free macrocycles 156-158) 
was ~ttempted. IH and l3C NMR spectroscopy of the intermediates, thought to be 
the crude bromide salts, looked promising. However, only the starting tetraamine 
was obtained after hydrolysis, with just trace amounts. of the macrocycles produced 
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at best. It was possible that the diaminocarbene insertion was taking place, but that 
the conformations were unfavourable for the formation of the fourth ring. This route 
was not pursued further. 
Scheme 2.9.3 
2.10. Conclusions 
153: n1,3 = 0, n2 = 1 
154: n1.3 = 1 
155: n1,3 = 1, n2 = 2 
rN~:~ 
1--+N,H I IiNf.1 
"1"-t-1 "3 
"4 
156: n1,3 = 0; n2 = 1; n4 = 2 
157: n1.4 = 1 
158: n 1.3 = 1 ; n4 = 2 
Four key synthetic observations are reported in this work. First, we have 
found that the synthesis of SES-chloride is greatly simplified by using ten times as 
much DMF catalyst as reported in the literature;! resulting in higher yields, and 
virtually no purification is required. Second, the scale up of macrocycle synthesis 
using SES-amides is ~ot as simple as it appears in the previous publication. 
However, it can be used to produce a range of triazamacrocycles, including four 
novel compounds, for derivatisation and testing as N-mustard analogues. . Third, 
although CsF causes problems for the purification and yield of the triazamacrocycles 
synthesised, it i~ the best reagent found so far for their deprotection and the products 
can be effectively purified using Kugelrohr distillation. Finally, linear triamines can 
also be built from SES-amides in high yield with little purification necessary. All of 
these results provide practical improvements on what has been reported in the 
literature. They also offered access to the series of compounds desired initially for 
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comparison of the cross-linking efficiency of macrocyclic N-mustards with different 
carbon bridge lengths. The successful synthesis of linear triamines and the range of 
novel triazamacrocycles described here, including the improved synthesis of SES-
chloride, has been accepted for publication.204 
n 
Chapter 3 
3. Synthesis of polyazamacrocyclic nitrogen 
mustard derivatives 
Initially, the formation of the mustard derivatives proved problematic for 
some of the triazamacrocycles, especially for compounds with unsymmetrical carbon 
bridge lengths. Attempts at hydroxyethylation in water and ethanol with excess 
ethylene oxide (as used previously in the groUp)121 resulted in polymerisation of the 
material to give poly(ethyleneglycol)-substituted amines. Using less than a large 
excess of ethylene oxide gave mixtures of material that was not fully alkylated. Two 
alternative routes to N-(2-chloroethyl) derivatives were investigated, but were not 
successful. During this investigation, the ethylene oxide alkylation was optimised. 
3.1. Unsuccessful 
chloroacetamides 
routes: 
3.1.1. Reductive alkylation 
reductive alkylation; 
Using 1,4,7-triazacyclononane (tacn, 53) as a model triazamacrocycle, a one-
step reductive alkylation process was investigated for the synthesis of 
poly-N-(2-chloroethyl) derivatives (Scheme 3.1.l.1). This type of reductive 
alkylation has been reported before with linear amines, using NaCNBHlo5 and 
Na(OAchBH2o6 as red\~dng agen~s. The reaction was carried out using each 
borohydride. Using an excess of NaCNBH3 as the reducing agent in methanoVaq. 
Hel at pH 6 for four days resulted in a mixture of products, as shown by TLC ~nd IH 
NMR spectroscopy. Although this mixture did appear to contain some of the desired 
tri-substituted p~oduct 159, too many amine impurities were present for purification 
via conversion into an acid salt. The material was too sensitive to aziridinium ion 
formation and hydrolysis to purify by column chromatography. 
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Scheme 3.1.1.1 
53 
o 
~CI 
a) NaCNBH3 
or 
b) Na(OAc)sBH 
---------------~ 
a) MeOH, pH 6 
or 
b) AcOH 
159 
Using Na(OAc)3BH in acetic acid also appeared to give some of the desired 
product. After 2.75 hours, IH NMR spectroscopy showed that most of the tacn was 
unreacted, but mono-, di- and tri-substituted material were also present. Repeating 
the reaction and monitoring it by TLC showed that the reaction was still incomplete 
after three days, but beyond that time side reactions took place that resulted in a 
complex mixture of products. IH NMR spectroscopy of the mixture showed it did 
not contain a significant amount of the desired material. 
Given the protonation behaviour of triazamacrocycles such as 53,207 it is 
probable in solutions of pH 4-6 (as in the above reactions), that the macrocycle is not 
fully protonated. This could allow the formation of aziridinium ions, resulting in 
alkylation of residual amines from starting material that was not fully reacted. The 
observation that the material initially ~oes react to some degree, but over time 
produces a complex mixture of similar compounds supports this hypothesis. Given 
the relative simplicity of other routes, the reductive alkylation strategy was 
abandoned. 
3.1.2. Chloroacetamides 
Parker et al. reported the synthesis of N-(2-chloroethyl) macrocycles via 
acylation to their chloroacetamide intermediates.208 Three of the triazamacrocycles 
(126, 37 and_ 127) were acylated with chloroacetyl chloride to give the 
chloroacetamides (Scheme 3.1.2.1), which Could be purified by column 
chron;:mtography. Parker et ai. used BH3.S(Me)2 to reduce the chloroacetamides.208 
Use of BH3.THF gave a mixture of products, some of which appeared to be over-
reduced to the N-ethyl derivatives. None of the desired N-(2-chloroethyl) material 
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could be isolated from the mixture. During this time, the ethylene oxide alkylation 
procedure was optimised so this route was also abandoned. 
Scheme 3.1.2.1 
o 
CI~CI 
126: n1,n2,n3 = 1 ([3,3,3]) 
37: n1 = 2, n2,n3 = 1 ([3,3,4]) 
127: n1 = 3, n2 = 2, n3 = 1 ([3,4,5]) 
TEA 
OCM 
.. 
o ~10 
CI0~\ '~~CI 
J~~J)n2 
CI 
160: [3,3,3] 
161: [3,3,4] 
162: [3,3,5] 
: BH3'THF 
I 
t THF 
CI~~1~CI 
N N nJC~J)n2 
CI 
3.2. Poly-N-(2-hydroxyethyl) derivatives 
The parent macrocyc1es were converted into their poly-N-(2-hydroxyethyl) 
derivatives .using ethylene oxide.209 The optimum reaction conditions were found to 
be stirring in ethanol overnight at less than 10°C,; with a large excess of ethylene 
. -' 
oxide (Scheme 3.2.1). Details of compounds 163·183 and yields are given in Table 
3.3.1. In this way, most of the triazamacrocycles could be successfully tri-
substituted (examples of spectroscopic identification for 170 are given in Figs. 3A 
and 3D). The [3,3,4] and [3,3,5] macrocyc1es 37 and 127 proved to be particularly 
.. difficult to alkylate at all three nitrogens. However, the products of various degrees 
of alkylation could be separated by Kugelrohr distillation. In one case, the 
symmetrically eli-substituted' derivative of the [3,~,5] compound (167) was isolated 
in high purity from the distillations. It was converted into its mustard derivative and 
included in the testing to compare the effects of di-substituted vs. tri-substituted 
macrocyclic mustards. The [2,2,2,3] tetraazamacrocycle was also synthesised as 
80 
detailed in Section 2.9 and converted into its hydroxyethyl derivative (184) in 85% 
yield. 
Fig.3A. FAB Mass spectrum of 170 
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3.3. Macrocyclic nitrogen mustard derivatives 
The mustard derivatives were formed by heating the poly-N-(2-hydroxyethyl) 
compounds in thionyl chloride overnight (Scheme 3.3.1).210 The material was 
usually isolated without the need for purification, but could be precipitated from 
methanol with diethyl ether if necessary. The peaks in the IH and 13C NMR spectra 
for these hydrochloride salts were usually broad and sometimes unclear, but the 
evidence for the presence of each compound could be obtained by mass 
spectrometry. An example of the characterisation using IH NMR and mass 
spectrometry (for bis-substituted mustard 177) is given in Fig. 3C. Compound 
details and yields are given in Table 3.3.1. 
The macrocyclic nitrogen mustards were tested for their ability to cross-link 
DNA and for their cytotoxicity against the human chronic myeloid leukaemia cell 
line K562.. The biological test procedures are discussed in Chapter 5. One 
additional tetraazamacrocyclic mustard was latet,l prepared (185) in quantitative 
yield, but was not included in the first round of testing. 
184: X=OH 
185: X = CI (2HCI salt) 
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Scheme 3.3.1 
Table 3.3.1 
X'lJ~-~fX 
N N 163-173: X = OH ~(c~)~ 174-183: X = CI (HCI salt) 
X 
n1, n2, n3 ring size yield X= OH yield X= CI (%) (%) 
0,0,0 [2,2,2] 163:85 174:99 
0,1,1 [2,3,3] 164:85 nla 
1,1,1 [3,3,3] 165:88 175:61 
1,1,2 [3,3,4] 166:44 176:89 
1,1,3 [3,3,5] (bis) 167: 13 (bis) 177: 99 
1,1,3 [3,3,5] . (tris) 168: 57 (tris) 178: 93 
1,2,2 [3,4,4] 169:68 179:85 
1,2,3 [3,4,5] 170:96 180:99 
3,3,1 [5,5,4] 171:99 181:99 
4,4,1 [6,6,4] 172:99 182:99 
2(1,1,2) ,. [2,2,4,2,2,4] 173:74 183:83 
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Fig.3C. Characterisation ot bis-substituted [3,3,5] mustard 177. 1H NMR spectrum 
(top) and FAB mass spectrum (bottom) 
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Chapter 4 
4. Coordination chemistry 
polyazamacrocycles 
4.1. Synthesis of metal complexes 
Scheme 4.1.1 
38: n = 0 
185: n = 1 
.. 
of 
186: n = 0 
187: n = 1 
novel 
+ 
CI 
+2HCI 
The formation of metal complexes of the poly-N-(2-chloroethyl) ligands was 
not always simple, because the typical way to complex an azamacrocycle (from its 
halide salt) with a metal is to neutralise the salt first then add a solution of a desired 
metal salt.93-96 The neutralisation of the mustard ligands is complicated by how 
easily they can be hydrolysed in water .. At neutral or basic pH, aziridinium ion 
formation and hydrolysis of the 2-chloroethyl functionality causes decomposition of 
the ligand. Fortunately, the Cu(lI) complexes of 3~ and 185 (186 and 187) could be 
formed from their hydrochloride salts (Scheme 4.1.1) and precipitated in acceptable 
yield from the resulting solution. Yields are given in Table 4.1.1 (eight pages on). 
186 was crystallised as its tetrafluoroborate salt and analysed by X-ray 
,. crystallography. All X-ray crystallography was performed by Louis Farrugia'in this 
department. The crystal structure is illustrated in Fig. 4A. The complex exhibits 
bowl-shaped conformation ·and the geometry around the Cu(lI) ion is square-
pyramidal with the Cu(U) sitting well out of the plane of the four coordinating 
nitrogen atoms. 
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Fig.4A. X-ray crystal structure of 186. 
C13 
Bond I~ngths Bond angles 
(A) (0) 
Cu1-N1 2.099 N1-Cu1-N4 85.11 
Cu1-N4 2.060 N1-Cu1-N7 146.0 
Cu1-N7 2.062 N4-Cu1-N7 86.51 
Cu1-N10 2.065 N4-Cu1-N10 148.95 
Cu1-CIS 2.361 (8) N7-Cu1-N10 87.03 
N10-Cu1-N1 85.33 
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Fig.4B. Crystal structure of 187. 
Bond I~ngths Bond angles 
(A) (0) 
Cu1-N1 2.077 N1-Cu1-N4 84.87 
Cu1-N4 2.097 N1-Cu1-N7 162.25 
Cu1-N7 2.126 t-J4-Cu1-N7 84.96 
Cu1-N11 2.116 N4-Cu1-N11 149.2 
Cu1-C11 2.406(3) N7-Cu1-N11 95.27 
N11-Cu1-N1 86.14 
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The complex of homocyclen N-mustard [2,2,2,3] (187) was crystallised as its 
hexafluorophosphate salt. The crystal structure and important bond lengths and 
angles are given in Fig. 4B. The Cu(ll) ion adopts a similar geometry to that for 186 
(square pyramidal), however this complex has Z- (or saddle-) shaped conformation. 
Unfortunately, easy complexation from the acid salt was not the case for 
ligands 40, 174 or 175. Initial attempts to complex the hydrochloride salt of 40 with 
Cu(ll) without neutralisation resulted in no complex formation. Neutralising the salt 
with either 1 M NaOH or triethylamine resulted in swift hydrolytic decomposition 
and complexation of the resulting 2-hydroxyethyl compound 188 (as indicated by the 
crystal structure shown in Fig. 4C and UV-Vis spectroscopic analysis). 
CI~n~CI 
C )'2HCI 
N N CI/'JV~CI 
40 
CI lNr\N~CI 
(,NJ '3HCI ( 
CI 
174 
The Amax of the tetra-N-(2-hydroxyethyl) compound 188 is significantly 
higher than that for the tetra-N-(2-chloroethyl) complex 190. This allowed the 
identification of 188 (using UV-Vis spectroscopy) as the primary complex in the 
solution from which it crystallised. This was supported by X-ray crystallographic 
analysis. The crystal structure shows that the 2-cl))oroethyl substituents have been 
hydrolysed to 2-hydroxyethyl, either before or after complexation. This 
phenomenon is discussed further in ,section 4.2. Here the Cu(ll) sits only slightly out 
of the plane of the foUr coordinating nitrogen atoms and one of the oxygens 
coordinates as well to give the complex overall square pyramidal geometry, with the 
.. Cll atom participating in a non-bonding interaction (Fig. 4C). 
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Fig.4C. X-ray structure of 188. 
0 5 
Bond I~ngths Bond angles 
(A) (0) 
Cu1-N1 2.070 N1-Cu1-NS 93.83 
Cu1-N5 2.080 N1-Cu1-N8 1n.11 
Cu1-N8 2.086 NS-Cu1-N8 84.68 
Cu1-N12 2.102 N5-Cu1-N12 157.6 
Cu1-01 2.275 N8-Cu1-N12 96.68 
Cu1-C11 4.006 N12-Cu1-N1 85.65 
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In order to obtain the complex of the cyc1am mustard (190), it was necessary 
to first form the complex of the corresponding 2-hydroxyethyl compound 189. 
Heating the resulting material with thionyl chloride did lead to formation of the 
chloroethyl derivative, but also resulted in displacement of the Cu(II) ion. 
Dissolving the resulting chloroethyl derivative/CuCh mixture in a minimum of water 
and adding a few drops of I M NaOH solution gave the complex 190, which was 
isolated as the dihydrochloride trihydrate (as indicated by microanalysis, Scheme 
4.1.2). Perhaps the excess chloride ion present in solution from the thionyl chloride 
reaction discouraged the hydrolysis (Le. release of more chloride into solution was 
unfavourable to the equilibrium). See Table 4.1.1 for yield. 
Scheme 4.1.2 
HO~n~OH 
C ) 
HO~U~OH 
189 
190 
CuCI2 
MaOH II 
HO~n/"....., 
C· .. 'I I 'Cu2+- - - -OH . . ., .) HO~O~OH 
188 j SOCI, 
40 + CuCI2 
Similarly, the ligands 174 and 175 would not form complexes from their 
hydrochloride salts. Addition of I M NaOH resulted in some complex formation, as 
apparent from the color change of the solution. However, the complexation of 174 
resulted in the mono-N-(2-hydroxyetbyl) compound 191 [as shown by isolatien and 
X-ray crystallography of the PF6- salt (Fig. 4D)]. A proposed mechanism for this 
selective hydrolysis is shownin Scheme 4.1~3. 
The complex 191 adopts distorted octahedral geometry, as evidenced by the 
elongated bonds for Cul-Clll and Cul-N4, and the distortion from 90° of the angles 
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between CuI and the coordinating atoms around the central plane (NI, N7, 071 and 
Cll, Fig. 4D). 
Scheme 4.1.3 
CuCI2 
NH4PFe 
1 M NaOH 
+ 
PFe -
Free coordination sites at the metal centre in the complexation of 174 with 
Cu(II) could allow for the coordination of a water molecule. The Cu(II) acts as a 
Lewis-acid, allowing the water to be deprotonated at neutral pH and activating it for 
intramolecular hydrolytic attack on a 'nearby 2-chloroethyl substituent on N7 
(Fig 4D). The resulting 2-hydroxyethyl substituent then occupies the coordination 
site, preventing further water complexation and hydrolysis. This type of Lewis-acid 
activation in macrocyclic metal complexes is well known for CU(II)183, 184 and also 
for Zn(II) , 178 and may be. an issue fQr most tridentate complexes of triazamacrocyclic 
mustards (e.g. also for 175). Although this is an interesting outc~me, it may have an 
adverse effect on the potency of the parent mustard compound. Also, the yield~ were 
,. unsatisfactory (Table 4.1.1)-in fact no significant amount of the complex of 175 
could be isolated or crystallised for X-ray analysis. The complexation of 
triazamacrocyc1es is known to be more difficult, than for tetraazamacrocycles, as 
their formation/stability constants are generally lower, which could account for the 
. 
problem of low yields. Attempts to form the complex of 175 from the 
2-hydroxyethyl analogue in a similar manner to Scheme 4.1.2 were unsuccessful. 
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Fig. 40. X-ray crystal structure of 191. 
Bond I~ngths Bond angles 
(A) (0) 
Cu1-N1 2.048(7) N1 -Cu1-N4 85.22 
Cu1-N4 2.249(0) N1-Cu1-N7 85.38 
Cu1-N7 2.030(5) N4-Cu1-N7 84.42 
Cu1-0(7)1 2.029(9) N1-Cu1-CI1 98.06 
Cu1-C11 2.268(3) N1-Cu1-0(7)1 166.32 
Cu1-C111 3.086(1 ) N4-Cu1-CI1 99.92 
N4-Cu1-0(7)1 101.62 
N7-Cu1-CI1 174.64 
N7-Cu1-0(7)1 83.53 
93 
In addition to the tetra-N-(2-hydroxyethyl)cyclam complex 188, complexes of 
the other tetra-N-(2-hydroxyethyl) compounds were also made (192 and 193) in 
order to compare their properties with those of the tetraazamacrocyclic mustard 
complexes. Aside from the tacn mustard complex 191 (of which there was not 
enough material for analysis), all complexes were analysed by UV-Vis spectroscopy 
and yields and spectroscopic data are given in Table 4.1.1. The 2-hydroxyethyl and 
2-chloroethyl derivatives are listed next to each other for comparison. 
+ 
~ CI HO~N N~OH C 'Cu2-L:LCI 
, . ) N 'N 
HO/"---/ '---l ~OH 
192: n = 0 
193: n = 1 
Table 4.1.1 
, 
complex yield structural Amax £~ff (%) analysis (nm) (Lcm" mor1) 
192 >99 607 309 
186 75 [1:1 ] 622 515 
193 >99 588 315 
187 22 [1:1 ] 599 315 
188 >99 [1:1 ] 636 n.d. 
190 23 590 817 
191 10 [1:1 ] .' n.d. n.d. 
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4.2. Stability of polyazamacrocycle metal complexes 
4.2.1. Discussion of stability 
Although they are different qualities, the selectivity of a ligand for various 
metal ions and the stability of the resulting complex can often be correlated.97 The 
'size-match selectivity' idea is the most popularly accepted theory for stability and 
selectivity in macrocycle-metal complexation. It holds that macrocycles will 
favourably bind metal ions whose atomic radii best match their cavity size. Despite 
the widespread use of this theory, most of the evidence suggests that chelate ring size 
is much more important in predicting the relative thermodynamic stabilities between 
macrocycles with different carbon bridge lengths and metal ions of various sizes. 
The conformation adopted by the ligand (determined by the chelate rings) plays an 
important role in the preorganisation of the ligand for complexation and can 
contribute to the thermodynamic stability. The denticity (number of chelating 
moieties in the molecule) vs. metal ion size is also a factor. 
n (l 
[NHHNJ (HHN) NHHN NH HN LJ V 
36 194 
Accordingly, (and as suggested by molecular mechanics calculations),98 it is 
expected that macrocycles complexing to form five-membered chelate rings are less 
strained when complexi~g with (an,d thus 'prefer') bigger metal ions. Macrocycles 
complexing to form six -membered chelate rings are less strained when complexing 
with smaller metal ions. Thus, cyclam (194), with its two six-membered ~d two 
five-membered chelate rings, has a higher stability constant (defined by Kstab 
according to Eq. 4.2.1.1) wi~h Cu(II) than that for cyclen (36) which has four five-
membered chelate rings (Table 4.2.1.1). 
Eq.4.2.1.1 
M + L ===== ML K _ [ML] 
stab - [M][L] 
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The addition of donor pendant arms such as N-(2-hydroxyethyl) to cyclam 
and cyclen decreases the stabilities of their complexes. The decrease is most 
pronounced with smaller metal ions, especially Cu(II) (see Table 4.2.1.1). A 
number of factors contribute to this change. The primary contribution is probably 
from the higher strain created by the increased steric bulk, as a similar effect is seen 
with the tetra-N-methyl substituted derivatives. It is interesting to note, though, that 
the decrease in stability for cyclen is less pronounced than for cyclam. Indeed, as the 
size of the N-alkyl group increases, the substituted cyclen Cu(II) complex is 
eventually more stable than that of the corresponding cyclam complex. This is 
probably due to the tetrahedral nitrogens being preorganised for coordination to a 
small ion such as Cu(II). 
Table 4.2.1.1 98 
R,n,R 
C ) R"U'R 
194,195,189 
parent backbone 
Cyclam[Cu(II)] (log K) 
Cyclen[Cu(II)] (log K) 
R=H 
194 (28.09) 
36 (24.8~ 
36,196,197 
R=Me 
195 (18.3) 
196 (18.37) 
189 (15.7) 
197 (-19.5) 
There are a number of reasons why it was not possible to determine stability 
constants for the ligands reported here. In order to be relevant for comparison to 
existing data, the stabil~ty constan!s for metal complexes' need to be determined 
under specific conditions with specialised titration equipment, as detailed by Martell 
and Motekaitis.99 However, the facile hydrolysis of these ligands in neutral o~ basic 
solution makes it nearly impossible to obtain meaningful titration data. Other 
methods using .:uv -Vis spe~troscopy, such as competition studies, are unsuitable 
because they require the protonation constants ·for the ligand to be known.211 
Protonation constants are also very difficult to determine for the nitrogen mustard 
ligands, because the ligands decompose under neutral or basic conditions. However, 
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the stabilities of the novel complexes in relation to each other could be qualitatively 
estimated from UV -Vis decomposition and cyclic voltammetry data. 
4.2.2. 'Aqueous stability' of mustard macrocycle complexes 
The mustard ligands are highly susceptible to hydrolysis and decomposition 
at neutral pR. When complexed with a metal ion, they should only hydrolyse to a 
significant extent if there is a sufficient concentration of the free ligand present at 
equilibrium (Scheme 4.2.2.1). Complexes with high thermodynamic stability will 
only have low concentrations of free ligand and should not decompose in aqueous 
solution. Complexes with low thermodynamic stability will decompose to their 
2-hydroxyethyl analogues. 
Scheme 4.2.2.1 
R R'-(l~ 
N N C ::Cu.: ) 
N N ~V'-R R 
(' 
+2 
]
1) aziridinium ion formation 
2) hydrolysis , 
initially all R = CI 
now some R = OH 
In Scheme 4.2.2.1, initially R = Cl. If the complex is less stable, a cycle 
begins whereby the 2-chloroethyl substiiuents. are successively hydrolysed to 
R = OR. This may continue until R = OR for all substituents, or it may stop at some 
point if the intermediate complex is sufficiently stable. The Amax values for Cu(II) 
complexes of the 2-hydroxyethyl substituted ligands are sufficiently different from 
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those of the tetra-N-(2-chloroethyl) analogues. Thus the 'decomposition' of each 
mustard complex can be monitored by UV -Vis spectroscopy, giving qualitative 
information about the stability of that complex in aqueous solution. 
4.2.3. Electrochemistry and complex stability 
The electrochemistry of metal complexes in solution can be studied using a 
variety of techniques, including polarography, cyclic, square wave and differential 
pulse voltammetry.212 Although these techniques can provide valuable information 
on the viability of biological electron transfer, factors such as metabolism, 
membrane transport and tissue pH can have unpredictable effects on actual redox 
behaviour in vivo. Therefore it is not possible to correlate the behaviour observed by 
electroanalytical techniques directly with in vivo bioreduction or oxidation. 
However, reduction potentials measured through these techniques can provide 
benchmark estimates for the feasibility of bioreduction. It is generally accepted that 
cOJ;npounds with reduction potentials between -0.2 and -0.4 V vs. the normal 
hydrogen electrode (NHE) can be reduced by endogenous reductase enzymes.50 
However, many compounds with reduction potentials outside this range still exhibit 
bioreductive activity in vivo, suggesting that reductive activation is unpredictable 
and values obtained in the laboratory should not be used exclusively for screening 
purposes. Still, electroanalytical techn\ques can be employed in the interest of 
characterising the properties of new potentially bioreducible drugs as long as the 
conditions are reproducible and relevant to bi~logical systems. Here cyclic 
voltammetry has been used to examine the redox behaviour and estimate the 
reduction potentials of the mustard complexes under simulated approximations of 
physiological conditions: 
Cyclic voltammetry uses a changing potential in an electrochemical 'cell to 
monitor the electron transfer behaviour of the components of the solution studied. 
The potential is scanned through a range of voltages to a maximum and back again 
and an electrode measures the current produced in the sample when the compound is 
oxidised and reduced. The voltage (V or m V) of potential applied is plotted against 
the observed current density (J.1A), giving a spectrum representing the reduction and 
subsequent back oxidation of the species in the solution. The reduction produces a 
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negative peak (cathodic peak ipe at potential Epe) and the oxidation gives a positive 
peak (anodic peak ipa at potential Epa). The redox potential (BII2) is the halfway 
point between those two peaks [E1I2 = (Epe + Epa)/2] . The speed of the potential scan 
is the 'scan rate.' The shape of the peak illustrates the change in concentration of the 
reacting species vs. the product near the electrode. The size and appearance of the 
peaks are a function of the scan rate and the 'reversibility' of the redox reaction, 
depending on whether the reduced species remains in contact with the measuring 
electrode within the time scale for reoxidation. Reversible behaviour is characterised 
by the spectrum shown in Fig. 4E. For a system to be classically reversible, the 
potential difference between the cathodic and anodic peaks should be less than 60 
mY. Greater distances between the peaks indicates a 'quasi-reversible' process. 
Fig. 4E. Example of a reversible cyclic voltammagram.213 
1 
-....... 
B 
Epa 
c 
C ~ 0 /-::::::A_-=.....-t--r------l 
::J 
U 
Epc 
D 
-100 0 200 400 600 
Potential (mV) 
The speed of the electron transfer reaction also affects the appearance of the 
cyclic voltammagram. Fast electron transfer generally gives the same peak 
potentials even with increasing scan rate, resulting in conditions nearer to 'ideal' 
which can show predictable diffusion and concentration behaviour. Slow electron 
transfer results in a maximum peak potential shift towards more positive values with 
increasing scan rate, due to a slower decrease in the concentration of the reduced 
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species at the electrode. Metal deposition on the electrode can cause sharp spikes in 
the current and is usually remedied by thorough polishing of the working electrode. 
Other spectral abnormalities can occur as a result of adsorption of other solution 
components onto the electrode, including reactant species, reduction products, or 
their intermediates. 
Irreversible behaviour produces a cathodic peak, but no corresponding equal 
but opposite anodic peak, implying that the back oxidation does not occur reliably. 
The oxidation peak for an irreversible reaction may just be smaller than the reduction 
peak, or it may not appear at all. The cause of the irreversibility is sometimes a 
chemical change in the reduced species, but can be physical (e.g. due to precipitation 
of the reduced species from solution). 
The reversibility of the cyclic voltammagram can give valuable information 
about the thermodynamic stability of the reduced complex. Thermodynamically 
staple reduced complexes will remain intact near the electrode until the potential is 
reversed and they are reoxidised (Scheme 4.2.2.1A). If the reduced complex 
changes significantly during the sweep time, the redox behaviour will change and 
thus the voltammagram will show irreversible or quasi-irreversible behaviour. 
Complexes of lower stability can undergo irreversible chemical change before they 
are reoxidised (Scheme 4.2.2.1B), resuJting in less reliable redox reactions and 
negative sh~fts in the Epc with increasing scan rate. However it is sometimes possible 
to obtain reversible spectra by increasing the sqan rate and thus oxidising the 
d b ed . . 212 214 compoun elOre eCOmposltlon can occur. ' 
Scheme 4.2.2.1 
A: 
B: chemical 
Bred 
reaction C 0 
---_. + etc. 
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These properties can have implications for the selectivity of bioreductive 
drugs. For example, the Co(ITI) complexes like 14, described previously by Denny 
and Wilson showed quasi-irreversible redox behaviour.72 They also showed fairly 
high toxicity to oxygenated tumour cells. Denny and Wilson originally proposed 
that the cytotoxicity of the compounds in the presence of O2 was probably due to the 
dissociation of the reduced Co(IT) complex before reoxidation to the Cocm) complex 
could occur.7S However, they also reported that the half life of the activity of their 
complex when incubated in the medium was only a few hours. The complexes lost 
their aerobic and anaerobic cytotoxicity after short periods of time in aqueous 
solution. This implies that the complex dissociated in solution and was hydrolysed 
to the inactive 2-hydroxyethyl analogue even without being reduced by cellular 
systems. Additionally, the complexes like 14 showed significant cytotoxicity that 
was independent of the oxygenation of the cell culture. Complexes of this linear 3° 
amine ligand are much less thermodynamically stable in general compared to 
complexes of 1° amine as well as linear and macrocyclic 2° amine ligands.2IS It is 
possible that the Co(IIT) metal itself was toxic, but it does appear that there is some 
other mechanism of activity taking place, e.g. the mustard was available in the 
uncomplexed form in solution. 
II 
CI 
CI,-- {"\,-1 
N N 
C ''co~~CI -- ,'\ / N N . rL.l~CI CI 
199 
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Excessive toxicity was observed for the Co(TII) complex of our macrocyclic 
mustard ligand 198 as well, which was formed from the Co(II) complex 199.216 If 
thermodynamic stability is lower, the eqUilibrium for the complex formation reaction 
will lie to the W + L side. That leaves the free ligand available for reaction with 
nucleophiles before the metal is reduced. Reaction of L with nucleophiles (N) 
decreases the concentration of L as it forms LN, which in turn means that more free 
L will be produced by the eqUilibrium process (Scheme 4.2.3.1). So, it seems 
possible that the low selectivity observed for Co(III) complexes of macrocyclic 
nitrogen mustards is due to the inherent instability of the oxidised complex itself. 
Scheme 4.2.3.1 
low stability constant K: 
as L is removed, 
eqUilibrium shifts 
to produce more L 
ML 
Accordingly, it was desirable to produce mustard complexes that showed 
sufficient thermodynamic stability to prevent hydrolysis and/or reaction while 
oxidised. It was also important that the reduced complex should be sufficiently 
stable to allow time for reoxidation, to ensure that active mustard release would be 
minimal in aerobic tissue. 
The known in vivo hypoxia selectivity of Cu(TI) bis(thiosemicarbazone) 
complexes76 (e.g. 15, section 1.2.2), made Cu(II) an attractive candidate for mustard 
complex formation. More powerfully, empirical evidence from biodistribution 
studies of radiolabelled Cu(II) complexes of cyclen and cyclam derivatives (e.g. 16, 
"section 1.2.2) suggests that they are bioreducible. 24 hours after injection with 
64Cu(II) complexes of a variety of azamacrocycle complexes, the highest 
concentration of 64Cu was found in the tUmour ,tissue of tumour-bearing Golden 
Syrian hamsters.s1 The authors suggested that the observance of 64CU in tumours as 
well as other tissues was due to transchelation with enzymatic cold Cu(II). This 
should be seen most frequently.where the 64Cu(II) ion was reduced to the less stable 
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64Cu(I), as in hypoxic tissue. These data were simply reported as 'good tumour 
uptake' as compared to uptake by tissues in normal Sprague-Dawley rats, but it can 
also be interpreted to suggest that bioreductive behaviour will probably be observed 
for Cu(ll) complexes of cyclam and cyclen derivatives. 
4.3. Electrochemistry of novel mustard complexes 
186: n1 = 0; n2 = 0 
187: n 1 = 1; n2 = 0 
190: n1 = 1; n2= 1 
200: n1 = 0; n2 = 0 
201: n1 = 1; n2 = 0 
202: n1 = 1; n2 = 1 
The novel macrocyclic mustard complexes studied (186, 187, 190 and 191) 
showed a marked difference in their aqueous stability and their electrochemical 
behaviour. The redox potential of each compound was measured with cyclic 
voltammetry in aqueous phosphate buffer at pH 7.2 with ferrocenecarboxylic acid 
(PCA) as an internal standard (+533 mV vs. NHE, or +334 mV vs. sat. AglAgCI),217 
using a three-electrode cell with a Pt macrodisc working electrode (2.0 mm), Pt wire 
counter electrode and either the AgI AgN03 electrode [EO(vs. AgI AgN03) = EO + 253 
~} 
mV (vs. AglAgCI)], or the saturated AglAgCI reference electrode [EO(vs·. AglAgCI) 
= EO _ 199 mV (vs. NHE)].218 The potentials were corrected for the published 
potential of PCA and reported vs. Sat. AgI AgCl. The solutions were degassed with 
N2 before analysis, to simulate the hypoxic environment. 
Scheme 4.3.1 
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The redox potentials of the parent macrocyc1e complexes [cyc1en[Cu(II)]Ch 
(200), homocyc1en[Cu(II)]Ch (201) and cyc1am[Cu(Il)]Ch (202)] and the 2-
hydroxyethyl analogues (188, 192 and 193) were also measured, in order to compare 
the reduction potentials with the stability constants. The tetra-N-ethyl derivative of 
cyc1am was prepared and complexed as well (204) (as in Scheme 4.3.1), in order to 
investigate if the 2-chlorethyl substituents had an effect on the reduction potential. 
The tetra-N-ethyl derivative of cyc1en could not be synthesised in the same way as 
for cyc1am (due to difficulties in fully acylating the compound), so it was not 
prepared. The two most significant voltammagrams, for 186 and 190, are shown in 
Figs. 4F and 4G. The rest are reproduced in Appendix 1. For comparison of the 
reduction potentials of various complexes to each other, they are listed to at least two 
significant figures. However due to experimental variation, these values are only 
accurate to one significant figure when comparing them to data obtained from other 
published experiments. Results are listed in Table 4.3.1 (four pages on). 
The voltammagram for 190 shown in Fig. 4G probably represents either an 
electrochemical-chemical-electrochemical (ECE) reaction pathway (Fig. 4H top), or 
a electrochemical-chemical (BC) pathway (Fig 4H bottom).213 In the ECE pathway, 
the initial reduction of the mustard complex is followed by a chemical reaction, 
probably the dissociation and hydrolysis of the ligand. Subsequent complexation of 
the new ligand with Cu(II) [from Cu(I) that had been reoxidised] in solution results 
in another electrochemical reaction taking place, giving the additional smaller peaks. 
The EC pathway would occur if the ligand was diss9ciating and hydrolysing after the 
reduction took place, so the reoxidation would be less apparent. This could be the 
case for many of the other irreversible spectra as well (Appendix 1). 
104 
Fig. 4H. ECE (top) and EC (bottom) voltammagrams 
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Table 4.3.1. Reduction potentials for main peaks Epc (mV) vs. sat. Ag/AgC( of Cu(lI) 
complexes In 100 mM phosphate buffer (pH 7.2) unless otherwise stated, with FCA as 
Internal standard (E112 = 344 m V vs. sat. Ag/ AgCI) 
backbone 
parent parent tetra-N- tetra-N- tetra-N-
(aqueous) (OMF) ethyl (2-hydroxyethyl) (2-chloroethyl) 
compound # 200 200 192 186 
cyclen 
[2,2,2,2] -749 -914 nla -464 -404 -236 -191 
(behaviour) Irrevers. Revers. E112 Revers. E112 
compound # 201 193 187 
homocyclen 
[2,2,2,3] -833 nla nla -536 
-459 
(behaviour) Irrevers. Irrevers. Irrevers. 
compound # 202 202 204 188 190 
cyclam 
[2,3,2,3] -1221 -971 -470 -406 -341 
(behaviour) Irrevers. Irrevers. Irrevers. Irrevers. Irrevers. 
• (for values vs. NHE add 199 mY) 
The reversible behaviour of the two substituted cyclen complexes is very 
int~resting, especially in contrast to the behaviour of the parent cyclen complex. 
Reversibility implies sufficient stability of the reduced complex, so 186 and 192 
seem to be more stable when reduced than the rest of the complexes studied. 
Additionally, however, higher chelate ring strain is characterised by a more negative 
redox potential.219 The more negative reduction potential observed for 192 suggests 
that its chelate rings are more strained-' a property that would normally result in 
lower themlodynamic stability for the complex. Also, the reduction potential for 204 
is more negative than for 190, so it is possible tllat the 2-chloroethyl substituents 
facilitate the reduction of these complexes. 
The redox potential of 186 was also evaluated under other relevant simulated 
conditions: lower pH (tumours are typically more acidic than normal tissue), ,higher 
oxygen concentration at normal pH (normal tissue) and in DMF (with ferrocene as 
internal standa:d) to com~are the behaviour in a lipophilic vs. hydrophilic 
. environment. 186 was not very soluble in DMF, but addition of ~BF4 and 
sonication for 20 minutes allowed the preparation of a 1.0 mM solution. Aside from 
analy~is of 190 at lower pH, these additional tests were not performed with other 
compounds due to lack of material. The results are listed in Table 4.3.2. 
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Table 4.3.2. Epc (vs. sat. Ag/AgClf under alternative conditions 
N2• pH 7.2, aq. N2, pH 4.9, aq. O2, pH 7.2, aq. 
compound phosphate phosphate phosphate N2,DMF 
buffer buffer buffer 
186 -236 mV -270 mV -303 mV Epc: -963 mV 
(behaviour) Reversible Reversible Reversible Irreversible 
190 Epc: -341 Epc: -349 m V . 
(behaviour) Irreversible Irreversible 
• (for values vs. NHE add 199 mY) 
Again, the difference in E1I2 for 186 under oxic vs. hypoxic conditions 
appears to be significant (comparison of the voltammagrams shown in Fig. 41). The 
reduction potential difference observed (70-80 m V) can lead to a lO-fold change in 
the reduction rate.50 The slower reduction rate in the presence of oxygen might well 
playa part in the selective release of the cytotoxin under hypoxic conditions. 
Another point of interest is the large difference between the redox behaviour 
of (186 in DMF vs. phosphate buffer. The redox reaction is no longer reversible 
(Fig. 4J). There appear to be two reduction peaks (although one is more likely to 
correspond to 186 and the other perhaps to another component of the solution). 
Denny and Wilson 72 measured the reduction potentials of their bioreducible Co(III) 
complexes in dichloromethane (as their complexes were not soluble in aqueous 
solution) and also saw irreversible reduetions. The redox behaviour observed for 
186 in DMF corresponds better to the behaviour seen by Denny and Wilson. It 
appears that reduction potentials measured in non-protic solvents don't compare 
easily with those measured in aqueous solution. Without knowing the precise 
mechanism for enzymatic reducti?n of these complexes (and thus whether the 
reduction takes place in the aqueous or the lipophilic membrane environment), it is 
difficult to know which potential is more relevant to the activity. However, aqueous 
.. systems provide better information about the thermodynamic stabilities of the 
oxidised (Cu[II]) and reduced (Cu[l]) complexes and so are more useful in predicting 
hypoxia selectivity (discussed further in Chapter 5). 
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4.4. Aqueous stability of novel complexes 
The aqueous stability was assessed by observing the hydrolysis from the 
tetra-N-(2-chloroethyl) complex (186,· 187 and 190) to a poly-N-(2-hydroxyethyl) 
complex (Scheme 4.2.2.1). The reaction was monitored by UV -Vis spectroscopy, 
with the Amax known for each complex, watching for a shift towards the Amax for the 
tetra-N-(2-hydroxyethyl) complex. The Arnax values were sufficiently different so 
that the hydrolysis could be effectively observed. The aqueous stability is defined 
here as t1l2(O): the time necessary for a Amax shift of half the difference between those 
for their mustard and poly-(2-hydroxyethyl) derivatives. If the complex is 
thermodynamically stable, no change in Amax should be seen even after the material is 
left for extended periods of time in aqueous solution. If it is not thermodynamically 
stable, it should go through the series of reactions shown in Scheme 4.2.2.1. 
Table 4.4.1 
complex 186 187 190 
t112(8) > 14 days > 7 days - 24 hours 
Values for tln<O) for three of the mustard complexes are given in Table 4.4.1. 
186 and 187 exhibited no significant change in Amax (622 nm and 599 nm 
respectively) after long periods of time' at concentrations of 1-5 mM in 100 mM 
aqueous phosphate buffer at pH 7.2 (see Fig. 4K for 186 and 4L for 187). 
Additionally, 186 retained its potency against Trypanosoma brucei even after three 
weeks as a 2 mM solution in water (this is discussed further in Chapter 5). A 1 mM 
solution of the cyclam-based must~d complex 190 in 100 mM aqueous phosphate 
buffer at pH 7.2, however, showed a marked shift in its Amax after just 48 h (from 636 
nm to 624 nm) (Fig. 4M). This indicated the ligand was decomposing and the 
resulting 2-hydroxyethyl substituted cyclam was then complexing with Cu(II) 
(Scheme 4.2.2.1). Althoug~ it was not possible to quantify the extent of hydrolysis 
of 190, it was clear that the complex was not stable under aqueous conditions. 
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Fig.4K. t1l2(0) analysis (UV-Vis spectroscopy) for 186. 
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Fig. 4L. tll2(O) analysis (UV-Vis spectroscopy) for 187. 
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Fig. 4M. tl/2(~) analysis (UV-Vis spectroscopy) for 190. 
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4.5. Additional complexation 
4.5.1. Co(lI) complex of cyclen mustard 
The Co(IT) complex 199 was fonned easily and crystallised as the PF6- salt. 
The crystal structure is given in Fig. 4N and the chel;:tte rings formed are similar in 
conformation to those in the Cu(II) co.mplex. The Co(II) ion exhibits square 
pyramidal geometry and, as for the Cu(II) complex, the cobalt sits well out of the 
plane created by the four coordinating nitrogen atoms. This complex is much more 
soluble in organic solvents e.g. acetonitrile or methanol than in water; in fact it does 
not dissolve significantly in 100 ruM phosphate buffer at pH 7.2. Oxidation of the 
Co(Il) to Co(ID) was attempted but only starting material 199 was obtained. 
Alternative methods involving oxidation of the cobalt prior to complexation were 
. also attempted, but the product could not be isolated. Due to the difficulties 
encountered with bioreducible cobalt complex formation and the relative success 
with Cu(II) complexation, cobalt complexes were not pursued further. 
+ 
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Fig.4N. Co(II) complex of cyclen mustard (199). 
ClIO 
e ll 
Bond I~ngths (Cu(II) Bond (Cu(II) 
(A) complex) angles (0) complex) 
Co-N1 2.1503 (2.099) N1-Co-N4 83.90 (85.11 ) 
Co-N4 2.1426 (2.060) N1-Co-N7 139.01 (146.0) 
Co-N7 2.1565 (2.062) N4-Co-N7 83.02 (86.51 ) 
Co-N10 2.1515 (2.065) N4-Co-N10 139.70 (148.95) 
Co-CI 2.2490 (2.3618) N7-Co-N10 82.15 (87.03) 
N10-Co-N1 83.22 (85.33) 
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4.5.2. Complexation of novel parent triazamacrocycles 
Attempts were made to prepare and crystallise complexes of the [4,4,3] (128) 
and [3,4,5] (129) novel triazamacrocycles with Cu(N03h. Initially very small yields 
of crystals did form in the complexation reaction solutions, but they were not of x-
ray quality and attempts to recrystallise the materials resulted in decomposition to a 
deep green solution from which no crystallisation would occur, even upon 
evaporation to dryness. The color change [from bright blue Cu(N03h solution to a 
dark green solution of the ligand with the Cu(II) salt] indicated that some kind of 
coordination was taking place. Since X-ray crystallography was proving 
problematic, NMR spectroscopic studies of the complexations were undertaken 
using Zn(II), since it does not have an effect on the acquisition of interpretable NMR 
spectra. Compounds 128 and 129 were titrated with a solution of ZnBr2 and 
monitored by IH NMR spectroscopy with the addition of increasing amounts of the 
ZnBr2 solution. The degree of formation of the 1: 1 complex could be observed at 
each step, as shown in Figs. 40 and 4P. For both 128 and 129, the changes in 
chemical shift induced in all of the signals corresponding to CH2-N indicated that all 
three of the amine groups of each macrocycle were complexing to the Zn(II). The 
structures of the complexes were analysed by 2-dimensional NMR spectroscopy 
(COSY, HMQC, HMBC) and the structural assignments are suggested in the 
experimental section for this chapter (refer to Appendix 2 for 2-dimensional NMR 
spectra). The circled peak in the final complex of 129 (Fig. 40) may correspond to a 
coordinated water molecule (supported by the lack of HMQC and HMBC 
correlations for that proton peak). Titration of this complex with base would provide 
some insight into the pKa of this bound water, however this was beyond the scope of 
.. 
the present studies. Initial attempts to crystallise these complexes were unsuccessful, 
but changing the crystallisation conditions (e.g. solvent system, counter ion, etc.) 
-
.. may allow for the production of X-ray quality crystals and structural 
characterisation. 
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Fig. 40. Titration of 128 with Zn(lI) 
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Fig. 4P. Titration of 129 with Zn(lI) 
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4.6. Conclusions 
As suggested in the literature, it was found that azamacrocycles generally fonn 
thennodynamically stable Cu(II) complexes. The substituted cyclen-based mustard 
ligand gave the most stable complex, which was advantageous for its biological 
activity. The thennodynamic stability of the oxidised [Cu(II)] and reduced [Cu(l)] 
complexes could be assessed using cyclic voltammetry and UV -Vis spectroscopy 
and reversible redox behaviour and high thennodynamic stability were found to 
correlate positively with the desired biological activity. The reduction potential for 
the hypoxia selective complex was less negative than the so-called 'ideal range,' but 
the activity and selectivity were still better than previously published for this type of 
bioreducible prodrug (discussed Chapter 5). 
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Chapter 5 
5. Biological testing and results 
5.1. DNA-crosslinking 
uncomplexed mustards 
and cytotoxicity of 
The novel nitrogen mustards 174·183 (see Table 3.3.1 for structures) were 
assessed for their cytotoxicity and DNA cross-linking efficiency by Prof. John 
Hartley at University College London. The results are listed in Table 5.1.1. The 
cytotoxicities were determined against the human chronic myeloid leukemia cell line 
K562 using the MTT cell proliferation assay after a one hour exposure to each drug. 
For the cross-linking assays, the drugs were each reacted with linearised plasmid 
DNA for 2 h, after which the DNA was precipitated and incubated with strand 
, 
separation buffer. Gel electrophoresis was performed against single-stranded and 
double-stranded DNA as controls, reSUlting in the cross-linked DNA migrating with 
the double-stranded control. The percent double-stranded DNA in each band was 
determined from densitometry of autoradiographed images of the gels. The cross-
linking activity is expressed as XLso: the concentration of drug which resulted in 
50% cross-linked DNA. 
Table 5.1.1 " 
Compound 174 175 176 177 178 179 180 181 [rlf,lg size] [2,2,2] [3,3,3] [3,3,4] [3,3,5]· [3,3,5]- [3,4,4] [3,4,5] [5,5,4] 
bis Ids 
ICso- (J-tM) 10.5 6 25 6.25· 25 >100 21 >100 :to.9 :t2 :t14 :t1 :t12 :t7 
XL50 (JA;!III) 0.060 0.090 0.045 0.010 0.035 n.d.b n.d.b 0.035 
# ofatoms 9 12 13 In ring 14 14 14 14 17 
-against human chronic myeloid leukaemia cell line' K562j bunable to acquire 
meaningful cross-linking data 
182 
[6,6,4] 
35 
0.100 
20 
The cytotoxicities vary widely, and don't show an obvious relationship to the 
cross-linking efficiency. This is probably due to hydrolytic decomposition of the 
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183 
[2,2,4]2 
100 
>0.300 
22 
mustard drugs in cell growth medium, but could also result from differences in 
uptake of the drugs. It is possible that the hydrolysis was not as rapid under the 
conditions required for the cross-linking reaction. With the exception of the 
hexaaxamacrocyclic mustard, all of the compounds are remarkably potent DNA 
cross-linking agents, with XLso activities in the nanomolar range. Particularly 
notable is the increased cross-linking efficiency in the bis-substituted mustard 177 as 
opposed to the tris-substituted compound 178. It is likely that the free secondary 
amine in 177 exists in its protonated form at physiological pH, thus the improvement 
may arise from the increased possibility for electrostatic interaction of 177 with 
DNA. 
Otherwise, it is difficult to see a clear structure-activity relationship for the 
cross-linking activities of this series of drugs. It seems roughly that 9 to 
17 -membered rings are all capable of highly efficient cross-linking, but ring sizes 
greater than 17 are too large. This agrees with previous cross-linking data from the 
group, with XLso values (inferred) falling between 10 and 100 nM for macrocyclic 
mustards with 12-15-membered rings. 
Flg.5A 
'cis-ring' 'trans-ring' 
It is not possible to determine which bifunctional cross-links are being 
.. formed from the tetra-substituted mustards-Leo between 'cis-' or 'trans-ring' 
alkylating substituents (Fig. SA). Bifunctional N-mustard drugs usually form 
'diagonal' cross-links between non-adjacent guanines (5'-GNC-3'/3'-CNG-5'), 
rather than forming the 5'-GC-3'/3'-CG-5' cross-link (Fig. SB). This is thought to 
be due to distortion of the classical B-DNA str.ucture induced by the initial alkylation 
to the mono-functional adduct. 220 All of the parent ring structures are quite flexible, 
so it is probable that nearly all the possible cross-links are being formed. Without 
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detailed molecular modelling of these compounds in aqueous solution, it is difficult . 
to estimate the diameters of the different rings and between alkylating moieties. 
Thus it is not possible at this time to compare the actual distances with the cross-
linking efficiency. 
Fig. 58 
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5.2. Hypoxia selectivity of Cu{lI) complexes of 
selected macrocycllc mustards 
186 190 
Results for the testing of 186, 190 and 191 as bioreducible prodrugs were 
very exciting. They were tested in vitro, by Prof. Ian Stratford's group at the 
University of Manchester, under aerobic and anaerobic conditions against the lung-
derived tumour cell line A549 using the MTT cell proliferation assay. The 
cytotoxicities of the complexes under aerobic and hypoxic conditions supported the 
prediction that redox revet:sibility would, give hypoxia selective release of the N-
mustard. The water solubility of the complexes' (up to at least 10 mM) made their 
testipg and possible use as pharmaceutic~s much more practical than for the 
previous Co(III) complexes. 186 is one of the best hypoxia selective cytotoxins that 
has been tested on the cell line used in this study, the lung-derived A549. The results 
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of the testing are given in Table 5.2.1. The cytotoxicities of the free ligands (against . 
K562) and the reduction potentials for the complexes are included for comparison. 
Table 5.2.1 
Parent Free ICso• Cu(U) Ttl2(o) Etl2 (rev) Cell kill {J.tMt 
macro- ligand (~M) complex (days) or ICso (air) ICso (N2) HCRd ACRe 
cycle E (b) pc 
Cyclen 38 22 186 >14 -37 53.35 2.18 24 
(rev) ±9.71 ±0.25 
Cyclam 40 7.5 190 1 -142 10.10 51.28 
(irrev) ± 1.29 ± 10.58 
Tacn 174 10.5 191 n.d. -240 8.44 15.87 
(irrev) ±0.68 ±O.85 
a against human chronic myeloid leukaemia cell line K562; b mV (vs. NHE)j C against 
human lung tumour cell line A549; d HCR is the hypoxic cytotoxicity ratio: ICso (air) I 
ICso (N2); e ACR Is the aerobic cytotoxicity ratio: ICso (N2) IIC50 (air) 
186 was 24 times more active under hypoxic conditions, indicating that it 
targets slow-growing hypoxic cells selectively in vitro through reduction of the 
( 
complex and release of the mustard (probably via cytochrome p450 or a similar 1 e-
reductase). Its aerobic toxicity was approximately ten times less than that previously 
reported for the most promising Co (III) complex of a linear mustard, 
SN24771 (14).72 So the complexation of this mustard to Cu(II) as a bioreducible 
prodrug also provided the advantage of ~otent delivery of the cytotoxin. 
190 and 191 showed no evidence of deactivation via complexation. They 
exhibited typical characteristics of classical nitrogen mustard drugs. . Their 1Cso 
values under aerobic conditions were similar to those for their free ligands and they 
even showed some degree of aeroJ)ic selectivity, common behaviour in drugs which 
target fast growing oxic cells. This supported the observations from UV -Vis 
analysis that suggested the stability of the oxidized complex was very important for 
deactivation of the mustard ligand. It is likely that these complexes (190 and 191) 
exist significantly as their fr:~ ligands in solution, making bioreduction less relevant 
as a mechanism for activation. They could iilso be activated via a different 
biore.duction pathway, e.g. by NQOI (which ~s oxygen-independent). However, it is 
clear that in essence, these compounds have no selectivity for hypoxia and are not 
good prodrugs. As discussed in Chapter 4, polyazamacrocycle metal complex 
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2 
stabilities can vary widely depending on the metal ion, parent ring size and the 
conformation of the chelate rings formed.98, 124, 21S The biological evidence given 
here shows that these properties are critical to the behaviour of metal complexes as 
prodrugs. 
Two new key observations have been made in this work regarding the 
characteristics that are necessary in the design of hypoxia selective, metal-
complexed N-mustard prodrugs. Firstly, the thermodynamic stability of the oxidised 
complex must be sufficient to render the complex robust in aqueous solution. 
Secondly, reversible redox behaviour suggests optimum stability of the reduced 
complex for avoiding undesirable release of the cytotoxin under oxic conditions. 
Also, previous applications of macrocyclic Cu(II) complexes for targeting hypoxic 
tissue have used the ligands as vectors for radioactive copper.81 Here, we have used 
the copper as a delivery agent for the cytotoxic ligand. This new strategy could 
provide a significant therapeutic advantage in the fields of alkylating agent 
therapeutics and selective targeting of hypoxic tissue. 
5.3. Anti-parasitic activity of polyazamacrocycles 
and selected Cu(lI) complexes 
Anti-parasitic activity of polyazamacrocycles has not been published 
previously: We were interested in assessing the activity of these polyamine 
analogues against parasites, which are known to be sensitive to disruption of their 
polyamine metabolism and transport. A series of polyazamacrocycles was tested by 
Dr. Michael Barrett (University of Glasgow) against Leishmania mexicana and 
Trypanosoma brucei. This included some tetraazamacrocyclic N-(2-hydroxyethyl)-
substituted derivatives [e.g. 1,4,7,1O-tetra(2-hydroxyethyl)cyclen (197)] and three of 
the novel triazamacrocyc1es reported in this thesis (128, 129 and 146). Cultures of 
the two parasites in logarithmic phase wert~ treated with serial concentrations of the 
drugs and incubated at 37°C for five days. ICso values for the activity against 
L. me.~icana were determined from the acid-p~osphatase activity assay. Survival of 
the parasite was measured from the extent of bis-p-nitrophenylphosphate hydrolysis 
by acid-phosphatase in live cells, giving yellow p-nitrophenolate ion which could be 
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measured using UV -Vis spectroscopy. ICso values for the activity against T. brucei 
were determined from the alamar blue cell staining assay.221 living parasites 
convert the alamar blue dye into a colourless form, thus the level of surviving 
parasites can be determined from the concentration of alamar blue left in the culture 
after incubation at 37°C for 24 h (measured by UV-Vis spectroscopy). The results 
are listed in Table 5.3.1. 
n 
[NHHNJ NHHN 
LJ 
36 
128 129 
Table 5.3.1. Screening for anti-parasitic activity of polyazamacrocycles 
compound 
36 
197 
148 
184 
194 
128 
129 
146 
186 
ICso (JAM) 
L. mexlcllnll 
>3,000 
no effect 
120 
90 
135 
150 
250 
65 
52 
IC50 (JAM) 
T. brucel 
75 
no effect 
430 
no effect 
600 
no effect 
no effect 
45 
5 
It is difficult to determine any trends in the activities from these results. 
However it is clear that the activity profiles of polyazamacrocycles in the two 
parasites are quite different. Cyclen (36) was moderately active against T. brucei, 
yet virtually inactive in L. mexicana. The opposite was true for the un substituted 
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novel triazamacrocycles 128 [3,4,4] and 129 [3,4,5], as well as for the 
N-(2-hydroxyethyl)-substituted [2,2,2,3] tetraazamacrocycle 184. These differences 
could suggest that L. mexicana and T. brucei use different pathways in the uptake of 
polyazamacrocycles, or that they have variable sensitivity to transition metal 
sequestration by chelating drugs. The only compound which gave similar activity in 
the two parasites was the novel naphthyl-bridged triazamacrocycle 146 
[3,4,(l,4-naphth)]. This was probably due to its greater lipophilicity, which would 
increase its cell membrane permeability. 
The high potency and interesting activity difference for the cyclen mustard 
complex 186 prompted further investigation. Trypanosomatid parasites, including 
L. mexicana and T. brucei, are known to have increased levels of reductase as a 
protection against oxidative stress imposed as a defence strategy by their host 
organisms.222• 223 Trypanothione reductase (TRYR) is their primary reductase 
enzyme, similar to glutathione reductase but specific to these types of parasites.222 It 
seemed possible that the nitrogen mustard was being selectively released in T. brucei 
through reduction of the Cu(II) to Cu(I), in a similar manner to the selective release 
in hypoxic tumour cells (Section 5.2). Alternatively, if the organisms were merely 
sensitive to copper or copper complexes, other ligands complexed to copper should 
show similar cytotoxicity. To probe the mechanism of the cytotoxicity, the Cu(m 
complex of the inactive ligand 197 (192) was tested again on T. brucei alongside the 
mustard complex 186, as well as the free ligands for both. A previously prepared 
solution of 186 (three weeks old) which had been stored under refrigeration was also 
included, in order to assess whether the mustard complex would retain its activity 
after storage in aqueous solution. ~esults are given in Table 5.3.2. 
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CI~N~~CI C ) 2HCI 
CI~N\_.r~CI 
38 
Table 5.3.2. Comparison of cytotoxicities for complexes of active and Inactive ligands 
against T. brucel 
Compound 197 192 38 
IC50 (PM) >600 >450 21 4.3 4.5 
a freshly prepared; b stored at 4 °c for three weeks 
Like its corresponding ligand 197, the Cu(II) complex 192 was essentially 
inactive at concentrations below 200 J..tglml. This supported the theory that the 
cytotoxicity arose from the mustard being released due to bioreduction of the Cu(II), 
rather than some general Cu(II) toxicity. The mustard complex was approximately 
five times more active than its corresponding ligand, which showed that 
complexation seemed to be protecting the mustard from being deactivated by 
hydrolysis to 197 in the aqueous test medium. Also, the complex retained its activity 
after reasonably long storage in aqueous solution. This agreed with the lack of Amax 
shift observed for this complex by UV -Vis spectroscopy after extended storage in 
water (Chapter 4), further supporting the qualitative determination of the high 
thermodynamic stability of this complex .. 
It is not clear why the mustard complex 18,~ is less cytotoxic to 1:. mexicana 
than for T. brucei. As was the case for the free polyazamacrocycles, the difference 
may be due to some variation in uptake or metabolism of the compound. 
Alternatively the specifiCity of the reductase may be slightly different in leishmania 
parasites. More testing is necessary to find possible reasons for all these activity 
.. differences. Methotrexate-resistant mutant leishmania cell lines have been found to 
over-express the pteridine reductase PfR1.224 If these cell lines show increased 
sensitivity to bloreducible drugs, the mustard c?mplex could provide a possible 
solution to methotrexate-type resistance. 
Given the encouraging results for trypanosomes and leishmania, the activity 
of the cyc1en mustard complex was also assessed against malaria parasites. Due to 
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the short time frame remaining for the project, we decided to perform in vivo tests 
first in order to obtain some qualitative information about the toxiciology of these 
mustard prodrugs. The susceptibility of malaria parasites to oxidative stress and 
bioreducible drugs has been documented.22s-227 In the light of the apparent 
bioreductive activation in trypanosomes, it seemed plausible that this complex would 
also be reduced by malarial reductases (of which glutathione reductase dominates). 
Given the structural differences between human and malarial glutathione reductase 
(the latter of which has a much larger active site),228 it was hoped that malaria 
parasites would be more sensitive to cytotoxins released through bioreduction than 
their host organism. At this time we are still waiting for the results of the in vivo 
antimalarial testing. 
5.4. Conclusions 
The series of polyazamacrocyclic nitrogen mustards described here generally 
showed potent DNA cross-linking activity, but the cytotoxicities were variable. 
Polyazamacrocycles were found to have variable but generally low activity in vitro 
against two parasites, L. mexicana and T. brucei. The cyclen mustard Cu(II) 
complex showed interesting biological activity in a number of areas. It was 
somewhat selective for T. brucei over L. mexicana, which may have been due to 
bioreductive activation in the reductase-rich trypanosomes. Most importantly, this 
complex was found to be an effective bioreducible cytotoxin in tumour cells in vitro. 
This is the first example of a macrocyclic N-mustard complex that shows hypoxia 
selectivity and provides an exciting lead into the further development of this new 
strategy for bioreducible prodrug d~sign. 
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5.5. Future Work 
It would be useful to investigate further the utility of the SES-protecting group 
for the synthesis of azamacrocycles. The heterocycle cyclophane synthesis 
discussed in this thesis could be optimised and expanded to include other 
heterocycles and sensitive functionality. Also, it is important to find an alternative 
deprotection and purification route in order to improve the yields of the parent 
macrocycles. One possibility is to use TBAF or TEAF to remove the SES-group and 
to separate the byproducts from the macrocycle using ion-exchange chromatography. 
This would require some method development, but could provide far better yields of 
material. 
It would also be interesting to produce more macrocyclic polyamine analogues 
for anti-parasitic testing. Analogues with increased lipophilicity and/or polyamine 
tags168 should show better uptake into parasites and thus perhaps better activity. 
Another area that could be explored further is the mechanism of uptake and 
cytotoxicity of the macrocycles tested in L. mexicana and T. brucei. Given the 
difference in the profiles of activity seen for polyazamacrocycles in the two 
parasites, it would be useful to investigate whether they are acting as unnatural 
polyamine analogues or by some other pathway. 
Mo~t importantly, there is extensive opportunity for the development of 
macrocyclic N-rriustard complexes as bioreducibl~ prodrugs. The first. aim is to 
produce a series of analogues of 186, looking to find compounds with more negative 
reduction potentials in order to obtain increased hypoxia selectivity (as reported for 
Cu-ATSM derivatives by Maurer et al.).77 This can be achieved by increasing the 
electron-withdrawing character of the ligand.77 There are a number of .structural 
.. features which should impart this effect. The simplest variation would be to alter the 
leaving group of the mustard (e.g. from CI to Br, mesylate, or tosylate, Scheme 
5.5.1) Given tlie trend observed in the reduction potentials of cYclen-based Cu(m 
complexes (Table 4.3.1), this should have an effect on the electron transfer to and 
from Cu(IT) and therefore the reduction potential. 
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Scheme 5.5.1 
SOBr2, 
MsCI, or 
TsCI 
" 
x X 
~nr 
eN NJ N N 
r'---l~ 
X X 
X= Br, Ms, Ts 
Another possibility is to substitute the parent cyclen-based ring with 
functionality that will change its electronic character. Although not trivial, there are 
a few possible routes to synthesise these analogues. The bisimidazoline route 
(Scheme 1.4.1.10, section 1.4) is a cheap and straightforward option and various 
substituted dibromoalkanes or diol ditosylates could be used (e.g. Scheme 5.5.2). 
The dibromoalkanes or ditosylates could either be purchased (if commercially 
available) or synthesised from alkenyl or styryl precursors.229• 230 The main 
drawback of this approach is the susceptibility of the dibromoalkanes etc. to 
eliInination.231• 232 However with the right choice of base this problem might be 
overcome. 
Scheme 5.5.2 
n N N 
X 1)base n 
C4~J + n MeCNIl eNHHNJ Br Br 
.. N N 2) KOH, H20 N~ 
X 
,. " 
Another novel route to substituted cyclen-based macrocycles could involve 
coupling N-protected amino acids to ethane-1,2-diamin~ with 
.. dicyc1ohexylcarbodiimide (DCC) or 1,1-carbonyldiimidazole (CDI), followed by 
reduction of the resulting diamide to the tetraamine (Scheme 5.5.3). 
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Scheme 5.5.3 
DCC 
or 
COl 
II 
RHO H pg'N~N~NAyN,pg 
. H 0 H R 
jBHiTHF 
R H H pg'N~N~N~N,pg 
H H R 
These tetraamines could then be cyclised as in Scheme 5.5.2, or via normal 
Richman-Atkins cyclisation after conversion into the sulfonamides. Fluorine 
substituents could be incorporated through the use of protected fluoroglycine (205) 
(synthesised as in Scheme 5.5.4 using the potassium salt of bis-BOC-protected 
ammonia233.234). C-Fluorinated amides are known to be stable to reduction using 
lithium aluminium hydride235 and borane.236-238 An advantage of building 
tetraamines from amino acids is that the stereochemistry of the substituents could be 
more easily controlled. Another advantage of this route is that it may circumvent 
any problems with elimination of substituted dibromoalkanes etc. Using lysine as 
the amino acid would allow for the preparation of polyamine-tagged macrocycles 
(Scheme 5.5.5), which should be able to utilise the polyamine transport system for 
entrance into cells,168 which might improve the targeting of the mustard complexes. 
Scheme 5.5.4. 
o 
HOYyN(BOC)2 
F 
205 
Cyclen analogues syflthesised by these routes could be converted into their 
mustard derivatives and complexed to Cu(II). Mustards substituted with linear 
polyainine functionality should still complex to Cu(II) preferentially with the 
macrocyclic hydrochloride salt over the linear triamine salt. The reduction potentials 
and thermodynamic stabilities of the oxidised (Cu[IID and reduced (Cu[lD 
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complexes could be assessed using UV -Vis spectroscopy and cyclic voltammetry 
(as in Chapter 4). This should provide improved selectivity for the bioreduction of 
the complex and release of the cytotoxin. 
Scheme 5.5.5 
!J1) deprotect 
2) convert to mustard 
Eventually it will be important to understand the biodistribution of these 
complexes. This can be accomplished by complexing the ligand to a radioactive 
copper ion~ e.g .. 64CU(IT) or 67CU(IT) and tracking the levels of radioactivity in 
.) 
different tissues over time. Indeed, if accumulation of radioactive copper is seen in 
tumour tissue (as for similar Hgands),81 this strategy might also provide a two-
pronged attack against tumours: tatgeted radiotherapy and release of cytotoxin. 
Cu(IT) complexes of the analogues described above would be assessed for 
hypoxia selectivity by Prof. Stratford's group. The best candidates from in vitro 
testing against tl range of tUJ:nour cell lines. would be selected for in vivo studies by 
the Stratford group. It should be possible to progress rapidly towards more selective 
compounds and a better understanding of these drugs. The results presented in this 
. . 
thesis should stimulate the discovery and development of new hypoxia selective 
cytotoxins that are useful in the treatment of cancer. 
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Chapter 6 
6. Experimental Section 
All experiments were carried out under an atmosphere of N2 or Ar. 
Glassware was oven-dried and N2 cooled. Chemicals were purchased from Aldrich 
Chemical Company (Gillingham, Dorset, UK) or Lancaster Synthesis Ltd 
(Morecambe, Lancs, UK) and used without further purification. DMF and ethanol 
were dried by 3 times sequential drying over 3 A molecular sieves.239 'Wet DMF' 
refers to DMF that was used as purchased and not dried. Melting points were 
measured with a GaUenkamp apparatus and are uncorrected. IH and 13C NMR 
spectra were recorded on a Bruker DPX 400 spectrometer, with chemical shift values 
reported in on the ~ scale (TMS = 0) relative to residual chloroform (~H = 7.27 or ~c 
= 77.2) as internal standards unless otherwise stated. Coupling constants (1) are 
reported in Hertz (Hz). Mass spectrometry was performed on a JEOL JMS-700 
spectrometer and infrared spectra obtained via solution phase (in CDCl)) IR using an 
Ff-IR spectrophotometer. 
6.1. Experimental to Chapter 2 
Generalpr0c.edures 2a-1 
a) Formation of diol tosylates:24o p-Toluenesulfonyl chloride (1.5 eq., 2.3 M) 
was dissolved i~ dry pyridi~e and held below 0 °C. A solution of the diol (1 
eq, 6 M) in dry pyridine was added slowly dropwise while stirring. After 4 
h, the mixture was poured into water and the resulting precipitate filtered 
and washed well with water. It was dried by suction and recrystallized from 
hot ethanol. 
b) Formation of mesitylenesulfonamides:240 The triamine (1 eq., 1 M) was 
dissolved in 10% aqueous NaOH solution. A solution of mesitylenesulfonyl 
chloride (3 eq., 1 M) in diethyl ether was added very slowly dropwise and 
the mixture stirred extremely vigorously overnight. Methanol was added to 
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the resulting coagulated precipitate and it was filtered, washed with " 
methanol and dried under vacuum. 
c) Richman-Atkins cyclisation of Mts-protected sulfonamides:24o The 
sulfonamide (1 eq., 0.02 M) was dissolved in dry DMF. NaH (3 eq., 60% 
suspension in oil) was added, causing fizzing. After stirring for 1 hour, a 
solution of the diol ditosylate (1 eq., 0.2 M in dry DMF) was added 
dropwise. The mixture was heated to 100 ·C while stirring overnight. The 
solvent was concentrated in vacuo to approximately 10% of its original 
volume and dripped into 20 times its volume of ice water while stirring. The 
resulting cream coloured precipitate was filtered, washed well with water 
and purified by column chromatography (99: 1 CHCIJ-MeOH, alumina) or 
recrystallization. 
d) Deprotection of mesitylenesulfonamide-macrocycles (adapted from Reddy et 
al.):170 
1) Attempted deprotection: The protected macrocycle (1 eq., 0.09 M) 
was dissolved in dichloromethane. A solution of phenol (40 eq., 2 M in 
30% HBr/AcOH) was added and the mixture stirred very vigorously at 
reflux for 7 - 9 d. The solqtion was cooled to r.t., distilled water was 
added and the mixture extracted with dichloromethane (3 x 50" ml) to 
remove phenol, some of the acid and unreacted starting material. The 
... ) . , 
dichloromethane was removed via rotary evaporation, the residue was 
taken up in acetone and left in the freezer to crystallize the unreacted 
sulfonamide". The aqueous layer of the extraction was concentrated to 
dryness via rotary evaporation at - 1.0 mm Hg (achieved with a vacuum 
pump). The resulting crude hydrobromide salt of the polyazamaciocycle 
was taken up in a minimum of distilled water, basified to above pH 12 
with NaOH and extracted with dichloromethane (3 x 50 ml). The 
organic layer was dried with MgS04, filtered and the solvent removed 
via rotary evaporator to give an oil which contained the desired 
macrocycle plus impurities. Column chromatography was attempted 
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using 80:20 CHCh-MeOH as eluent on alumina, but no product was 
isolated. 
2} Reaction conditions were as above, except that benzyltriethylammonium 
chloride (0.02 eq.) was also added to the initial reaction mixture and the 
solution heated at reflux for 14 days followed by 14 days of standing at 
room temperature. By the end of this period, crystals had formed in the 
solution, which were filtered off and shown by IH NMR spectroscopy to 
be the HBr salt of the product. The filtrate was worked up as above, but 
the crude HBr salt from the aqueous layer was washed in hot ethanol 
and isolated instead of being converted into the free base. 
e} Synthesis of 2-(trimethylsilyl}ethanesulfonic acid, sodium salt (adapted from 
Weinreb et al.}:195 Vinyltrimethylsilane (28 ml, 1 eq.) was combined in a 
250 ml round-bottom flask, equipped with a two-neck adaptor, reflux 
condenser and thermometer, with 70 ml MeOH and t-butyl peroxybenzoate 
(0.02 eq.). A solution of 36.1 g sodium bisulfite in 70 ml distilled water was 
added and the suspension stirred and heated to 50°C for 48-72 h (monitoring 
the internal temperature). Upon completion, the suspension was transferred 
to alL flask and the solvent removed by rotary evaporation, adding 50 mL 
of MeOH twice to assist the removal of residual water. The resulting white 
solid was taken up in 200 ml MeOH and stirred for 10 min, after which it 
was filtered through a pad of Celite. The filter cake was removed from the 
Celite and stirred again with an additional 200 ml of MeOH for 10 min. The 
process was repeated once more, for a total of 3 washes of the solid. All the 
filtrates were combined in· a tared 500 ml round bottom flask and rotary 
evaporated. The solid product was dried on the rotary evaporator with a 
water bath temperature of 60-80 °C for 4 hours. 
f) Synthesis of 2-(trimethylsilyl)ethanesu~fonyl chloride (adapted from 
Weinreb et al.}:195 The sulfonate salt (1 eq.), was crushed to a fine powder 
. in a round bottom flask equipped with stir bar, oil bubbler and pressure-
equalizing addition funnel and cooled to 0 ·C with an ice water bath. 
Thionyl chloride (16 eq.) was added dropwise via the addition funnel, 
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causing evolution of S02. After all the thionyl chloride was added, catalytic 
DMF (0.4 eq.) was added slowly via syringe. The solution was allowed to 
come to room temperature and stirred overnight. The excess thionyl 
chloride was removed by rotary evaporation and the resulting slurry diluted 
twice with hexane and the hexane evaporated. The slurry was washed well 
with 200 ml hexane and filtered through a pad of Celite, thoroughly washing 
through with more hexane. The filtrate was concentrated under reduced 
pressure to yield the pure product. No further purification was necessary. 
g) Formation of primary sulfonamides from sulfonyl chlorides: The sulfonyl 
chloride was pre-cooled in an ice-water bath. A solution of concentrated 
NH3 (0.88) was added dropwise with stirring. The resulting suspension was 
held at reflux for 2 h. After cooling to room temperature, water was added 
to assist precipitation of the product, which was filtered off under suction 
and washed with water. The resulting crystalline solid was dried under 
vacuum at 100°C. 
h) Alkylation of primary sulfonamides and cyclisation of SES-protected 
sulfonamides: 151 The sulfonamide was dissolved in dry DMF (1 eq., 0.05 M 
in DMF) in a 3-neck round bottom flask fitted with a pressure equalizing 
addition funnel. Caesium carbonate (3 eq.) was added and the mixture 
stil!ed. For the alkylation of primary sulfonamides, the alkyl bromide was 
added via syringe. For the cyclisations, th,~ diol ditosylate was ~ssolved in 
dry DMF (1 eq., 0.18 M in DMF) and added via syringe. The suspension 
was stirred for 3 - 4 d. The reaction was monitored by TLC (20: 1 CH2Ch-
EtOAc, silica) of evaporated aliquots, watching for disappearance of starting 
material. Upon completion, the solvent was thoroughly removed in vacuo, 
the residue taken up in CH2Ch and washed with 25 ml distilled water and 25 
ml brine. The organic layer was dried with Na2S04 and rotary evaporated to 
give the crude product. The material was,purified by flash chromatography 
(for tris-SES-sulfonamides: 20: 1 CH2Ch-EtOAc, silica; for nitriles and 
. alcohols: as specified). 
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i) Reduction of nitriles:241 The nitrile was dissolved in dry THF in a 3-necked -
round-bottom flask with reflux condenser. BH3-THF complex (8 eq., 1 Min 
THF) was added via syringe. The solution was held at reflux for 2 h. Upon 
cooling to room temperature, the excess borane was carefully quenched with 
6 M HCI (5-10 mI). The solution was basified to pH 13-14 with NaOH 
pellets, extracted with CH2Ch (3 x 75 ml), dried with Na2S04, filtered and 
rotary evaporated to give the pure amine. 
j) Formation of SES-sulfonamides (Hoye et al.):151 The triamine in dry DMF 
(1 eq., 0.7 M in DMF) was combined with triethylamine (5 eq.) in a round 
bottom flask with a septum and brought to 0 ·C. The sulfonyl chloride in 
dry DMF (4 eq., 3 Min DMF) was added via pressure-equalizing addition 
funnel. The mixture was stirred overnight at 0 °C. The solvent was 
thoroughly removed in vacuo and the residue taken up in distilled water and 
extracted with dichloromethane (3 x 50 ml). The organic extracts were 
combined, dried with Na2S04 and concentrated under reduced pressure to 
give the crude product. The material was purified either by recrystallization 
in methanol or 2-propanol, or by flash chromatography (9: 1 CH2Ch-EtOAC, 
silica), giving the product as a white solid. 
k) Deprotection of macrocyclic 2-(trimethylsilyl)ethanesulfonamides: 151 The 
m~crocyclic sulfonamide was dissolved in dry DMF (1 eq., 0.05 Min DMF) 
in a round bottom flask fitted with a reflux condenser and oil bubbler. 
- ,-
Caesium fluoride was added (20 eq.) and the mixture held at 95 ·C while 
stirring overnight. The solvent was thoroughly removed in vacuo, the white 
solid residue taken up in CHCh and filtered through Celite with CH2Ch. 
The filtrate was concentrated to give the products as oils or waxy solids, 
which were purified by Kugelrohr distillation. 
I) Synthesis of bisbromomethyl aromatic compounds: 201 The dimethyl 
aromatic compound (1 eq.) and N-bromosuccinimide (NBS) (4 eq.) were 
. dissolved in CC4. The solution was exposed to UV radiation while stirring. 
The reaction was monitored by TLC (9:1 DCMlEtOAc) for disappearance of 
the dimethyl compound. Upon completion, DCM was added (50 ml) to 
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dissolve all solids and the solvent was evaporated. The residue was purified . 
by recrystallisation to give the bisbromomethyl compound. 
Experimental details 
6.1.1. Diol ditosylate formation 
n 
TsO OTs 
107 
1,2-Ethanediol ditosylate (107) 
Using 1,2-ethanediol (3.50 g, 56.1 mmol), 107 was prepared according to general 
procedure 2a as white crystals (17.2 g, 90% yield). m.p. 121.3-123.7·C (lit. m.p. 
123-125 ·C); NMR spectroscopy agreed with literature values.24o OH (CDCI3) 2.47 (6 
H,. s, ArCH3), 4.19 (4 H, s, TsOCHz), 7.34-7.76 (8 H, m (AA'BB'), ArH); Oc 22.1 
(CH3), 67.1 (CH2), 128.4 and 130.4 (CH), 132.7 and 145.7 (C) 
(l 
OTs OTs 
f08 
1,3-Propanediol ditosylate (108) 
Using 1,3-propanediol (5.00 g, 65.7 mmol), 108 was prepared according to general 
procedure 2a as white crystals (18.'3 g, 79% yield). m.p. 90.4-92.8 ·C (lit. m.p. 91-
93 ·C); NMR spectroscopy agreed with literature values.240 OH (CDCh) 2.01 (2 H, 
quintet, J 5.6, CHz), 2.47 (6 H, s, ArCH3), 4.07 (4 H, t, J 6.0, TsOCHz), 7.35-1.77 (8 
H, m (AA'BB'), ArH); Oc 22.1 (CH3), 29.1 (CH2), 66.2 (TSOCH2), 128.3 and 130.4 
(CH), 133.0 and 145.5 (C) 
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n 
OTs OTs 
109 
1,4-Butanediol ditosylate (109) 
Using 1,4-butanediol (3.50 g, 38.8 mmol) , 109 was prepared according to general 
procedure 2a as white crystals (10.28 g, 66% yield). m.p. 79.7-80.6 'C (lit. m.p. 80-
81 'C); NMR spectroscopy agreed with literature values.242 OH (CDCh) 1.70 (4 H, 
broad s, CHz), 2.46 (6 H, s, ArCH3), 3.99 (4 H, broad s, TsOCHz), 7.34-7.78 (8 H, m 
(AA'BB'), ArH); Oc 22.1 (CH3), 25.4 and 69.8 (CH2), 128.2 and 130.3 (CH), 133.3 
and 145.3 (C) 
() 
OTs OTs 
110 
1,5-Pentanediol ditosylate (110) 
Using 1,5-pentanediol (6.84 g, 65.7 mmol), 110 was prepared according to general 
procedure 2a as white crystals (22.5 g, 90% yield). m.p. 73.9-75.0 'C; NMR 
spectroscopy agreed with literature vahies.243 OH (CDCh) 1.26-1.39 (2H, m), 1.57-
1.64 (4H, m), 2.46 (6H, s), 3.96-3.99 (4H, m), 7.34-7.78 (8H, aa'bb'); Oc (CDCh) 
22.0 (CH3), 21.9, 28.6 and 70.4 (CH2), 128.2 antI 130.3 (ArCH), 133.4 and 145.2 
(ArC). 
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6.1.2. Mesitylenesulfonamides 
H 
Mts'N/"....../N~N~Mts 
H . H 
68 . 
1,7-Bis(mesitylenesulfonyl)triazaheptane (68) 
According to general procedure 2b, using 66 (10.0 g, 96.9 mmol), 68 was isolated as 
a white powder (10.4 g, 23% yield). m.p. 108.9-111.3 'C; Vmax (CDCb solution cell) 
1160, 1322, 1560, 1604, 2855, 2984, 3310, 3406 cm,I; OH (CDCb) 2.30 (6 H, s, 
CH2NHS02C~2-o-(CH3)2-P-CH3), 2.63 (12 H, s, CH2NHS02C~2-o-(CH3)rP­
CH3), 2.65 (4 H, t, J 5.2, (CH2)2NH), 2.94 (4 H, m, Mts-NHCH2), 6.96 (4 H, s, 
CH2NHS02C6H2(CH3)3); Oc 21.3 (P-CH3), 23.3 (m-CH3), 42.2 (HNCH2), 48.2 (Mts-
NHCH2) , 132.4 (CH), 133.7, 139.5 and 142.6 (C); mlz (C:r mode isobutane) 468.2 
([M+H]\ 38%), 255.2 (100), 119.2 (45). Found: [M+Ht 468.1988. C22H340~2S2 
requires 468.1991. 
Mts'N~~~N~Mts 
H Mts H 
. 70 
1,5,9-Tris(mesitylenesulfonyl)triazanonane (69) 
According to general procedure 2b, using 67 (10.0 g, 76.2 mmol), 69 was isolated as 
a white powder (47.7 g. 92 % yield). m.p. 121.3-124.3 'C; Vmax (CDCb solution cell) 
1154, 1213, 1320, 1604, 2508, 2898, 2984, 3390 cm,I; OH (CDCh) 1.61 (4 H, 
quintet, J 6.4, NHCH2CH2CH2N), 2.29 (3H, s, (CH2)2NS02C~2-0-(CH3)2-p-CH3), 
2.30 (6 H, s, CH2NHS02C6H2-o-(CH3)2-P-CH3), 2.54 (6 H, s, (CH2hNS02C~2-o­
(CH3)rp-CH3), 2.59 (12 H! s, CH2NHSO~C6H2-o-(CH3h-p-CH3), 2.80 (4 H, broad 
q, J 5.6, NHCH2CH2), 3.19 (4 H, t, J 6.8, CH2CHzNR,), 4.77 (2 H, broad t, NHCH2), 
6.93 (2 H, s, (CH2)zNS02C6H2(CH3h), 6.95 (4 H, s, CH2NHS02C6H2(CH3h); Oc 
. . 
21.3 (P-CH3), 23.3 (m-CH3), 28.0 (CH2) , 39.7 (Mts-NCH2), 43.3 (Mts-NHCH2), 
132.4 and 132.6 (CH), 139.3, 140.4, 142.5 and 143.4 (C); mlz (C:r mode isobutane) 
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678.2 ([M+Ht, 15%), 494.2 (42), 439.2 (10), 283.2 (31), 269.2 (20), 183.1 (19),-
119.2 (100), 105.1 (36). Found: [M+Ht 678.2714. C33I4806N3S3 requires 
678.2705. 
6.1.3. Cyclisation of mesitylenesulfonamides 
MtS .... ['WMts 
CN~ I 
Mts 
70 
1,4,8-Tris(mesitylenesulfonyl)-1 ,4,8-triazacycloundecane (70) 
Using 69 (3.60 g, 5.31 mmol) and 107 (1.82 g, 5.31 mmol), 70 was prepared 
according to general procedure 2c and purified by column chromatography as a 
white foamy solid (0.282 g, 7.5% yield). Vmax (CDCh solution cell) 1158, 1311, 
1605, 1645, 2896, 2975 cm'I; OH (CDCh) 1.97 (4 H, quintet, J 6.4, MtsNCH2CHz), 
2.30 (3 H, s, (CH2)3N(S02C6H2-o-(CH3h-p-CH3)(CH2h), 2.32 (6 H, s, 
(CH2hN(S02C6H2-o-(CH3h-p-CH3)(CH2)2), 2.50 (6 H, s, (CH2hN(S02C~2-o­
(CH3)2-P-CH3)(CH2h), 2.58 (12 H, s, (CH2hN(S02C6H2-0-(CH3h-p-CH3)( CH2)2), 
3.19-3.28 (8 H, m, MtsNCHzCH2CH2), 3.47 (4 H, s, MtsNCHz), 6.94 (2 H, s, 
(CH2hN(S02C6Hz-o-(CH3h-p-CH3)(CH2)3), 6.97 (4 H, s, (CH2hN(S02C6HZ-o-
(CH3h-p-CH3K CH2h); oe 21.3, 23.3 and 23.8 (CH3), 24.9, 42.6, 47.5 and 49.4 
. -
(CH2) , 132.4 and 132.7 (CH), 139.6, 140.7, 143.1 and 144.3 (C); mlz (FAB+ mode) 
704.4 ([M+Ht, 100%), 521.4 (20), 520.4 (62), 338.3 (26), 336.3 (12), 226.1 (13), 
183.1 (19), 119.2 (98). -Found: [M+Ht 704.2862. C3sHso06N3S3 requires 704.2862. 
Microanalysis results: 59.71% C, 7.18% H, 5.79% N. Theoretical: 59.71% C, 
7.02% H, 5.97% N. 
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71 
1,5,9-Tris(mesitylenesulfonyl)-1 ,5,9-triazacyclododecane (71) 
Using 69 (6.10 g, 9.00 mmol) and 108 (3.17 g, 9.00 mmol), 71 was prepared 
according to general procedure 2c and purified by column chromatography as a 
white foamy solid (0.983 g, 15% yield). m.p. 206.4-208.9 ·C; Vmax (CDCh solution 
cell) 1154, 1213, 1315, 2898, 2973 cm- I ; OH (CDCh) 1.98 (6 H, quintet, J 6.8, 
[CH2hCH2), 2.31 (9 H, s, S02C6H2-0-(CH3)z-P-CH3), 2.58 (18 H, s, S02C~2-0-
(CH3)z-P-CH3), 3.24 (12 H, t, J 6.8, MtsNCH2), 6.95 (6 H, s, S02C6H2-0-(CH3)z-p-
CH3); oe 21.2 and 23.4 (CH3), 26.2 and 44.5 (CH2) , 132.5 (CH), 140.6 and 143.1 
(C); m/z (FAB+ mode) 718.4 ([M+Ht, 19%), 534.4 (11), 307.1 (31), 289.1 (12). 
Found: [M+Ht718.3016. C3~520~3S3 requires 718.3018. Microanalysis results: 
60.04% C, 7.14% H, 5.75% N. Theoretical: 60.22% C, 7.16% H, 5.85% N. 
MtS .... (1 .. Mts 
C~~ 
Mts 
72 
1,5,9-Tris(mesitylenesulfonyl)-1 ,5,9-triazacyclotridecane (72) 
Using 69 (4.07 g, 6.00 mmol) and 109 (2.39 g, 6.00 mmol) , 72 was prepared 
according to general procedure 2c and purified by recrystallization from' EtOAc as 
white crystals (1.7 g, 39% yield). m.p. 211.3-213.1 ·C; Vmax (CDCh solution cell) 
1152, 1310, 1565, 1610, 1732, 2861, 298.5 cm-I ; 0 H (CDCh) 1.79-1.88 (8 H, m, 
CH2CH2N), 2.299 and 2.306 (3 H and 6 H, s, i'J"C6H2-0-(CH3)2-p-CH3), 2.55 and 
2.57.,(6 H and 12 H, S, NC6H2-0-(CH3)z-p-C~3), 3.12 (4 H, t, J 5.9, NCH2CH2), 3.23 
(8 H, m, NCH2CH2CH2N), 6.93 and 6.96 (2 Hand 4 H, s, NC6H2-0-(CH3)2-P-CH3); 
oe 21.3 (P-CH3), 23.2 and 23.5 (m-CH3), 27.1 and 28.6 (CH2), 43.3, 47.9 and 49.6 
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(NCH2), 132.4 and 132.6 (CH), 132.8, 133.1, 140.4, 140.6, 142.8, 143.0 (Ck 
Microanalysis results: 60.47% C, 7.27% H, 5.64% N. Theoretical: 60.71 % C, 7.30% 
H,5.74%N. 
6.1.4. Deprotection of mesitylenesulfonamides 
'3HBr 
73 
1,5,9-Triazacyclododecane trihydrobromide (73) 
Using 71 (0.500 g, 0.696 mrnoles), 73 was prepared according to general procedure 
2d-2 as a peach powder (0.256 g, 89% yield); NMR spectroscopy agreed with 
literature values.244 OH (D20 ) 2.16 (6 H, quintet, J 6.8, (NCH2)zCHZ), 3.28 (12 H, t, J 
r 
6.8, NCHz); Oc (D20IDMSO) 20.5 (CH2), 42.3 (NCH2). 
6.1.5. Synthesis of SES-chloride 
o - + 
\. /'0.. •. 8,.0 Na 
-Sl~ .............. " 
\ 0 
84 
2-(Trimethylsilyl)ethanesulfonic acid, sodium salt (84) 
.. ~, 
Using vinyltrimethylsilane (28 mI, 181 mrnol), 84 was prepared according to general 
procedure 2e as a white solid (32.0 g, 86% yield); NMR spectroscopy agre~d with 
.. literature values.195 OH (DMSO); 0.00 (9H, s), 0.83-0.88 (2H, m), 2.36-2.41 (2H, m); 
Oc (DMSO) 0.00 (CH3), 13.6 and 48.2 (CH2). 
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85 
2-(Trimethylsilyl)ethanesulfonyl chloride (85) . 
Using 84 (30.8 g, 151 mmol), 85 was prepared according to general procedure 2f as 
a clear oil (25.7 g, 85% yield). TLe (1:1 Pet. Ether-EtOAc, silica) rf. 0.80; NMR 
spectroscopy agreed with literature values.19S OH (eDeh) 0.12 (9 H, s, Si(eH3)3), 
1.30-1.34 (2 H, m, SieH2), 3.59-3.64 (2 H, m, S02eH2); -1.61 (SieH3), 12.4 
(SieH2), 63.8 (S02eH2). 
6.1.6. Building triamines from sulfonamides 
2-Nitrobenzenesulfonamide (90) 
Using 2-nitrobenzenesulfonyl chloride (10.0 g, 45.1 mmol) and conc. NH3 (100 ml), 
90 was prepared according to general procedure 2g and recrystallized n:om EtOH to 
give light yellow crystals (5.3 g, 58% yield). Melting point agreed with literature 
value.24S m.p. 190-193 °e (lit. 190-191 °e); OH (DMSO) 7.83-7.96 (6 H, m, ArH and 
NH2); Oc (DMSO) 124.6, 129.2, 133.0 and 133.8 (eH), 136.1 and 147.5 (e). 
~ 
'si~*-NH2 
.,; \ 0 
94 
(2-Trimethylsilyl)ethanesulfonamide (94) 
Ammonia gas, produced by gentle warming (30-40 °e) of 8M aqueous ammonia 
solution, was bubbled through a stirred solution of 85 (11.0 g, 55 mmol) in 
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dichloromethane (100 ml) at 0 °c. After 2 h the reaction mixture was filtered, 
washed with water, dried (MgS04) and concentrated to give 94 as a cream crystalline 
solid (8.73 g, 88% yield) m.p. 85-88 °C; IR: Vmax (Golden Gate) 1147, 1271, 1327, 
1547, 2900 and 2952 cm-I ; OH (CDCl) 0.08 (9 H, s, Si(CH3h), 1.08-1.12 (2 H, m, 
SiCHz), 3.03-3.08 (2 H, m, S02CHz) and 4.59 (2 H, bs, NHz); Oc (CDCl) -1.60 
(SiCH3), 11.3 (SiCH2) and 52.0 (S02CH2); m/z (FAB+ mode) 352.5 ([M+Ht 
100%), 226.2 (7), 169.2 (3), 84.6 (24), 73.7 (95). Found [M+Ht 352.2452, 
CIsH3802N3SiS requires 352.2454. 
91 
N-(2-Nitrobenzenesulfonyl)-bis-(3-cyanopropyl)amine (91) 
Using 90 (5.00 g, 24.7 mmol) and 4-bromobutyronitrile (7.32 g, 49.5 mmol), 91 was 
prepared according to general procedure 2h and recrystallized from MeOH to give 
yellow crystals (5.6 g, 67% yield); m.p. 85-86 °C; Vmax (CDCl) solution cell) 1126, 
1165, 1217, 1371, 1468, 1547, 2401, 2902, 2947 and 3020 cm-I; OH (CDCI3) 1.93-
2.00 (4 H, quintet, J = 7.2, CHz), 2.40-4.44 (4 H, t, J = 7.1, CHzCN), 3.42-3.46 (4 H, 
t, J = 7.4, NCHz), 7.66-8.10 (4 H, m, ArH); Oc (CDCl) 14.9,24.8 and 46.9 (CH2), 
124.9, 131.7, 132.6 and 134.7 (ArCH), 118.9~nd 148.4 (ArC); m/~ (CI+ mode 
isobutane) 363.2 (5%), 337.2 ([M+Ht, 100),307.2 (32), 290.3 (18),288.3 (3), 276.1 
(2), 240.1 (2), 208.2 (2), 181.2 (4), 152.2 (68), 150.1 (28), 124.1 (4), 97.1 (4) and 
69.1 (5); Found [M+Ht 337.0971·~ CI4H170~4S requires 337.0971. 
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95 
N-(2-(Trimethylsilyl )ethansulfonyl )-bis-(3-cyanopropyl )amine (95) 
Using 94 (2.00 g, 11.0 mmol) and 4-bromobutyronitrile (3.27 g, 22.1 mmol), 95 was 
prepared according to general procedure 2h (no purification necessary) as a beige oil 
(3.35 g, 96% yield); IR: Vmax (Golden Gate) 1138, 1167, 1250, 1327, 1421, 1460, 
1672, 2247 and 2953 em-I; OH (CDCh) 0.07 (9 H, s, Si(CH3)3), 0.98-1.04 (2 H, m, 
SiCH2), 1.95-2.03 (4 H, quintet,J = 7.2, CH2), 2.44-2.48 (4 H, t, J = 7.0, CH2CN), 
2.84-2.96 (2 H, m, S02CH2), 3.32-3.36 (4 H, t, J = 7.1, NCH2); m/z (FAB+ mode) 
338.1 ([M+Nat, 100%), 271.1 (10), 73.8 (30); Found [M+Nat 338.1334, C13H-
2s02N3SiSNa requires 338.5017. 
N-(2-(Trimethylsilyl)ethanesulfonyl)-bis-( 4-cyanobutyl) amine (96) 
"" 
Using 94 (1.5 g, 8.27 mmol) and 5-bromovaleronitrile (2.68 g, 16.54~ol), 96 was 
prepared according to general procedure 2h and purified by column chromatography 
(EtOAc, silica) to give 11 yellow oil (2.16 g, 76% yield); r.f. = 0.64 (EtOAc); IR: Vmax 
(Golden Gate) 1140, 1167, 1250, 1329, 2249 and 2952 em-I; IH NMR: OH (CDCh) 
.. 0.06 (9 H, s), 0.97-1.01 (2 H, m), 1.68-1.81 (8 H, m), 2.42-2.45 (4 H, t, J = 6.6), 
2.85-2.90 (2H, m), 3.24-3.28 (4 H, t, J = 6.8); 13C NMR: Oc (CDCh) -1.6, 10.7, 
17.1,22.6,47.8,48.0, 119.6; MS: m/z (CI+ mode) 344.3 ([M+Ht, 35%), 316.2 (9), 
280.3 (2),252.2 (30), 226.2 (4), 211.2 (3), 180.2 (2), 138.2 (1), 111.1 (1), 73.1 (3), 
57.1"(100); Found [M+Ht 344.1827, CIsH3002N3SiS requires 344.1828. 
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97 
N -[ (2-Trimethylsilyl)ethanesulfonyl]-bis-( cyanopentyl)amine (97) 
Using 94 (1.5 g, 8.27 mmol) and 6-bromocapronitrile (2.91 g, 16.5 mmol), 97 was 
prepared according to general procedure 2h purified by column chromatography 
(EtOAc, silica) to give a yellow oil (2.26 g, 73% yield); rJ. = 0.61 (EtOAc); IR: Vmax 
(Golden Gate) 1139, 1250, 1327 and 2951 cm-I; IH NMR: OH (CDCb) 0.06 (9 H, s), 
0.97-1.02 (2 H, m), 1.45-1.53 (4 H, m), 1.61-1.74 (8 H, m), 2.35-2.39 (4 H, t, J = 
7.0), 2.84-2.88 (2 H, m), 3.19-3.22 (4 H, t, J = 7.5); l3C NMR: Be (CDCb) -1.6, 
10.7, 17.5, 25.3, 26.1, 29.0, 48.2, 48.3, 119.85; MS: m/z (FAB+ mode) 372.4 
([M+Ht 12%), 280.4 (92), 226.2 (12), 197.2 (12), 149.1 (28), 73.7 (100), 56.0 (9). 
Found [M+Ht 372.2153, C17H3402N3SiS requires 372.2141. 
N-(2-Nitrobenzenesulfonyl)-bis-(3-aminopropyl)amine (92) 
Using 91 (1.00 g, 2.97 mmol), 92 was prepared according to general procedure 2i as 
an orange oil (0.70 g, 70% yield); 8H (CDCh) 1.37-1.44 (4 H, m, CH2), 1.51-1.64 (4 
H, m, CHz), 2.66-2.69 (4 H, t, J =7.0, Ns-NCHz), 3.28-3.32 (4 H, t, J = 7.8, NCHz), 
.. 7.60-8.03 (4 H, m, ArH). 
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98 
6-[(2-Trimethylsilyl)ethanesulfonyl]-l ,6, 11-triazaundecane (98) 
Using 95 (3.28 g, 10.4 mmol), 98 was prepared according to general procedure 2i as 
a clear oil (3.24 g, 96% yield); IR: Vmax (Golden Gate) 1136, 1165, 1215, 1252, 1323, 
1458, 1560,2341,2360 and 2943 cm-1; OH (CDCh) 0.06 (9 H, s, Si(CH3)3, 0.98-1.04 
(2 H, m, SiCHz), 1.42-1.49 (4 H, m, CHz), 1.60-1.68 (4 H, m, CHz), 2.71-2.73 (4 H, 
t, J =7.0, SES-NCHz), 3.20-3.24 (4 H, t, J = 7.7, NCHz); Oc (CDCh) -1.6 (SiCH3), 
10.7 (SiCHz), 26.9, 31.1, 42.1, 48.4 and 48.9 (CHz); m/z (FAB+ mode) 324.2 
([M+Ht, 50%), 253.1 (10),226.1 (5), 136.1 (6), 101.4 (5), 73.8 (100) and 70.9 (23); 
Found [M+Ht 324.2147, Cl3H340zN3SiS requires 324.2141. 
7-[(2-Trimethylsilyl)ethanesulfonyl]-1,7,13-triazatridecane (99) 
Using 96 (2.10 g, 6.11 mmol), 99 was prepared according to general procedure 2i as 
a clear oil (2.05 g, 95% yield); IR: Vmax (Golden Gate) 1167, 1248, 1327, 1560,2862 
and 2927 em-I; IH~: OH (CDCh) 0.06 (9H, s), 0.98-1.02 (2H, m), 1.24-1.51 (12 
H, m), 1.56-1.64 (4 H, quintet, J = 7.3), 2.68-2.72 (4 H, t, J = 7.0), 2.83-2.88 (2 H, 
m), 3.18-3.22 (4 H, t, J = 7.6); 13C NMR: Oc (CDCh) -1.7, 10.7, 24.3,29:3, 33.6, 
42.3,48.1,48.3; MS: m/z (FAB+ mode) 352.5 ([M+Ht 100%),226.2 (7), 169.2 (3), 
84.6 (24), 73.7 (95). Found lM+Ht 352.2452, ClsH3sOzN3SiS requires 352.2454. 
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8-[(2-Trimethylsilyl)ethanesulfonyl]-1,8,15-triazapentadecane (100) 
Using 97 (2.24 g, 6.03 mmol), 100 was prepared according to general procedure 2i 
as a clear oil (2.22 g, 97% yield); IR: Vmax (Golden Gate) 1165, 1250, 1325, 1464, 
1572, 2856 and 2929 cm-I; IH NMR: OH (CDCh) 0.04 (9 H, s), 0.97-1.01 (2 H, m), 
1.21-1.48 (16 H, m), 1.54-1.61 (4 H, quintet, J = 7.4), 2.68 (4H, t, J = 6.9), 2.82-2.86 
(2 H, m), 3.18 (4 H, t, J = 6.7); 13C NMR: Oc (CDCh) -1.6, 10.7, 26.9, 26.9, 29.4, 
33.9,42.3,48.1,48.3; MS: mlz (FAB+ mode) 380.5 ([M+Ht 72%),288.4 (3), 226.2 
(4), 185.3 (4), 98.5 (16), 73.7 (100). Found [M+Ht 380.2773, CI7I-4202N3SiS 
requires 380.2767. 
6.1.7. SES-amide synthesis 
H H 
SES ... N~N~N'SES 
I 
SES 
87 
1,4,7-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,4,7-triazaheptane (87) 
.l 
Using 66 (1.5 g, 14.5 mmol) and 85 (10.2 g, 50.9 mmol), 87 was prepared according 
to general procedure 2j and puriied by column chromatography to give a cream 
solid (4.03 g, 46% yield); IH and 13C NMR data agreed with literature values. lS1 oH 
(CDCh) 0.06 (27 H, S, Si(CH3)3), 1.00-1.05 (6 H, m, SiCH2), 2.96-3.05 (6 H, m, 
S02CH2), 3.34-3.38 (4 H, q, J 6.0, NHCH2), 3.44-3.46 (4 H, t, J 5.6, N(CH2h), 5.09 
(2 H, broad s, NH); Oc -1.~9 (CH3), 10.4 and 10.8 (SiCH2), 43.0 (NCH2), 47.8 and 
49.4 (S02CH2), 50.8 (NHCH2) 
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88 
1,5,9-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,5,9-triazanonane (88) 
Using 67 (0.820 g, 6.23 mmol) and 85 (5.00 g, 24.9 mmol) , 88 was prepared 
according to general procedure 2j and purified by column chromatography to give a 
white waxy solid (2.77 g, 71 % yield); m.p. 100.2-101.5 °c (lit. 106.5-107.5 °Cl5l); 
IH and 13C NMR and IR data agreed with literature values. lSI Vrnax (CDCh solution 
cell) 1340, 1166, 1213, 1253, 1330, 1711,2897,2978, 3398 em-I; OH (CDCh) 0.07 
(27 H, s, Si(CH3)3), 0.97-1.04 (6 H, m, SiCHa), 1.85 (4 H, quintet, J 8.0, 
(CH2)zCHa), 2.89-2.96 (6 H, m, S02CHa), 3.21 (4 H, broad q, J 7.9, CHaNH), 3.36 
(4 H, t, J 8.0, CHaN), 4.94 (2 H, t, J 8.0, NH); Oc -1.58 (SiCH3), 10.6 and 10.9 
(SiCH2), 32.7 (CH2), 41.9 (NCH2), 48.7 and 48.9 (S02CH2), 50.8 (NHCH2). 
H SES"'N~N~N"'SES 
H SES 
89 
1,5,10-Tris[(2-trimethylsilyl)ethanesulf~nyl]-1,5,10-triazadecane (89) 
Using 59' (2.60 g, 36.1 mmol) and 85 (14.5 g, 72.2 mmol) , 89 was prepared 
according to general procedure 2j and recrysta1li;ed from methanoVwater (-1 :2) to 
give a cream powder (10.0 g, 87% yield); m.p. 104-106°C; Vrnax (CDCh solution 
cell) 1142, 1169, 1254, 1327, 1383, 1468, 2900, 2956, 3294 and 3394 em-I; OH 
(CDCh) 0.06 (27 H, s, SiCH3), 0.98-1.04 (6 H, m, SiCH2), 1.57-1.64 (2 H, quintet, J 
= 6.8, CHa), 1.69-1.76 (2 H, quintet, J = 6.8, CHa), 1.82-1.88 (2 H, quintet, f = 6.0, 
CHa), 2.87-2.96 (6 H, m, S02CHa), 3.12-3.37 (8 H, m, NCHa), 4.63-4.66 (1 H, t, J = 
6.4, NH) and_5.15-5.18 (l H, t, J = 6.8, NH); Oc (CDCh) -1.60 (SieH3), 10.9 
(SiCH2), 26.5, 27.7, 30.6, 40.3, 43.0, 46.1, 47.7 'and 49.0 (CH2); mlz (FAB+ mode 
NaI).660.1 ([M+Na]+, 100 %), 494.2 (11.5),.330.2 (6.5), 273.1 (7), 147.1 (5), 73.8 
(98) and 60.0 (8); Found [M+Nat 660.2457, C22HSS06N3ShS3Na requires 660.2459. 
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104 
1,6,II-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,6,II-triazaundecane (104) 
Using 98 (1.27 g, 3.97 mmol) in DMF (10 ml) and 85 (2.00 g, 9.94 mmol), 104 was 
prepared according to general procedure 2j and purified by column chromatography 
to give a white solid (1.33 g, 52% yield); m.p. 145.5-146.8 °C; IR: Vmax (Golden 
Gate) 1036, 1072, 1109, 1130, 1171, 1244, 1267, 1284, 1311, 1421,2954 and 3278 
cm- l ; IH NMR: OH (CDCh) 0.07 (27 H, s), 0.98-1.03 (6 H, m), 1.60-1.67 (4 H, m), 
1.74-1.80 (4 H, m), 2.86-2.97 (6 H, m), 3.14-3.20 (4 H, q, J = 6.2),3.23-3.27 (4 H, t, 
J = 7.2), 4.93-4.96 (2 H, t, J = 6.2); 13C NMR: oe (CDCh) -1.6, 10.5, 10.9, 26.5, 
27.6, 43.0, 47.6, 48.7, 49.2; MS: mlz (FAB+ mode NaI) 674.1 ([M+Nat, 56 %), 
560.2 (13), 486.1 (10), 305.1 (22), 136.0 (9), 73.3 (100); Found [M+Nat 674.2609, 
CZ3H5706N3SbS3Na requires 674.2615. 
SES"'N~N~N ... SES 
H SES H 
105 
1,7,13-Tris[(2-trimethylsilyl)ethanesulfonyl-l,7,13-triazatridecane (105) 
Using 99 (2.00 g, 5.69 mmol) and 85 (2.86 g; 14.2 mmol), 105 was prepared 
according to general procedure 2j and recrystallised from isopropanol/water (-2: 1) 
to give a cream solid ~2.42 g, 62~ yield); m.p. 95-99 °C; IR: Vmax (Golden Gate) 
1171, 1246, 1315 and 2951 cm- l ; IH NMR: OH (CDCh) 0.05 (9 H, s), 0.06 (18 H, s), 
0.97-1.03 (6 H, m), 1.39-1.45 (4 H, m), 1.57-1.67 (8 H, m), 2.84-2.88 (2 H, m), 2.91-
.. 2.95 (4 H, m), 3.12 (4 H, q, J= 6.6),3.20 (4 H, t, J = 7.4), 4.49 (2 H, t, J = 6.1); 13C 
NMR: Oe (CD~h) -1.6, 1~.7, 11.0, 23.8, ?9.0, 30.3, 43.4, 48.0, 48.4, 49.0, 138.4; 
MS: mlz (FAB+ mode NaI) 702.6 ([M+Nat 38%), 664.5 (5), 616.6 (6), 588.6 (18), 
516.5 (22), 514.5 (18), 333.4 (18), 279.3 (9),215.2 (8), 136.1 (20), 73.4 (99); Found 
" . 
[M+Nat 702.2898, C25~lN306SbS3Na requires 702.2928. 
150 
H H 
SES~N~N~N'SES 
I SES 
106 
1,8,15-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,8,15-triazapentadecane (106) 
Using 100 (2.20 g, 5.79 mmol) and 85 (3.02 g, 15.0 mmol), 106 was prepared 
according to general procedure 2j and purified by column chromatography to give 
white crystals (2.67 g, 65%); m.p. 89-91 °C; IR: Vmax (Golden Gate) 1173, 1246, 
1284, 1313, 1460,2856 and 2929 cm-l ; IH NMR: ~H (CDCh) 0.05 (9 H, s), 0.06 (18 
H, s), 0.97-1.03 (6 H, m), 1.35-1.44 (8 H, m), 1.54-1.63 (8 H, m), 2.83-2.88 (2 H, 
m), 2.91-2.95 (4 H, m), 3.11 (4 H, q, J = 6.7), 3.19 (4 H, t, J = 7.5), 4.50 (2 H, t, J = 
6.1); 13C NMR: ~c (CDCh) -1.6, 1.4, 10.7, 11.0, 26.3, 29.3, 30.7, 43.5, 48.1, 48.3, 
49.0; MS: mlz (FAB+ mode NaI) 730.7 ([M+Nat 12%),616.7 (4), 542.5 (3),293.3 
(1), 226.2 (1), 147.1 (2), 73.3 (100), 44.1 (12); Found [M+Nat 730.3224, 
C27~5N306ShS3Na requires 730.3241. 
6.1.8. Cyclisation of SES-amides 
SES,(l~SES 
(~) 
SES .\ 
111 
1,4,7-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,4,7-triazacyclodecane (111) 
Using 87 (0.650 g, 1.09 mmol) and 108 (0.380 g, 1.09 mmol) in DMF (20 ml), 111 
was prepared according to general procedure 2h and purified by column 
chromatography to give a ",:,hite solid (0.334 g, 53% yield); mp = 82.1-84.5 °C; Vmax 
(Golden Gate) 1068, 1136, 1167, 1248, 1325, 1454 and 2952 cm-l ; OH (CDCh) 0.07 
(27 H, s, Si(CH3h), 1.02-1.06 (6 H, m, SiCH2), 1.67 (2 H, m, NCH2CH2), 2.95-3.00 
- .' (6 H, m, S02CH2), 3.31-3.54 (12 H, m, NCHz); Oc -1.61 (SiCH3), 9.97 and 10.2 
(SiCH2), 30.7 (CH2), 45.9 and 46.4 (S02CH2), 48.2,52.4 and 52.7 (NCH2); mlz (EI+ 
151 
mode) 620.3 ([M-CH3]+' 6%), 470.3 (45), 406.3 (10), 378.3 (10), 350.3 (7), 212.2 
(10), 140.2 (13), 73.1 (100); Found [M-CH3t 620.2170, C2IHsoN306S3Sh requires 
621.0990. 
112 
1,4,7 -Tris[(2-trimethylsilyl)ethanesulfonyl]-1 ,4,7 -triazacycloundecane (112) 
Using 87 (0.570 g, 0.954 mmol) and 109 (0.380 g, 0.954 mmol), 112 was prepared 
according to general procedure 2h and purified by column chromatography to give a 
cream solid (0.176 g, 28% yield); m.p. 193-195 °c (dec.); Vmax (Golden Gate) 978, 
1009,1136,1167,1248,1325,1367,1417,1464 and 2952 cm-1;llH (CDCh) 0.07 (27 
Ii, s, Si(CH3)3), 0.975-1.10 (6 H, m, SiCHz), 1.93 ( 4 H, broad m, NCH2CHz), 2.91-
3.08 (6 H, m, S02CHZ), 3.30-3.49 (12 H, m, NCHz); llc-1.60 (SiCH3), 10.2 (SiCH2), 
25.1 (CH2), 45.7 (S02CH2), 50.2, 51.5 and 53.8 (NCH2); m/z (FAB+ mode NaI) 
1322.0 ([2M+Nat, 13%), 672.3 ([M+Nat, 100%), 484.4 (68), 342.3 (23), 136.1 
(63), 73.4 (98); Found [M+Nat 672.2478, C23HssN306ShS3Na requires 672.2459. 
113 
1,5,9-Tris[ (2-trimethylsilyl)ethanesulfonyl]-I,5,9-triazacycloundecane (113) _ 
Using 88 (0.98 g, 1.57 mmol) and 107 (0.54 g, 1.57 mmol), 113 was prepared 
according to general procedure 2h and recrystallised from MeOH to give a cream 
solid (0.43 g, 45% yield); m.p. 181.4-184.6 °C;vmax (Golden Gate) 1016, 1134, 1164, 
1248", 1325, 1417, 1454 and 2952 cm-I; llH (CDCh) 0.07 (27 H, s, Si(CBJ)3), 0.98-
1.04 (6 H, m, SiCHz), 2.02-2.05 (4 H, m, NCH2CHz), 2.85-2.97 (6 H, m, S02CHZ), 
3.19-3.49 (12 H, m, NCHz); llc (CDCh) -1.61, 10.1, 10.4, 26.1, 44.3, 45.4, 46.7, 
152 
49.2, 52.6; m/z (FAB+ mode NaI) 1321.8 ([2M+Nat, 20%),. 672.3 ([M+Nat, 
100%), 586.5 (37), 484.4 (37), 136.1 (60), 73.4 (37); Found [M+Nat 672.2478, 
C23H55N306ShS3Na requires 672.2459. 
SES ... n ... SES 
C~J 
SES 
114 
1,5,9-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,5,9-triazacyclododecane (114) 
Using 88 (2.00 g, 3.20 mmol) and 108 (1.23 g, 3.20 mmol) in DMF (40 ml), 114 was 
prepared according to general procedure 2h and purified by column chromatography 
to give a white solid (1.03 g, 48% yield); m.p. 176.3-178.2 °c (lit. 177.6-178.7 
. 
°C151); IH and 13C NMR data agreed with literature values;151 DH (CDCh) 0.07 (27 H, 
s~ Si(CH3h), 0.98-1.03 (6 H, m, SiCHz), 2.01-2.06 (6 H, m, NCH2CHz), 2.85-2.90 (6 
H, m, SiCHz), 3.37-3.41 (12 H, m, NCHz); Dc -1.73 (SiCH3), 10.4 (SiCH2)' 28.4 
(CH2), 45.8 (NCH2), 46.5 (S02CH2)' 
SES ... n ... SES 
C~~ 
SES 
115 
1,5,9-Tris[ (2-trimethylsilyl)ethanesulfonyl]-1 ,5,9-triazacyclotridecane (115) 
Using 88 (2.00 g, 3.13 mmol) and 109 (1.20 g, 3.13 mmol) in DMF (40 ml), 
115 was prepared according to general procedure 2h and recrystallised from MeOH 
to give a white solid (1.38 g, 64% yield); m.p. 189.4-191.8 ·C; Vmax (Golden Gate) 
- . . 
1018, 1064, 1107, 1130, 1167, 1215, 1248, 1325', 1358, 1450, 1466 and 2952 cm-I ; 
DH (CDCh) 0.05-0.06 (27 H, 2s, Si(CH3)3), 0.98-1.01 (6 H, m, CH2CHzSi), 1.84 (4 
. . 
H, broad s, CHzCH2NSES), 1.95 (4 H, m, CHz(CH2NSESh), 2.83-2.89 (6 H, m, 
S02CHZ), 3.32-3.35 (8 H, m, CH2(SESNCHzh), 3.45-3.48 (4 H, m, SESNCHzCH2); 
153 
Oc (ref. CHCh = 79.0) 0.00 and 0.048 (CH3Si), 12.1 and 12.3 (CH2Si), 30.1 and 30.7 
(S02CH2), 45.5, 47.7, 49.8, 51.4 and 53.6 (CH2); mlz (FAB+ mode) 678.3 ([M+Ht, 
9%), 614.4 (10%), 512.3 (25%), 348.3 (12%), 210.1 (9.5%); Found: [M+Ht 
678.2955, C2sH6006N3ShS3 requires 678.2952. 
SES-n-SES 
C70 
SES 
116 
1,5,9-Tris[ (2-trimethylsilyl)ethanesulfonyl]-1 ,5 ,9-triazacyclotetradecane (116) 
Using 88 (2.00 g, 3.20 mmol) and 110 (1.32 g, 3.20 mmol) in DMF (40 ml), 116 was 
prepared according to general procedure 2h and purified by column chromatography 
to give a white solid (1.21 g, 54% yield); m.p. 175.0-177.3 °C; Vmax (CDCh solution 
( 
cell) 1142, 1167, 1254, 1333, 1381, 1464, 2866, 2902 and 2956 em-I; OH (CDCh) 
0.06 (27 H, s, SiCH3), 0.96-1.04 (6 H, m, SiCHz), 1.57-1.64 (2 H, m, CHz), 1.67-
1.72 (4 H, m, CHz), 1.90-1.97 (4 H, m, CHz), 2.84-2.89 (6 H, m, S02CHZ), 3.23-
3.40 (12 H, m, NCHz); oc(CDCh) -1.6 (SiCH3), 10.4 and 10.6 (SiCH2), 23.7, 29.4, 
31.0,45.8,46.9,48.5,48.7 and 50.7 (C!l2); mlz (FAB+ mode NaI) 714.1 ([M+Nat, 
15%),548.2 (4), 526.2 (4), 362.2 (3), 360.2 (2.9), 268.2 (1), 210.1 (5), 98.S. (5) and 
73.8 (100); Found [M+Nat 714.2930, C26~I06N3ShS3Na requires 714.2928. 
:..) 
SES,(l ... SES 
···C7:) 
SES 
117 
1,5,10-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,5,~0-triazacyclotetradecane (117) 
Using 89 (2.00 g, 3.13 mmol) and 109 (1.25 g, 3.13 mmol) in DMF (40 ml), 117 was 
prepared according to general procedure 2h and purified by column chromatography 
to give a white solid (0.90 g, 41 % yield); m.p. 145.0-147.6 °C; Vmax (CDCh solution 
154 
cell) 1142, 1167, 1254, 1333, 1379, 1460, 2866, 2922 and 2956 cm-1; BH (CDCh) 
0.05 (27 H, s, SiCH3), 0.97-1.03 (6 H, m, SiCH2), 1.76 (8 H, bs, CH2), 1.99-2.05 (2 
H, m, CH2), 1.90-1.97 (4 H, m, CH2), 2.83-2.88 (6 H, m, S02CH2), 3.20-3.30 (12 H, 
m, NCH2); Be (CDCh) -1.6 (SiCH3), 10.37 and 10.42 (SiCH2), 27.5, 27.6, 32.8, 
45.9, 49.0, 50.4 and 51.6 (CH2); mlz (FAB+ mode NaI) 714.1 ([M+Nat, 27%), 
548.2 (6), 362.2 (5), 360.2 (4), 305.2 (1), 210.1 (5), 142.1 (2), 84.5 (10), 73.8 (100) 
and 59.9 (5); Found [M+Nat 714.2926, C26H6106N3Si3S3Na requires 714.2928. 
SES-n,SES 
. C7~ 
SES 
118 
1 ,5,10-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,5,10-triazacyclopentadecane (118) 
Using 89 (5.00 g, 7.82 mmol) and 110 (3.23 g, 7.82 mmol) , 118 was prepared 
according to general procedure 2h and purified by column chromatography to give a 
white glassy solid (2.41 g, 47% yield); m.p. 95.2-97.5 °C; Vmax (CDCh solution cell) 
1140, 1167, 1254, 1333, 1377, 1464,2868,2902 and 2956 cm-I ; BH (CDCh) 0.06 (27 
H, s, SiCH3), 0.96-1.03 (6 H, m, SiCHz.), 1.55-1.65 (10 H, m, CH2), 1.94-1.98 (2 H, 
m, CH2), 2.84-2.89 (6 H, m, S02CH2), 3.20-3.34 (12 H, m, NCH2); mlz (FAB+ 
mode NaI) 728:1 ([M+Nat, 93%), 654.1 (1.5),_,562.2 (17), 540.2 (4), 490.2 (1), 
420.2 (1), 398.2 (11), 376.2 (2.5), 341.2 (1), 210.1 (5), 177.2 (1.5), 84.7 (6.5) and 
73.8 (100); Found [M+Nat 728.3083, C27H630~3ShS3Na requires 728.3085. 
SES,('j ... SES 
C~:J 
SES 
119 
1,6, f 1-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,6, II-triazacyclopentadecane (119) 
155 
Using 104 (0.940 g, 1.45 mmol) and 109 (0.580 g, 1.45 mmol), 119 was prepared 
according to general procedure 2h and purified by column chromatography to give a 
white solid (0.294 g, 29% yield). m.p. 133.2-135.0 °C; Vmax (Golden Gate) 1045, 
1105, 1134, 1167, 1211, 1248, 1325, 1376, 1417, 1456, 2952 and 3020 em-I; OH 
(CDCh) -0.07 (27 H, s, Si(CH3)3), 0.80-0.93 (6 H, m, SiCH2), 1.58 (12 H, broad s, 
CH2), 2.66-2.81 (6 H, m, S02CH2), 3.11 (12 H, broad s, NCH2); Oc (CDCh) -1.59 
(SiCH3), 10.5,27.3,46.2 and 50.1 (CH2). m/z (FAB+ mode NaI) 728.3 ([M+Nat, 
70%), 690.2 (13), 642.3 (15), 540.3 (60), 476.3 (6), 376.2 (42), 374.2 (27), 210.0 
(31), 142.1 (10); Found [M+Nat728.3054, C27Fl()306N3Si3S3Na requires 728.3084. 
SES, (1 ... SES 
CN~ I SES 
120 
1,6, 12-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,6, 12-triazacyclo heptadecane (120) 
Using 105 (1.80 g, 2.64 mmol) and 109 (0.97 g, 2.64 mmol), 120 was prepared 
according to general procedure 2h and purified by column chromatography to give a 
white solid (0.56 g, 29% yield); m.p. 129-124°C; IR: Vmax (Golden Gate) 1136, 1165, 
1250, 1327 and 2951 em-I; IH NMR: OH (CDCh) 0.05 (27 H, s), 0.97-1.02 (6 H, m), 
1.40-1.47 (4 H,m), 1.59-1.69 (12 H, m), 2.84-2.~8 (6 H, m), 3.18-3.2~(12 H, m); 
l3C NMR: Oc (CDCh) -1.6, 1.4, 10.6, 10.7, 23.6, 27.6, 29.4, 30.1,47.3,47.7,48.6, 
49.6,49.7; MS: mlz (FAB+ mode) 734.8 ([M+Ht 2%), 718.7 (2), 670.8 (4),614.7 
(4), 568.6 (6), 404.5 (6),402.5 (4), 210.2 (6), 147.1 (3), 73.7 (100); Found [M+Ht 
734.3541, C29Fl()S06N3SbS3 requires 734.3578. 
156 
SES,n ... SES 
CN:J I SES 
121 
1,6, 13-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,6,13-triazacyc1o nonadecane (121) 
Using 106 (2.60 g, 3.66 mmol) and 109 (1.34 g, 3.66 mmol), 121 was prepared 
according to general procedure 2h and purified by column chromatography to give a 
white solid (0.59 g, 21% yield); m.p. 129-134°C; IR: Vmax (Golden Gate) 1167, 1248, 
1327,2860 and 2929 cm-I; IH NMR: BH (CDCb) 0.05 (27 H, s), 0.97-1.01 (6 H, m), 
1.37-1.44 (8 H, m), 1.62-1.68 (12 H, m), 2.83-2.88 (6 H, m), 3.16-3.23 (12 H, m); 
13C NMR: Be (CDCb) -1.6, 1.3, 10.5, 26.3, 26.3, 27.1, 29.7, 29.9,46.7,46.9,49.3, 
49.9, 50.0; MS: m/z (FAB+ mode) 762.8 ([M+Ht 2%), 746.8 (3),698.8 (7),642.7 
(6), 596.7 (17), 432.6 (13), 430.6 (11), 210.2 (6), 147.1 (3) 73.7 (100); Found 
[M+Ht 762.3885, ClsH3002N3SiS requires 762.3891. 
SE~n ... SES (N N") 
SES-N' N-SES 
eN N-.J 
SEs"U'SES 
122 
1,5,9,12,17,20-Hexa[(2-trimethylsilyl)ethanesulfonyl]-1,5,9,12,17,20-
hexaazacyclodocosane (122) 
Using 87 (2.00 g, 3.35 mmol) and 109 (1.30 g, 3.35 mmol) in DMF (40 mil, 122 was 
prepared general procedure' 2h and washed with boiling 2-PrOH (50 mI) for 2 h to 
~ - give a cream solid (1.12 g, 51 % yield); m.p. 218.1-221.2 °C; Vmax (Golden Gate) 989, 
1136, 1167, 1248, 1335, 1456 and 2954 cm.ol; OH (CDCb) 0.07 (54 H, s), 0.97-1.05 
(12 H, m), 1.72 (8 H, broad s), 2.91-2.98 (12 H, m), 3.30 (8 H, broad m), 3.46-3.80 
(16 H, broad m); oe(CDCb) -1.60, 10.2, 10.7,25.5,46.6,47.7,48.1,48.4,49.9; m/z 
157 
(FAB+ mode NaI) 1322.51 ([M+Nat, 20%), 1157.8 (6), 1135.8 (8), 991.7 (7) and 
969.7 (6); Found [M+Nat 1322.5068, C46HlllN6012Si6S<fia requires 1322.5098. 
6.1.9. Deprotectlon of SES-amides 
H2N~N~NH2 
H 
101 
1,6,11-triazaundecane (101) 
Using 98 (3.24 g, 10.0 mmol), 101 was prepared according to general procedure 2k 
to give a beige oil (1.34 g, 84%); IH and 13C NMR spectra agreed with literature 
values.196 OH (CDCh) 1.39-1.52 (8H, m), 2.57 (4H, t, J = 6.9), 2.66 (4H, t, J = 6.7); 
oe (CDCh) 27.8, 31.8, 42.4, 50.1. 
H2N~N~NH H 2 
102 
1,7,13-triazatridecane (102) 
Using 99 (0.200 g, 0.569 mmol) , 102.was prepared to give an oil (0.089 g, 84% 
yield); IH and 13C NMR spectra agreed with literature values. 169 OH (CDCh) 1.34-
1.61 (10H, m), 2.62 (4H, t, J = 7.2), 2.71 (4H, !, J = 6.9); oe (CDCI~) 25.1, 30.4, 
34.1,42.5,50.4. 
H2N~N~NH2 
H 
103 
1,8,15-triazapentadecane (103) 
Using 100 (1.45 g, 3.82 mmol), 103 was prepared according to general procedure 2k 
to give an oil (0.38 g, 46% yield); IH and I?C NMR spectra agreed with literature 
values.197 OH (CDCh) 1.33-1.~5 (12H, m), 2.60 (4H, t, J= 7.2),2.69 (4H, t, J= 6.9); 
oe (CDCh) 27.2, 27.7, 30.6, 34.2,42.5, 50.4. 
158 
1,4,7 -Triazacyclodecane (123) 
(l 
C~J 
123 
Using 111 (0.731 g, 1.15 mmol), 123 was prepared according to general procedure 
2k as an orange oil (0.090 g, 55% yield); IH and l3C NMR spectra were consistent 
with values reported for the trihydrochloride salt;207 OH (CDCh) 1.55-1.60 (2 H, m), 
2.52-2.83 (12 H, m); oe (CDCh) 26.8, 47.0, 48.3, 49.4. 
124 
1,4,7 -Triazacycloundecane (124) 
Using 112 (0.111 g, 0.170 mmol), 124 was prepared according to general procedure 
2k (using TBAF in place of CsF) and not isolated from byproduct (0.014 g, 52% 
yield); IH and l3C NMR spectra were consistent with values reported for the 
trihydrochloride salt;246] OH (CDCh) 1.82-1.88 (4H, m), 2.55-2.90 (12H, m); oe 
(CDCh) 26.5, 27.2, 46.8, 48.5 and 49.8: 
.. 1,5,9-Triazacycloundecane (125) 
Using 113 (0.960 g, 1.47 nlmol), 125 was prepared according to general procedure 
2k and purified by Kugelrohr distillation (0.035 mmHgl191 °C) to give a clear oil 
(0.102 g, 44% yield). IH and l3C NMR spectra were consistent with values reported 
for the trihydrochloride salt;24~ OH (CDCh) 1.78-1.84 (4 H, quintet, J = 5.2), 2.71 (4 
H, s), 2.79-3.00 (8 H, broad m); oe (CDCh) 24.2,46.8,48.3,48.5. 
159 
(l 
C~) 
126 
1,5,9-Triazacyclododecane (126) 
Using 114 (0.788 g, 1.18 mmol), 126 was prepared according to general procedure 
2k as an orange oil (0.117 g, 58% yield); IH and 13C NMR spectra agreed with 
literature values. l5l OH (CDCh) 1.81-1.87 (6 H, quintet, J 5.3), 2.87-3.0 (12 H, t, J 
5.4); oc(CDCh) 26.2 (CH2), 49.1 (NCH2). 
1;5,9-Triazacyclotridecane (37) 
n 
C~2) 
37 
Using 115 (0.670 g, 0.992 mmol), 37 was prepared according to general procedure 
2k and purified by Kugelrohr distillation (1.0 mmHglI44°C) to give a pale yellow oil 
(0.073 g, 39 % yield). IH and 13C NMR spectra were consistent with values reported 
for the trihydrochloride salt;159 Vrnax (CDCh solution cell) 2203, 2422. 2711. 2846, 
2924 cm-~; OH (CDCh) 1.80-1.87 (8 H. m. NCH2CH2). 2.77-2.78 (4 H. m, 
NCH2CH2), 2.80-2.89 (8 H. m. NCH2CH2CH2N);~c 26.9 and 27.6 (CHz), 49.2. 51.1 
and 50.5 (NCH2). 
127 
1.5,9-Triazacyclotetradecane (127) 
Using 116 (1.21 g, 1.75 mmol), 127 was prepared according to general procedure 2k 
and purified by Kugelrohr distillation (0.035 mmHg/l71 °C) to give a clear oil 
160 
(0.216 g, 62% yield); IH and 13C NMR spectra were consistent with values reported 
for the trihydrobromide salt;248 Vrnax (CDC!) solution cell) 1383, 1473, 1645, 1672, 
2856 and 2933; OH (CDC!) 1.43-1.57 (8 H, m, CHz), 1.67-1.73 (2 H, m, CHz), 2.65-
2.73 (12 H, m, NCHz); Oc (CDC!)} 20.9,25.7,28.5,47.2,47.5 and 49.2 (CH2); mlz 
(EI+ mode) 199.2 ([M"t,18%), 198.2 (3), 170.2 (2), 155.1 (5), 141.1 (6), 112.11 
(15), 98.1 (48), 82.9 (100), 70.1 (28) and 47.0 (30); Found [M"t 199.2049, 
CllH25N3 requires 199.2048. 
128 
1,5,10-Triazacyclotetradecane (128) 
Using 117 (0.897 g, 1.28 mmol) , 128 was prepared according to general procedure 
2k and purified by Kugelrohr distillation (0.1 mmHgl170 °C) to give a pale yellow 
oil (0.084 g, 33% yield); Vrnax (CDC!) solution cell) 1383, 1470, 1560, 1643, 1672, 
2902 and 2983; OH (CDC!) 1.55-1.64 (8 H, m, CHz), 1.68-1.74 (2 H, m, CHz), 2.64-
2.74 (12 H, m, NCHz); oe (CDC!) 25.2, 25.9, 46.2, 48.2 and 49.1 (CH2); mlz (EI+ 
mode) 199.2 ([M"t, 19%), 182.2 (3), 154.1 (5), 141.1 (7), 112.1 (15),98.1 (26),84.0 
(100), 63.~ (51) and 44.1 (23); Found [M"t 199.2047, CllH25N3 requires 199.2048. 
() 
'C() 
129 
1,5,10-Triazacyclopentadecane (129) 
Using 118 (0.898 g, 1.27 mmol), 129 was prepared according to general procedure 
2k and purified by Kugelrohr distillation (0.1 mmHgl170 °C) to give a pale yellow 
oil (0.093 g, 34% yield); Vrnax (CDCh solution cell) 1383, 1470, 1560, 1645, 1672, 
2854, 2933 and 2983; OH (CDC h) 1.49-1.60 (10 H, m, CHz), 1.64-1.70 (2 H, m, 
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CHz), 2.61-2.74 (12 H, m, NCHz); oe (CDCh) 23.9, 27.2, 27.9, 28.1, 28.6, 28.8, 
47.9,48.3,48.6,49.7 and 50.2 (CH2); m/z (El+ mode) 213.2 ([M't, 19%), 196.2 (3), 
183.2 (3), 155.2 (6), 141.1 (6), 126.1 (13),98.1 (53), 84.0 (100), 82.9 (48), 70.1 (36) 
and 47.0 (34); Found [M't 213.2206, C12H27N3 requires 213.2205. 
130 
1,6,11-Triazacyclopentadecane (130) 
Using 119 (0.294 g, 0.416 mmol), 130 was prepared and purified by Kugelrohr 
distillation (0.05 mmHgl160 °C) to give a pale tan oil (0.060 g, 67% yield); IH 
NMR: OH (CDCh) 1.59 (12 H, broad s), 2.68 (12 H, broad s); 13C NMR: oe (CDCh) 
2'J.3, 48.7; MS: m/z (FAB+ mode) 214.2 ([M+Ht, 100%), 212.2 (11), 126.1 (12), 
84.6 (7), 73.7 (10),48.0 (6); Found [M+Ht 214.2285, C12H28N3 requires 214.2283. 
131 
1,6,12-Triazacycloheptadecane (131) 
Using 120 (0.50 g, 0.681 mmol), 131 was prepared according to general procedUre 
2k and purified by Kugelrohr distillation (0.05 rinnHgl150 °C) to give 'a clear oil 
(0.054 g, 33% yield); IH NMR: BH (CDCh) 1.35-1.59 (19 H, m), 2.62-2.66 (12 H, 
m); 13C NMR~ Be (CDCh),24.7, 27.7, 29:1, 29.3, 48.7, 49.0, 49.1; MS: m/z (El+ 
mode) 241.3 ([M+Ht, 14%),225.3 (2),200.3 (3), 183.2 (4), 155.2 (11), 140.2 (22), 
112.2 (21), 84.1 (100), 70.1 (34), 44.1 (23); Found [M+Ht 241.2520, Cl.Ji31N3 
- . 
requires 241.2518. 
162 
132 
1,6,13-Triazacyclononadecane (132) 
Using 121 (0.49 g, 0.643 mmol), 132 was prepared according to general procedure 
2k and purified by Kugelrohr distillation (0.05 mmHg/165 °C) to give a clear oil 
(0.054 g, 31 % yield); IH NMR: ~ (CDCh) 1.38-1.58 (23 H, m), 2.62-2.68 (12 H, 
m); 13C NMR: Be (CDCh) 26.5, 26.7, 27.7, 29.4, 29.6, 28.7, 49.0, 49.4; MS: mlz 
(EI+ mode) 269.4 ([M+Ht, 43%), 237.3 (5), 225.3 (6),211.3 (14), 169.2 (25), 154.2 
(23), 126.2 (33), 112.2 (97), 84.1 (100), 70.1 (57), 55.1 (44); Found [M+Ht 
241.2520, CIJf31N3 requires 241.2518. 
n 
(NH HN~ 
NH HN 
CNH HN~ 
U 
133 
1,5,9,12,17,20-Hexaazacyclodocosane (133) 
Using 122 (1.35 g, 1.03 mmol), 13~ was prepared according to general procedure 2k 
.. " 
and purified by Kugelrohr distillation (0.035 mmHg/220 °C) to give a pale yellow 
solid (0.092 g, 28% yield); IH and 13C NMR spectra were consistent with values 
.. reported for the hexahydrochloride salt;249 OH (CDCh) 1.54-1.56 (8 H, m), 1.67 (6 
H, broad s), 2.63 (8 H, broad s), 2.67-2.75 (16 H, m); oe (CDCIJ) 28.5, 49.1, 49.6, 
50.1. 
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6.1.10. Synthesis of cyclophanes 
1,4-Bis(bromomethyl)naphthalene (140) 
Using 1,4-dimethylnaphthalene (1.00 g, 6.40 mmol) and NBS (4.6 g, 25.6 mmol), 
140 was prepared in 3 h according to general procedure 21 and recrystallised from 
MeCNlhexane (-1:2) to give yellow crystals (0.593 g, 30% yield); IH and 13C NMR 
spectra agreed with literature values;2S0 OH (CDCh) 4.95 (4H, s, CH;zBr), 7.50 (2H, 
s, ArH), 7.66-7.70 (2H, m, ArH), 8.20-8.24 (2H, m, ArH); oc(CDCh) 31.4 (CH2), 
125.0, 127.3, 127.6 (ArCH), 132.3, 135.3 (ArC). 
o 
142 
2,3-Bis(bromomethyl)anthraquinone (142) 
Br 
Br 
Using 2,3-dimethylanthraquinone (0.50 g, 2.1 mmol) and NBS (1.51 g, 8.47 mmol), 
142 was prepared overnight acc~rding to general procedure 21 and recrystallised 
from BtOH to give a yellow solid (0.224 g, 37% yield); IH and 13e NMR spectra 
agreed with literature values;251 OH (CDCh) 4.77 (4H, s, CH;zBr), 7.82-7.85 ~2H, m, 
ArH), 8.32-8.34 (4H, m, ArH); oc(CDCh) 28.2 (CH2), 127.4, 130.0, 134.5, (ArCH), 
133.4, 133.7, 142.8 (ArC), 182.2 (CO). 
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144 
1,5,10-Tris [(2-trimethylsil yl)ethanesulfonyl]-1 ,5,1 O-triaza( 1,4 )naphthalenophane 
(144) 
Using 140 (0.593 g, 1.89 mmol) and 89 (1.21 g, 1.89 mmol) , 144 was prepared 
according to general procedure 2h and recrystallised from 2-propanol to give a 
cream solid (0.795 g, 53% yield); OH (CDCh) 0.00 (9H, s, CH3Si), 0.13 (18H, s, 
CH3Si), 0.69-0.87 (6H, m), 1.14-1.21 (4H, m), 1.27-1.36 (2H, m), 2.14-2.27 (2H, 
m), 2.51-2.69 (4H, m), 2.92-3.13 (6H, m), 3.24-3.41 (2H, m), 4.10-4.13 (IH, d, J = 
13.2),4.20-4.17 (1H, d, J = 13.2),5.45-5.48 (IH, d, J = 13.2), 5.53-5.56 (1H, d, J = 
13.2),7.47-7.53 (2H, m), 7.65-7.70 (2H, m), 8.49-8.63 (2H, m); oc(CDCh) -1.6 and 
-1.5 (CH3), 10.5, 10.6,25.7,26.2,28.2,30.9,45.9,46.1,46.8,46.9, 47.5, 48.6,48.7, 
53.1, 53.9 and 64.8 (CH2), 125.4, 125.7, 127.6, 127.8, 128.4 and 128.7 (ArCH), 
132.7, 132.9, 133.8 and 134.1 (ArC); m/z (FAB+ modelNOBA) 790.7 ([M+Ht, 
6%), 726.7 (13), 698.7 (11),624.6 (32); 560.6 (4),458.5 (7), 252.3 (5), 226.2 (16), 
141.1 (11) and 73.7 (100). Found [M+Ht 790.3272, C3J164N306S3Sh requires 
790.3265. 
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145 
1,5,10-Tris[(2-trimethylsilyl)ethanesulfonyl]-1,5,10-triaza(1,8)naphthalenophane 
(145) 
Using 1,8-bisbromomethylnaphthalene (0.50 g, 1.59 mmol) and 89 (1.02 g, 1.59 
mmol), 145 was prepared according to general procedure 2b and purified by column 
chromatography to give a white foamy solid (0.23 g, 18% yield); OH (CDCh) 0.06 
(9H, s), 0.14 (18H, s), 0.76-0.81 (2H, m), 1.13-1.29 (8H, m), 2.59-2.63 (2H, m), 
2.91-2.97 (4H, m), 3.05-3.15 (4H, m), 3.39-3.45 (4H, m), 7.44-7.53 (2H, m), 7.69-
7.90 (4H, m). 
( 
1,5,10-Triaza(1 ,4 )naphthalenophane (146) 
., 
Using 144 (0.795 g, 1.00 mmol), 146 was prepared according to general procedure 
2k to give a clear oil (0.074 g, 25% yield); OH (CDCh) 0.68-1.02 (4H, m), 1.~5-1.34 
.. (2H, m), 1.38-1.51 (2H, m), 1.64-1.78 (1H, m), 1.91-2.04 (IH, m), 2.12-2.27 (2H, 
m), 2.42-2.85 (5H, m), 3.70-3.91 (2H, m), 4.68-4.87 (2H, m), 7.32-7.67 (4H, m), 
8.20-8.33 (2H,-m); Oc (CDCh) 26.1, 28.0, 29.1, 4J.9, 45.7, 47.3, 48.0,50.9 and 51.7 
(CH2) , 124.7, 124.8, 125.9, 125.93, 126.6 and 126.9 (ArCH), 132.4, 132.5, 136.3 
and 137.2 (ArC); m/z (FAB+ mode) 298.3 UM+Ht, 96%), 280.3 (5), 254.3 (4), 
224.2 (8), 196.2 (5), 168.1 (8), .155.1 (19), 141.1 (12),98.4 (11), 73.7 (29), 70.8 (17), 
45.1 (8); Found [M+Ht 298.2222, C19H2SN3 requires 298.2283. 
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1,5,10-Triaza(1 ,8)naphthalenophane (147) 
Using 145 (0.233 g, 0.294 mmoI), 147 was prepared according to general procedure 
2k to give a It. brown oil (0.082 g, 93% yield); OH (CDCh) 1.52-1.76 (9H, m), 2.70-
2.73 (4H, m), 2.89-2.96 (4H, m), 4.23 (2H, s), 4.63 (2H, s). 
6.1.11. Carbon template routes 
9a,9b-Dimeth yl-octahydro-1 ,3a,6a,9-tetraaza-phenalene (149) 
N,N'-Bis(2-aminoethyl)-1,3-propanediamine (1.00 g, 6.24 mmol) was dissolved in 
.. . 
dry MeCN (12.5 ml) and cooled to 0 °c on an ice bath. A solution of butanedione 
(0.540 g, 6.24 mmol) in MeCN (12.5 ml) was dripped in slowly and the mixture 
stirred for 2 h. The solvent was removed by rotary evaporation and the resulting 
residue recrystallised from hexane to give 149 as white crystals (0.94 g, 69% yield); 
.. m.p. = 98-100 °c (lit. 110°C); IH and 13C NMR spectra agreed with literature 
values;148 OH (CDCh) 1.16-1.21 (IH, m), 1.33 (3H, s), 1.41 (3H, s), 2.21-2.63 (7H, 
m), 2.72-2.77 (lH, m), 2.91-2.94 (IH, m),3.13-3.35 (3H, m), 3.58-3.63 (IH, m); Oc 
(CDCh) 10.8 and 23.7 (CH3), 18.4,39.3,42.1,45.8,46.7,49.1 and 51.3 (CH2), 68.2 
and 73.4 (C). 
167 
150 
9b,9c-Dimethyl-decahydro-2a,4a, 7 a,9a-tetraaza-cyclopenta[ cd]phenalene (150) 
149 (0.940 g, 4.33 mmol) was dissolved in MeCN (43 ml) with K2C03 (6.00 g, 43.2 
mmol). 1,2-Dibromoethane (1.22 g, 6.49 mmol) was added via syringe and the 
mixture stirred at room temperature for 6 h. The solution was filtered, the solvent 
evaporated and the residue was purified by column chromatography (99: 1 
CHCl:JMeOH, neutral alumina) to give 150 as a yellow oil (0.47 g, 44% yield); IH 
and l3C NMR spectra agreed with literature values;148 OH (CDCh) 1.15 (3H, s), 1.17-
1.20 (lH, m), 1.40 (3H, s), 2.31-2.82 (HH, m), 2.92-2.96 (2H, m), 3.19-3.30 (3H, 
m), 3.63-3.74 (lH, m); Oc (CDCh) 12.06 and 13.1 (CH3), 18.7, 45.0, 46.1, 46.4, 
46.8, 48.6, 50.0 and 50.6 (CH2), 72.6 and 78.4 (C). 
151 
1,4,7,1O-Tetraazacyclotridecane (151) 
150 (0.467 g, 1.92 mm,ol) was cOtnbined with 10% aqueous HCI (40 ml) in EtOH 
(20 ml) and stirred at reflux for 2 days. The solvent was evaporated and the residue 
basified to pH 14 with NaOH. Toluene was added and the water removed using 
0' Dean-Stark apparatus. The toluene was evaporated and the residue recrystallised 
from hexane to give 151 as beige crystals (0.146 g, 39% yield); IH and l3C NMR 
spectra agreed-with literat~ values;252 o~ (CDCI3) 1.67-1.76 (2H, m), 2.67-2.85 
(16H, m); Oc (CDCh) 25.6, 44.3, 44.6, 45.8 and 46.9. 
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1,I-Ethylenedi-2-imidazoline (153) 
152 (S.15 g, 68.3 mmol) was added to triethylenetetraamine (5.00 g, 34.2 mmol) and 
the mixture was refluxed for 1 h. Excess solvent (MeOH, NH(Meh) was removed in 
vacuo and the residue recrystallised from THF to give 153 as white hygroscopic 
crystals (2.43 g, 43% yield); IH and 13C NMR spectra agreed with literature 
values;149 ~H (CDCh) 3.20-3.25 (SH, m), 3.S0-3.S5 (4H, m), 6.7S-6.79 (2H, m); ~c 
(CDCh) 47.1, 49.0 and 55.2 (CH2), 157.4 (CH3). 
154 
1,I-Ethylenedi-2-(1,4,5,6-tetrahydro-pyrimidine) (154) 
152 (20.5 g, 172 mmol) was added to N,N'-Bis(3-aminopropyl)-I,2-ethanediamine 
(15.0 g, S6.1 mmol) and the mixture was refluxed for 1 h. Excess solvent (MeOH, 
NH(Meh) was r,emoved in vacuo to give 154 as a white hygroscopic solid (16.7 g, 
99.9% yield); IH and 13C NMR spectra agreed with literature values;253 ~H (CDCh) 
1.77-1.S3 (4H, m), 3.11-3.15 (SH, m), 3.24-3.26 (4H, m), 6.89 (2H, s); ~c (CDCh) 
21.4,42.6,44.3 and 51..5 (CH2), 149.S (CH). 
CN~N~ .) ~ .. ) N N 
152 
1, I-Propylenedi-3-(1 ,4,5,6-tetrahydro-pyrimidine) (155) 
152 (0.640 g, 5.32 mmol) was added to N,N'-Bis(3-aminopropyl)-1,3-
propanediamine (0.500 g, 2.66' mmol) and the mixture was refluxed for 1 h. Excess 
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solvent (MeOH, NH(Meh) was removed in vacuo to give 155 as a clear oil which 
was distilled using Kugelrohr apparatus (212 °C/0.2 mmHg) (0.44 g, 78% yield); IH 
and l3C NMR spectra agreed with literature values;253 ~H (CDCh) 1.70-1.87 (6H, m), 
3.05-3.14 (6H, m), 3.23-3.35 (4H, m), 3.45 (2H, s), 6.95 (2H, s); ~c (CDCh) 21.5, 
27.2,43.3,44.0 and 50.4 (CH2), 150.2 (CH). 
1,4,7,10-Tetraazacyclododecane (cyclen) (36) 
The templated bromide salt (2.79 g, 10.2 mmol) was dissolved in water (10 ml) and 
dripped into a refluxing solution of KOH (3.19 g, 81.7 mmol) in water (10 ml). The 
solution was refluxed for 1 h, then filtered and concentrated until a white solid began 
to precipitate. This was filtered and the filtrate concentrated further, precipitating 
more white solid. The solids were combined (0.513 g, 29% yield); IH and l3C NMR 
spectra agreed with literature values;149 ~H (CDCh) 2.59 (16H, s); ~c(CDCh) 46.1. 
6.2. Experimental to Chapter 3 
Genera] procedures 3a-c 
a) Acylation of polyazamacrocycles:254 The polyazamacrocycle (either the 
free base or as an acid satt) was dissolved (or suspended) in dry DCM and 
cooled to 0 °c on an ice bath. Triethylamine (4 eq. for free bases, 8 eq. for 
salts) was added via syringe and the mixture stirred until dissolved. 
Chloroacetyl chloride was added via syringe and the solution stirred for 20 
min. - The ice bath was removed and the solution stirred at room 
temperature overnight. The solution was washed with water (2 x 25 ml), 
the organic layer dried with Na2S04 .. filtered and rotary evaporated to an oil. 
The crude amide was purified by column chromatography (97:3 CH2Ch-
MeOH, silica). 
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b) N-Hydroxyethylation of macrocyc1ic polyamines:209 The macrocyclic 
polyamine free base (1 eq.) was dissolved in EtOH (1 mllmg) in a round 
bottom flask fitted with a cold finger, was cooled to - 5 °c with a 
cryocooler. Ethylene oxide (approximately 10 drops) was dripped in by 
condensing on the cold finger. The mixture was stirred and held at 5 ·C 
overnight, after which the solvent was removed by rotary evaporation. The 
residue was typically pure, but could be purified by Kugelrohr distillation if 
necessary. 
c) Conversion to chloroethyl derivative:210 The hydroxyethyl macrocyc1ic 
polyamine was stirred with thionyl chloride as reagent and solvent while 
heating to -50°C overnight. The excess thionyl chloride was removed in 
vacuo leaving the trishydrochloride salt, which was usually sufficiently 
pure for analysis and testing. If necessary, the salt could be recrystallized in 
methanol or 2-propanol. 
Experimental details 
6.2.1. Chloroacetamides 
1,5,9-Tris-chloroacetyl-l ,5,9-triazacyclododecane (160) 
Using 1,5,9-triazacyclododecane trihydrobromide (0.100 g, 0.242 mmol), 160 was 
prepared according to general procedure 3a to give a tan oil (0.034 g, 35% yield); OH 
(CDCh) 2.10 (6 H, broad s, CHz), 3.52-3.54 (12 H, broad m, NCHz),4.1O (6 H, s, 
CHl~I); oe (CDCh) (rotamers present) 28.3, 41.4, 45.2 and 47.2 (CH2), 170.0 and 
172.1 (CO); mlz (EI+ mode) 364 ([M-Clt, 7%), 350 (100), 322 (83), 286 (15), 267 
(11), 231 (7), 217 (18), 203 (24), 189 (14), 162 (13), 160 (30), 134 (69), 124 (15), 
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112 (20), 91 (34), 70 (100), 56 (76), 44 (55); Found [M-Clt 364.1193, 
ClsH2403N3Ch requires 364.1195. 
1,6,10-Tris-chloroacetyl-l ,6, 10-triazacyclotridecane (161) 
Using 37 (0.112 g, 0.602 mmol), 161 was prepared according to general procedure 
3a to give a tan oil (0.046 g, 18% yield); OH (CDCh) 1.78 (4 H, broad s, CH2), 1.96-
2.04 (4 H, broad m, CH2), 3.38-3.56 (12 H, m, NCH2), 4.05-4.12 (6 H, m, CH2CI); 
Oc (CDCh) (rotamers present) 27.2, 28.2, 29.7, 41.4, 41.7, 44.6, 46.3, 47.5, 48.2, 
48.6 and 50.8 (CH2), 167.3, 167.8,168.6 and 169.4 (CO). 
( 
1,7 ,11-Tris-chloroacetyl-l,7 ,11-triazacyclotetradecane (162) 
Using 127 (HC} salt, 0.128 g, 0.418 mmol), 162 was prepared according to general 
procedure 3a to give a tan oil (0.042 g, 23% yield); OH (CDCb) 1.47 (2 H, ~road s, 
CH2) , 1.72-1.75 (4 H, broad m, CH2), 1.92-1.99 (4 H, broad m, CH2), 3.32-3.47 (12 
H, m, NCH2), 4.07-4.09 (6 H, m, CH2Cl); Oc (CDCh) (rotamers present) 23.0, 23.8, 
26.9, 27.5, 27.5, 28.4, 28.6; 28.9,29.5, 29:9, 30.5,41.6,41.7,45.2,45.6,45.9,46.6, 
48.1, 48.6, 49.1, 49.2, 49.4, 50.0 and 50.2 (CH2), 167.6, 167.7 (CO); m/z (FAB+ 
mode) 430.1 ([M+Ht, 98%, e 7CI]), 428.1 (fM+Ht, 100, eSCI]), 350.1 (12),316.2 
(2), 295.1 (5), 134.1 (5), 98.5 (10) and 56.1 (10); Found [M+Ht 428.1277, 
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C17H2903Nl5Ch requires 428.1275; Found [M+Ht 430.1269, C17H2903Nl7Ch 
requires 430.1247. 
6.2.2. Hydroxyethyl derivatives 
HO 
"(I eN N-/",OH N-J ~ 
HO 163 
1,4,7-Tris(2-hydroxyethyl)-1,4,7-triazacyclononane (163) 
Using 1,4,7-triazacyclononane (0.050 g, 0.387 mmol) and ethylene oxide (1 ml), 163 
was prepared according to general procedure 3b to give a clear oil (0.086 g, 85% 
yield); IH and 13C NMR spectra agreed with literature values;255 OH (CDCI3) 2.63 
" 
(12 H, s), 2.75-2.77 (6 H, t, J 5.1), 3.58-3.61 (6 H, t, J 5.1, ); Oc 53.3, 59.8 and 60.4 
(CH2)' 
HO'-l\fOH 
eN) ( 
OH 
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1,5,9-Tris(2-hydroxyethyl)-1,5,9-triazacycloundecane (164) 
.. Using 125 (0.039 g, 0.25 mmol), 164 was prepared according to general procedure 
3b as a light yellow oil (0.044 g, 65% yield); Vmax (CDCh solution cell) 1423, 1475, 
2401,2812,2954 and 3683~ OH (CDCh) 1.65 (4H, bs), 2.35-2.60 (18H, m), 3.50-3.69 
(6H, m); Oc (CDCh) 24.9, 52.8, 54.6, 55.4, 59.4, 70.9, 72.8; m/z (FAB+ mode) 290.3 
([M+Ht, 100%), 288.3 (9), 246.3 (2), 227.'1. (2), 203.2 (1), 166.2 (4), 154.1 (50), 
136.1 (33), 107.4 (10), 88.6 (12), 73.8 (9) and 56.1 (6); Found [M+Ht 290.2443, 
Cl.JI3203N3 requires 290.2444. 
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1,5,9-Tris(2-hydroxyethyl)-1,5,9-triazacyclododecane (165) 
Using 1,5,9-triazacyclododecane (0.050 g, 0.29 mmol), 165 was prepared according 
to general procedure 3b as a clear oil (0.079 g, 88% yield); OH (CDCh) 1.74 (6H, 
quintet, J = 6.0),2.35-2.65 (12H, m), 3.63-3.66 (6H, m); oc(CDCh) 24.1, 51.0, 56.0, 
58.7. 
HO~n~OH 
eN.) ( 
OH 
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1,5,9-Tris(2-hydroxyethy)I-1,5 ,9-triazacyclotridecane (166) 
Using 37 (0.040 g, 0.22 mmol), 166 was prepared according to general procedure 3b 
and purified by Kugelrohr distillation to give a clear oil (0.030 g, 44% yield); OH 
(CDCh) 1.62-1.65 (4H, m), 1.67-,1.71 (4H, m), 2.49-2.58 (18H, m), 3.59-3.63 (6H, 
m); Oc (CDCh) 23.6, 24.3, 51.7, 52.7, 53.3, 55.1, 56.4, 57.7, 57.9. 
174 
167 
1,9-Bis(2-hydroxyethyl)-1,5,9-triazacyclotetradecane (167) 
Using 127 (0.075 g, 0.38 mmol), 167 was isolated from an attempted preparation of 
168 according to general procedure 3b and purified by Kugelrohr distillation to give 
a clear oil (0.014 g, 13% yield); OH (CDCh) 1.40-1.57 (6H, m), 1.76 (4H, quintet, J 
= 5.6),2.42-2.64 (12H, m), 2.65-2.71 (4H, m), 3.60-3.64 (4H, m); Oc (CDCh) 23.1, 
25.4, 26.7, 49.1, 51.3, 54.1, 56.8, 60.4; m/z (FAB+ mode) 288.2 ([M+Ht, 100%), 
286.2 (10), 128.1 (5), 98.4 (7), 73.7 (17); Found [M+Ht 288.2653, ClSH3402N3 
requires 288.2651 
168 
~ 
1,5,9-Tris(2-hydroxyethyl)-1 ,5 ,9-triazacyclotetradecane (168) 
Using 127 (0'<~60 g, 0.30. mmol), 168 was prepared according to general 
procedure 3b as a clear oil (0.057 g, 57% yield); OH (CDCh) 1.55-1.78 (10H, m), 
2.42-2.71 (18H, m), 3.54-3.67 (6H, m); Oc (CDCh) 23.2, 24.5, 25.1, 25.5, 26;3,49.1, 
51.0, 52.2, 52.5, 53.3, 53.4, 56.4, 56.7, 57.5, 58.9, 59.1 and 59.7; m/z (CI+ 
mode/isobutan~) 388.4 (1O~), 349.2 (33)~ 332.3 ([M+Ht, 43), 288.3 (100), 279.2 
(22), 270.3 (10), 244.3 (6), 195.2 (4), 151.2 (7), 107.1 (8), 91.1 (4). Found [M+Ht 
332.2907, C17H3SN303 requires 332.2913. 
175 
169 
1,5,10-Tris(2-hydroxyethyl)-1,5,10-triazacyclotetradecane (169) 
Using 128 (0.041 g, 0.21 mmol) , 169 was prepared according to general procedure 
3b as a clear oil (0.046 g, 68% yield); OH (D20) 1.38-1.89 (10H, m), 2.36-2.59 (18H, 
m), 3.44-3.58 (6H, m); Oc (020 + CD30D) 21.3, 27.2, 27.8, 55.4, 56.8, 57.0, 57.4, 
59.7, 60.8 and 63.6; mlz (CI+ mode/isobutene) 388.4 (20%), 332.3 ([M+Ht, 100), 
330.3 (10), 288.3 (7). Found [M+Ht 332.2909, C17H38N303 requires 332.2913. 
170 
1,5,10-Tris(2-hydroxyethyl)-1,5,10-triazacyclopentadecane (170) 
Using 129 (0.040 g, 0.19 mmol), 170 was prepared according to general procedure 
3b as a clear oil (0.06~ g, 96% yield); OH (CDC13) 1.35-1.66 (12H, m), 2.37-2.57 
(18H, m), 3.53-3.57 (6H, m); Oc (CDCh) 25.7, 26.0, 27.7, 27.9, 53.9, 54.1, 54.2, 
55.1, 55.4, 56.0, 56.6, 57.5, 57.8, 59.3, 59.4; mlz (FAB+ mode) 346.3 ([M+Ht, 
100%), 344.3 (20), 302.3 (10), 128.1 (15), 98.4 (14), 84.6 (13), 73.7 (11), 56.9 (6); 
Found [M+Ht 346.3072, C18Rw03N3 requires 346.3070 
~ . . 
176 
HO,-, n r-/0H 
CN~ ~. 
HO 171 
1,6,12-Tris(2-hydroxyethyl)-1 ,6, 12-triazacyclopentadecane (171) 
Using 131 (0.040 g, 0.17 mmol), 171 was prepared according to general procedure 
3b as a clear oil (0.061 g, >99% yield); OH (CDCh) 1.32-1.49 (16H, m), 2.28-2.48 
(18H, m), 3.45-3.48 6H, m); oc (CDCh) 25.6, 26.5, 27.8, 28.0, 54.3, 54.4, 54.6, 56.4, 
58.4, 58.9 and 59.0 (CH2); mlz (FAB+ modelNOBA) 374.6 ([M+Ht, 40%), 372.6 
(12),327.2 (5), 281.2 (4), 207.1 (7), 147.1 (14),98.5 (9), 73.7 (100),44.1 (8); Found 
[M+Ht 374.3378, C2oH44N303 requires 374.3383. 
1,6,13-Tris(2-hydroxyethyl)-1,6,13-triazacyclononadecane (172) 
Using 132 (0.040 g, 0.15 mmol) , 172 was prepared according to general procedure 
3b as a clear oil (0.060 g, >99% yield); OH (CDCh) 1.26-1.51 (20H, m), 2.42-2.61 
(18H, m), 3.49-3.55 (6H, m); oc(CDCh) 25.8, 27.1, 27.2, 27.5, 27.6, 53.8, 54.1, 
54.3, 56.7, 56.9, 58.6, 58.7 and 77.5 (CH2); mlz (EI+ mode) 401.7 ([M+Ht, 7%), 
.. 371.6 (84), 370.6 (83), 324.6 (29), 323.6 (28), 255.4 (14), 225.4 (15), 170.3 (16), 
142.2 (38), 112.2 (96), 84.1 (100),55.1 (100); Found [M+Ht 401.3616, C22RnN30 3 
requires 401.3617. 
177 
1,4,7,10-Tetra(2-hydroxyethyl)-1 ,4,7, lO-tetraazacyclotridecane (184) 
Using 148 (0.080 g, 0.41 mmol), 184 was prepared according to general procedure 
3b as a clear oil that crystallised upon standing to a waxy solid (0.130 g, 85% yield); 
aH (CDCh) 1.66-1.73 (2H, m), 2.44-2.73 (24H, m), 3.59-3.65 (8H, m); ac (CDCh) 
25.9,52.0,52.4,53.5,54.6,57.1,57.5,59.6 and 59.8. 
1,4,8,11-Tetra(2-hydroxyethyl)-1 ,4,8, II-tetraazacyclotetradecane (189) 
Using 1,4,8,1l-tetraazacyclotetradecane (0.200 g, 0.998 mmol), 189 was prepared 
according to general procedure 3b and recrystallised from CHChlEt20 (-1:4) to give 
white crystals (0.190 g, 51% yield); IHand l3C NMR spectra and m.p. agreed with 
.o' • , 
literature values;209 aH (CDCh) 1.51-1.76 (4H, m), 2.24-2.59 (24H, m), 3.44-3.56 
(8H, m); ac (CDCh) 25.4, 49.3, 52.1, 55.8 and 59.5 (CH2). 
178 
173 
1,5,9,12,17 ,20-Hexa(2-hydroxyethyl)-1 ,5,9, 12,17 ,20-hexaazacyclodocosane (173) 
Using 133 (0.040 g, 0.13 mmol), 173 was prepared according to general procedure 
3b to give a clear oil (0.055 g, 74% yield); SH (CDCh) 1.47-1.56 (8H, m), 2.45-2.67 
(36H, m), 3.54-3.60 (l2H, m); Sc (CDCh) 25.3, 52.1, 52.5, 55.3, 56.3, 57.6, 59.5, 
59.7; m/z (FAB+ mode) 579.5 ([M+Ht, 37%), 535.4 (35), 491.4 (17), 393.3 (10), 
322.2 (13), 290.2 (8), 171.1 (22), 114.2 (80), 84.6 (100), 73.7 (87); Found [M+Ht 
579.4817, C28~306N6 requires 579.4809. 
6.2.3. Synthesis of chloroethyl derivatives 
CI 
~(I L N-/CI N~ '3HCI ~ " 
CI 
174 
1,4,7 -Tris(2-chloroeth yl )-1,4,7 -triazacyclononane trihydrochloride (174) < 
Using 163 (0.086 g, 0.329 mmol) and thionyl chloride (2 ml), 174 was prepared 
according to general procedure 3c to give.a cream hygroscopic solid (0.138 g, 99% 
yield); SH (DMSO-~) 2.94 (6H, broad s), 3.20 (6H, broad s), 3.39 (6H, broad s); Sc 
(DMSO-~) 40.5 (CICH2), 49.3 (N'lrCH2), 56.5 (N'lrCH2CH2CI); m/z (FAB+, 
glycerol) 316.1 ([(M-3HCI)+Ht, 100%), 197.1 (5%), 147.0 (8), 106.3 (20), 70.8 (4), 
+ 35 57.0 (4); Found [(M-3HCl)+H] 316.1106, C12H24N3 Ch requires 316.1114. 
179 
CI-..,. (l r-/CI 
t~)3HC1 
CI 
175 
1,5,9-Tris-(2-chloroeth yl)-1 ,5 ,9-triazacyc1ododecane trih ydrochloride (175) 
Using 165 (0.032 g, 0.11 mmol), 175 was prepared according to general procedure 
3c as a cream solid (0.030 g, 61% yield); OH (020) 1.90-1.93 (6H, m), 3.04-3.07 
(12H, m), 3.16-3.19 (6H, m), 3.62-3.65 (6H, m); oe (020, ref. to internal MeOH = 
38.0) 18.2, 38.7, 48.9 and 55.5; mlz (FAB+, glycerol) 358.1 ([(M-3HCI)+Ht, 
100%),340.2 (13), 324.2 (6), 296.1 (4),232.1 (4), 132.0 (13), 106.3 (33), 84.6 (12), 
70.8 (11), 58.9 (7); Found [(M-3HCl)+Ht 360.1553, ClsH31NlsCll7CI requires 
360.1556. 
( 
CI~n~CI 
N N CN~ '3HCI 
( 
CI 
176 
1,5,9-Tris(2-chloroethy)1-1,5,9-triazacyc1otridecane trihydrochloride (176) 
Using 166 (0.030g, 0.094 mmol), 176 was prepared according to general procedure 
3c as a yellow foamy solid (0.041 g, 89% yield); OH (020) 1.85-1.98 (4H, m), 2.13-
.. 2.19 (4H, m), 3.33-3.61 (18H, m), 3.91-3.98 (6H, m); oe (020) 17.7, 20.4, 37.8, 
38.0, 48.8, 49.4, 49.7, 51.4, 56.7, 56.8, 56.9; mlz (FAB+, NOBA) 372.3 ([(M-
3HCI)+Ht, 12%),357.3 (5),310.3 (10), 238.3 (5), 169.1 (54),85.6 (100), 84.6 (15), 
66.8 (5); Found [(M-3HCI)+Ht 372.1738, C16H33NlsCh requires 372.1740. 
180 
177 
1 ,9-Bis(2-chloroethyl)-1 ,5,9-triazacyc1otetradecane trihydrochloride (177) 
Using 167 (0.014 g, 0.042 mmol), 177 was prepared according to general procedure 
3c as a yellow foamy solid (0.022 g, >99% yield); OH (D20) 1.59 (2H, broad m) 1.73 
(4H, broad m), 2.01-2.09 (4H, broad m), 3.26-3.38 (12H, m), 3.59-3.64 (4H, m), 
3.91-3.94 (4H, m); Oc (D20) 16.9, 18.5, 20.2, 37.8, 40.1, 47.3, 49.6, 55.9; mlz 
(FAB+) 324.4 ([(M-3HCI)+Ht, 100%), 288.3, (22), 262.3 (11), 222.3 (4), 130.2 
(38), 102.3 (36),98.3 (22); Found [(M-3HCI)+Ht 324.1970, C17H3SN33SCh requires 
324.1973. 
178 
1,5,9-Tris(2-chloroethyl)-1 ,5,9-triazacyc1otetradecane trihydrochloride (178) 
Using 168 (0.057 g, 0.17 mmol), 178 was prepared according to general procedure 
3c as a yellow foamy solid (0.079 g, 93% yield); OH (D20) 1.28 (2H, broad m), 1.43-
1.44 (4H, broad m), 1.74-1.75 (4H, broad m); Oc (D20, [ref. CD30D 0 48.4]) 19.9, 
.. 20.6, 35.2, 37.0, 37.7, 50.4, 52.0, 56.2; mlz (FAB+) 386.3 ([(M-3HCl)+Ht, 63%), 
352.4 (10), 324.3 (100), 288.3 (21), 262.3 (20), 210.3 (12), 167.2 (5), 106.2 (35); 
Found [(M-3HCl)+Ht 386.1902, C17H3SNlsCh requires 386.1897. 
181 
CI~(l~CI 
CN::J 3HC1 
< CI 
179 
1,5,10-Tris(2-chloroeth yl)-l ,5,1 O-triazacyc1otetradecane trihydrochloride (179) 
Using 169 (0.040 g, 0.12 mmol), 179 was prepared according to general procedure 
3c as a tan foamy solid (0.051 g, 85% yield); ()H (D20) 1.51-1.98 (lOH, broad m), 
3.05-3.22 (12H, broad m), 3.30-3.39 (6H, m), 3.58-3.67 (6H, m); ()c (D20, [ref. 
CD30D () 48.4]) 19.9,20.6,35.2,37.0,37.6,37.7,50.4,52.0,56.2,56.3; mlz (FAB+) 
387.2 ([(M-3HCI)+H]+, 18%),326.2 (6), 289.2 (4), 240.0 (4), 191.1 (28), 135.0 (25), 
97.4 (100), 96.4 (93), 77.6 (44), 56.0 (32); Found [(M-3HCI)+Ht 386.1903; 
C17H3SNlsCh requires 386.1896. 
180 
1,5,10-Tris(2-chloroethyl )-1,5 ,I O-~azacyc1opentadecane trihydrochloride (180) 
Using 170 (0.053 g, 0.15 mmol), 180 was prepared according to general procedure 
.. 3c as a yellow foamy solid (0.079 g, >99% yield); ()H (D20) 1.42-1.99 (lOH, broad 
m), 2.05-2.25 (2H, broad m), 3.20-3.53 (12H, broad m), 3.58-3.67 (6H, m), 3.87-
3.94 (6H, m); ()c (D20) 20.6; 21.2, 21.6, 21;8, 35.~, 37.6, 37.8, 48.5, 50.9, 51.3, 52.2, 
56.0,56.2,56.4; ; mlz (FAB+) 401.2 ([(M-3HCI)+Ht, 48%), 400.2 (13), 367.2 (11), 
340.2 (8), 303.2 (5), 190.1 (35), 189.1 (23), 146.0 (22), 96.4 (100), 95.4 (53), 77.6 
(33),56.0 (19); Found [(M-3HCI)+Ht 402.2221; C1SH39NlsCh requires 402.2210. 
182 
CI",--, n .;--/CI CN-.:J °3HCI 
(-J 
CI 181 
1,6,12-Tris(2-chloroethyl)-1 ,6, 12-triazacyc1opentadecane trihydrochloride (181) 
Using 171 (0.055 g, 0.15 mmol), 181 was prepared according to general procedure 
3c as a yellow solid (0.080 g, >99% yield); OH (D20) 1.42-1.54 (4H, broad m), 1.71-
1.90 (12H, broad m), 3.15-3.98 (24H, broad m); Oc (D20) 20.6, 21.3, 22.0, 22.3, 
51.6, 52.0, 52.5, 52.7, 53.1, 54.8, 55.1; m/z (FAB+ mode) 428.5 ([(M-3HCl)+Ht, 
100%) 394.5 (43), 392.5 (25), 366.4 (18). 253.2 (19), 202.2 (22), 148.2 (52), 98.3 
(95); Found [(M-3HCl)+Ht 428.2360, C2oHnN3Ch requires 428.2366. 
1,6,13-Tris(2-chloroeth yl)-1 ,6, 13-triazacyc1ononadecane trihydrochloride (182) 
Using 172 (0.048 g, 0.12 mmol), 182 was prepared according to general procedure 
3c as a yellow solid (0.068g, >99!1o yield); OH (D20) 1.33-1.57 (8H, broad s), 1.61-
1.87 (12H, broad m), 3:12-3.98 (24H, m); Oc (D20) 20.3, 21.4, 21.6, 22.2, 22.6, 51.5, 
51.9,52.3,52.5,53.3,55.0,55.2; m/z (FAB+ mode) 456.6 ([(M-3HCl)+Ht, 100%), 
.- 359.5 (10), 329.5 (9),271.3 (8), 216.3 (15), 190.2 (35), 112.3 (32), 96.5 (100), 56.0 
(90); Found [(M-3HCl)+Ht 456.2680, C22:i-4sN3Ch requires 456.2679. 
183 
CI"--'. (l ,r-JCI 
N N C ) '2HCI 
. N N 
CI~'--1~CI 
185 
1,4,7,10-Tetra(2-chloroethyl)-1 ,4,7,1 O-tetraazacyc1otridecane dihydrochloride (185) 
Using 184 (0.044 g, 0.12 mmol), 185 was prepared according to general procedure 
3c as a yellow solid (0.062 g, 99.9% yield); ()H (DMSO-dt;) 2.10-2.20 (2H, broad s), 
2.90-3.43 (24H, broad m), 3.95-4.00 (8H, m); ()e (COCh) 15.5, 49.4, 49.7, 51.1, 
54.2,54.8,55.7,56.8, and 65.3 .. 
CI~ (l/'-.../CI 
N N C ) '2HCI 
CI....-.........-N N~ V CI 
40 
1,4,8,11-Tetra(2-chloroethyl}-1 ,4,8,II-tetraazacyclotetradecane dihydrochloride (40) 
Using 197 (0.188 g, 0.499 mmol), 40 was prepared according to general procedure 
3c to give a cream solid (0.258 g, 98% yield); IH and 13C NMR spectra agreed with 
. 256 literature values; ()H (020) 1.92-2.18 (4H, Ill), 3.13-3.37 (16H, rn), 3.72-3.79 
(16H, m); ()e (020) 17.5,43.5,47.9,56.1 and 57.9 (CH2)' 
184 
183 
1,5,9,12,17 ,20-Hexa(2-chloroethyl)-I,5,9, 12, 17 ,20-hexaazacyclodocosane 
hexahydrochloride (183) 
Using 173 (0.055 g, 0.095 mmol), 183 was prepared according to general procedure 
3c to give a tan powder (0.071 g, 83% yield); OH (D20) 1.82-1.95 (8H, broad m), 
2.94-3.97 (48H, broad m); Oc (D20) 20.5, 20.6, 37.8,48.8,53.1,55.2,55.6,56.0. 
6.3. Experimental to Chapter 4 
6.3.1. Formation of Cu(lI) complexes 
1,4,7,10-Tetra(2-hydroxyethyl)-I,4,7,10-tetraazacyclododecane[Cu(IT)]Ch (192) 
192 was formed from 197 (100 mg, 0.29 mmol) and anhydrous CuCh (39 mg, 0.29 
mmol) in methanol (4 ml). The solution was warmed to -50°C for 10 minutes. The 
~ . . 
deep blue-colored solution was evaporated to give 192 as a blue powder (121 mg, 
87% yield). 
185 
1,4,7,10-Tetra(2-chloroethyl)-1 ,4,7,1 O-tetraazacyclododecane[Cu(II)]Clz (186) 
186 was formed from the hydrochloride salt of 38 (754 mg, 1.52 mmol) and 
anhydrous CuClz (205 mg, 1.52 mmol) in methanol/water (30 ml, 5:1). The solution 
was warmed to -50°C for 10 minutes. The deep blue-colored complex precipitated 
upon cooling the solution and was filtered and dried with suction to give 186 as a 
blue powder (716 mg, 75% yield). m/z (FAB+ mode, glycerol) 520.3 (12%),485.3 
([(M-2CI)+Ht, 100%) 483.3 (57), 421.3 (7), 419.3 (3), 185.1 (14), 147.1 (6), 93.5 
(79), 75.7 (37), 57.9 (27); Found [(M-2CI)+Ht 485.0650, C16H32Nl5Cll7CICu 
requires 485.0651. The material was crystallized as its tetrafluoroborate salt by 
adding excess ~BF4 to a hot, saturated solution of the chloride in water. The 
crystals were analysed by X-ray crystallography to confirm the structure (shown in 
Fig.4A). 
1,4,7,10-Tetra(2-chloroethyl)-1,4,7,10-tetraazacyclododecane[Co(II)]Clz (199) 
199 (synthesised by Stephen Lacy) was dissolved in MeCNIH20 (10 n;ll, 1:1). 
.. Excess ~PF6 was added and the solution left open to the air. Slow evaporation of 
the MeCN gave long needle-like purple crystals that were of sufficient quality for X-
ray analysis. The crystal structure is given in Fig. 4N. m/z (FAB+ mode, glycerol) 
516.3 ([(M-PF6)+Ht, 43%), 514.3 (29), 480.3 (4), 355.3 (4), 263.2 (6), 235.1 (5), 
171.1' (63), 157.1 (60), 79.6 (100). 46.1 (I). Found [(M-PF6)+Ht 516.0380. 
C16H32Nl5Cll7CICu requires 5.16.0373. 
186 
1,4,7, 10-Tetra(2-hydroxyethyl)-1,4,7, 10-tetraazacyclotridecane[ Cu(II)]Ch (193) 
193 was formed from 184 (45 mg, 0.12 mmol) and anhydrous CuCh (16 mg, 0.12 
mmol) in methanol (3 mI). The solution was warmed to -50°C for 10 minutes. The 
deep blue-violet-coloured solution was evaporated to give 187 as a foamy blue-
purple solid (61 mg, >99% yield). 
+ 
CI~()/'o....../CI 
C ''ci~c, " \.,J N N CI~'--1~CI 
CI 
187 
1,4,7,10-Tetra(2-chloroethyl)-1,4,7,10-tetraazacyclotridecane[Cu(II)]Ch (187) 
187 was formed from the hydrochloride salt of 18S (34 mg, 0.065 mmol) and 
anhydrous CuCh (9 mg, 0.065 mmol) in methan~Vwater (3 mI, 5:1). -The solution 
was warmed to -50°C for 10 minutes. The bright green-coloured complex 
precipitated upon coolil}g the solution and was filtered and dried with suction to give 
187 as a light green powder (8 mg, 22% yield). m/z (FAB+, glycerol) 499.3 ([(M-
2CI)+Ht, 95%) 437.3 (40), 373.3 (12), 294.3 (5), 247.1 (4), 202.2 (18), 175.1 (5), 
,- 120.2 (7), 110.3 (48), 70.8 (8), 43.2 (3); Found [(M-2CI)+Ht 499.0982, 
C17H36Nl5C4~u requires _ 499.0990. !he material was crystallized as its 
hexafluorophosphate salt by adding excess NRJ>F6 to a hot, saturated solution of the 
chloride in water. The resulting precipitate was redissolved by heating in the 
supe~atant and the solution was left to crystallise. Blue-green crystals of X-ray 
quality grew from the solution after 5 d. The crystals were analysed by X-ray 
crystallography to confirm the structure (shown in Fig. 4B). 
187 
1,4,8,11-Tetra(2-hydroxyethyl}-1 ,4,8, II-tetraazacyclotetradecane[Cu(II) ]Ch (188) 
188 was formed from 197 (50 mg, 0.13 mmol) and anhydrous CuCh (18 mg, 0.13 
mmol) in methanol (2 ml). The solution was warmed to -50°C for 10 minutes. The 
blue-coloured solution was evaporated to give 188 as a bright blue solid (68 mg, 
>99% yield). "'max = 636 nm (phosphate buffer pH 7.2) [lit. "'max = 630 nm 
(EtOH)].257] 
1,4,8,11-Tetra(2-chloroethyl)-1 ,4,8, II-tetraazacyclotetradecane[Cu(II)]Ch (190) 
40 required neutralization in order to effect complexation. A solution of 40 
(159 mg, 0.256 mmol) and CuCh (36 mg, 0.26 mij'lol) in H20 (5 ml) was neutralized 
with 1 M aq. NaOH (15 drops), causing a color change to deep blue-violet. The 
solvent was removed in vacuo to give 190 as a bright green solid, which was washed 
with H20 (10 ml) and filtered (23mg, 14% yield). MS: mlz (FAB+, glycerol) 513.3 
([(M-2Cl)+Ht, 11%),511.3 (6),451.4 (23),449.4 (20), 387.4 (9), 369.3 (6), 277.2 
.. (15), 185.1 (100), 106.3 (16), 75.7 (67), 57.9 (77). Found [(M-2CI)+Ht 513.0969. 
ClSH36Nl5Ch37CICu requires 513.0965. Attempts to crystallize 190, regardless of 
counter-ion, resulted in hydrolysis of the ligan~ to the Cu(II) complex of 188 
(indicated by crystal structure shown in Fig. 4C). Microanalysis results: 31.86% C, 
5.30% H, 8.29% N, 39.47% Cl. Ttieoretical: -C19H39N4CI6Cu(2HCI)(3H20) requires 
31.40% C, 6.52% H, 7.70% N, 39.03% Cl. 
188 
+ 
PFs -
1,4-Bis(2-chloroeth yl)-7 -(2-h ydrox yeth yl)-l ,4,7 -triazacyclononane[Cu(II) ]Ch (191) .. 
191 was formed from the hydrochloride salt of 174 (115 mg, 0.270 mmol), 
neutralised with 5 drops 1 M aq. NaOH and anhydrous CuCh (36 mg, 0.270 mmol) 
in methanol/water (8 ml, 5:1). The solvent was removed in vacuo to give a green 
glassy solid which was taken up in H20 (5 ml). Excess Nl4PF6 was added and the 
solvent evaporated until dark blue-green crystals formed, which were suitable for x-
ray crystallography (15 mg, 10% yield). The crystal structure is given in Fig. 4D. 
rp/z (FAB+, glycerol) 362.3 ([(M-CIPF6)+Ht, 64%), 326.3 (6), 277.4 (13), 262.3 
(4), 185.2 (100), 93.5 (74), 75.7 (14), 58.0 (4), 46.1 (3). Found [(M-CIPF6)+Ht 
362.0648, C12H2SN303SCt37CICu requires 362.0647. 
1,4,8,11-Tetraacetyl-1 ,4,8, 11-tetraazacyclotetradecane (203) 
1,4,8,11-Tetraazacyclotetradecane (0.100 g, 0.499 mmol) was dissolved in 
dry MeCN (10 ml) with potassium carbonate (0.69 g, 4.99 mmol) and cooled to 0 °c 
with an ice batl.1. Acetyl ch!oride (0.31 g, 3.99 mmol) was added dropwise and the 
mixture was allowed to come to room temperature and stirred overnight. The solid 
was filtered off and the filtrate evaporated to give a clear oil which was washed with 
hot EtOAc to give 203 as a white solid (0.150 g, 82% yield); OH (CDCh) 1.91-2.01 
(4H, m), 2.12 (6H, s), 2.18 (6H, s), 3.41-3.63 (16H, m); Oc (CDCh) 21.6 and 22.0 
(CH3), 29.0,45.8,47.6,48.7,49.1 (CH2), 171.6 and 172.2 (CO). 
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1,4,S,12-Tetraethyl-l,4,S,12-tetraazacyclotetradecane[Cu(ll)]Ch (204) 
203 (0.156 g, 0.423 mmol) was dissolved in dry THF (20 ml) and treated 
with 1.0 M BH3'THF solution in THF (6.S ml). The solution was refluxed for 2h 
then cooled and carefully quenched with methanol (30 ml) 6 M aq. HCI (15 ml). 
The solution was concentrated to - 10 ml via rotary evaporation, basified to pH 14 
with NaOH pellets and extracted with DCM (10 x 30 ml). The combined organic 
layers were dried with Na2S04, filtered and evaporated to give a clear oil (0.047g, 
36% yield), which was taken up in MeOH (10 ml). CuCh was added (0.020 g, 0.15 
mmol) and the resulting blue-violet solution evaporated to give 204 as a purple solid. 
( 
6.3.2. X-ray crystallography 
Details of data collection procedures and structure refinement are given in 
Table 6.4.1. CIF data can be accessed online at 
http://www.chem.gla.ac.ukl-louis/datal (186: UFOS9; 188: UF096; 191: UFl00; 199: 
UF101; 187: UF102). Single crystals of suitabl~ size were attached t? glass fibres 
using acrylic resin and mounted on a goniometer head in a general position. Data were 
collected on an Enraf-Nonius KappaCCD diffractometer, running under Nonius Collect 
software and using graphite monoChromated X-radiation (.1..=0.71073 A). All data sets 
were collected at a temperature of 150K using an Oxford Instruments Cryostream. 
Typically scan angles of 1_20 were used, with integration times of 50-100 s pe~ image. 
Precise unit cell dimensions were determined by post-refinement of the setting angles 
of a large proportion of the data set. The ~e images were integrated using 
Denzo(SMN)258 and the resultant raw intensity files processed using a locally modified 
versic;m of DENZOX.259 Absorption corrections, either by gaussian quadrature,260 
based on the measured crystal faces, or by a semi-empirical correction261 were applied 
to all data sets. Data were then sorted and merged using SORTAV.262 Structures were 
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solved either by Patterson interpretation (DIRDIF_99)263 or by direct methods 
(SIR92).264 All structures except 191 showed disorder in the macrocyclic ring system, 
with the major component having - 80-90% occupancy and all structures showed some 
disorder in their respective cr, BF£ or PF6- anions. For the major componenent only, 
all non-H atoms were allowed anisotropic thennal motion. Aliphatic C-H hydrogen 
atoms were included at calculated positions, with C-H = 0.96 A and were refined with 
a riding model and with Uiso set to 1.2 times that of the attached C-atom. Refinement 
with SHELXL97_2265 using full-matrix least-squares on r and all the unique data. 
Neutral atom scattering factors, coefficients of anomalous dispersion and absorption 
coefficients were obtained from published work.266 The absolute configuration for 
structure 199 was confinned by the refinement of the Flack absolute structure 
parameter, which refined to zero within error. Calculations using PLATON267 indicated 
that there were no voids in the lattice capable of containing solvent molecules. Thennal 
ellipsoid plots were obtained using the program ORTEP-3 for Windows.268 All 
calculations were carried out using the WinGX package269 of crystallographic 
f 
programs. 
6.3.3. UV-Vls spectroscopy 
6.3.3.1. Characterisation: "-max and £coeff 
The "'max and Ecoeff were evaluated by measuring the absorbance of various 
" .. 
concentrations of the complex in aqueous solution in a quartz cuvette (3 ml) with a 1 
cm path length (1). The extinction coefficient was determined from Beers' Law (A = 
Ecl). Absorbances (A) vs. concentrations (c) for various dilutions were plotted, 
giving slope = Ecoeff. The "-max was taken as the average of the wavelengths at which 
the absorbance was greatest for each concentration. 
6.3.3.2. Aqueous stabl~ity of complexes 
A solution of the complex (1.0 mM) in 100 mM aqueous phosphate buffer, 
pH 7.2, was allowed to stand for the required period of time. The "'max of the 
solution was monitored by UV-Vis spectroscopy, watching for a shift towards the 
"'max known for the 2-hydroxyethyl complex. The time required for a "-max shift of 
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half the difference between those for the two complexes was defined as tll2(8). 
Solutions were monitored for a maximum of two weeks. 
6.3.4. Cyclic voltammetry 
The redox potential of each compound was measured with cyclic voltammetry using 
a PGZ301 Dynamic-EIS VoltaLab potentiostat. The analysis was performed on 
freshly prepared solutions of the complexes (1.0 mM) in aqueous phosphate buffer 
(100 mM) at pH 7.2, with ferrocenecarboxylic acid (PCA) as an internal standard 
(+533 mV vs. NHE, or +334 mV vs. sat. AglAgCI),217 using a three-electrode cell 
with a Pt macrodisc working electrode (2.0 mm), Pt wire counter electrode and either 
the AglAgN03 electrode [EO(vs. AglAgN03) = EO + 253 mV (vs. AglAgCl)], or the 
saturated AgI AgCI reference electrode. The potentials were corrected for the 
published potential of FCA and reported vs. NHE (correction factor: EO [vs. NHE] = 
EO [vs. AglAgCI] + 199 mY). The solutions were degassed with N2 for at least ten 
( 
minutes before analysis, to simulate the hypoxic environment. 
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Table 6.4.1. Experimental crystallography details 
Compound number 186 188 191 
Compound formula C16H32BCI5CuF 4N4 C1sH40C12CuN404 C12H25CIsCuF6NsOP 
Compound color blue' blue blue 
M, 608.06 510.98 542.21 
Space group P2.1/C P2.1/n P2.1/C 
Crystal system Monoclinic Monoclinic Monoclinic 
alA 15.0036(2) 15.4336(4) 8.0906(2) 
blA 8.3325(1) 9.3240(3) 18.3838(4) 
dA 20.3516(3) 15.7847(5) 13.7631(3) 
f3/deg 104.162(1) 103.472(1) 93.519(1) 
VlA's 2466.98(6) 2208.96(12) 2043.21(8) 
Z 4 4 4 
Des/dg cmoS 1.637 1.536 1.763 
F(OOO) 1244 1084 1100 
J.L(Mo-Ka)fmm,l 1.470 1.263 1.601 
Crystal size/mm 0.30x 0.12xO.09 0.25x 0.15xO.15 0.44x 0.38xO.30 
Transmission coefficients 0.882 - 0.672 0.709 - 0.645 0.644 - 0.490 
(range) 
e range/deg 2.06 - 27.52 1.26 - 27.55 1.85 - 30.01 
No. of data measured 41179 25122 31765 
No. of unique data 5651 5024 5945 
Rlnt 0.0517 0.0498 0.0350 
No. of data in refinement 5651 5024 5945 
No. of refined parameters 364 362 270 
Final R [I > 20'1+] (all data) 0.0296 0.0478 0.0322 
R/ [/ > 20'1'1 (all data) 0.0435 0.0702 0.0389 
Flack parameter nfa nfa n/a 
Goodness of fit s 1.039 ".082 1.034 
Largest residuals / eA's 0.418, -0.341 0.497, -0.643, 0.723, -0.518 
Max shift/esd in last clcle 0.001 0.566 0.009 
cont. next page 
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Compound number 199 187 
Compound formula C1sH32ClsCoFsN4P C17H34ClsCuFsN4P 
Compound color purple blue 
M, 661.61 680.24 
Space group P.212121 P.21/C 
Crystal system Orthorhombic Monoclinic 
alA 8.8203(1) 12.1978(3) 
blA 14.1553(2) 17.1387(5) 
dA 21.0638(4) 13.3259(3) 
~/deg 90 107.033(2) 
V/A"3 2629.90(7) 2663.64(12) 
Z 4 4 
DcaJclgcm-3 1.671 1.696 
F(OOO) 1348 1388 
/J.(Mo-Ka)/mm-1 1.278 1.439 
Crystal size/mm 0.47x 0.13xO.11 0.50x 0.30xO.15 
Transmission coefficients (range) 0.894 - 0.745 0.802 - 0.618 
( 
a range/deg 2.41 - 27.51 1.75 - 30.08 
No. of data measured 19793 46816 
No. of unique data 5999 7760 
Rint 0.0382 0.0403 
No. of data in refinement 5999 7760 
No. of refined parameters 362 463 
Final R [/ > 2(J1~ (all data) 0.0279 0.0553 
R/ [I > 2(J1~ (all data) 0.0347' 0.0720 
Flack parameter 0.002(10) n/a 
Goodness of fit S 1.026 1.004 
Largest residuals / eA"3 0.243, -0.272 1.658, ·1.025 
Max shifVesd in last cycle 0.001 0.056 
R = 1: ( I Fo I • I Fe I )II: (Fo); Rw = (I:(w(Fo • Fe)2) /I:(W(Fo)2\} 112; Rw 2 = {I:(w(Fo 2 • Fe 2)2) 
/I:(W(Fo2)2)}112; Ra = 1: [a(F02)] I 1: [F!]; RJnt = 1: {n/(n.1}1~ I Fo2. Fo2(mean) 111: Fo2 
(summation Is carried out only where more than one symmetry equivalent is 
averaged) 
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6.3.5. Complexation of novel triazamacrocycles 
The triazamacrocycle was dissolved in D20 in an NMR tube. A solution of 
ZnBr2 in D20 (100 mM) was added in four portions stepwise, providing 0.25 eq., 
0.50 eq., 0.75 eq. and 1.0 eq. ZnBr2 respectively. After the addition of each portion, 
the tube was shaken vigorously and analysed by IH NMR spectroscopy. After a total 
of 1.0 eq. ZnBr2 had been added, the resulting complex was analysed by 2-
dimensional NMR correlation spectra (COSY, HMQC and HMBC) to determine the 
extent of complexation and the structure of the ligand complex. 
1 (12 +2 
GNH,N~H 3 Zn2+ NH 4 
6 5 
206 
1,5,10-Triazacyclotetradecane[Zn(lnlBr2 (206) 
128 (0.013 g, 0.0163 mmol) was dissolved in D20 (0.50 ml) and titrated as described 
above. The structure was analysed in situ and the complexed product was not 
isolated. See Appendix 2 for spectra. . 
Characterisation of 206 
assign. 'M shift (ppm) 13C shift (ppm) (Integ., multip.) 
1 1.78-1.86 (2H, m) 24.3 
2 2.96-3.02 (4H, m) 47.7 
3 2.86-2.92 (4H, m) 42.5 
4 1.66-1.75 (8H, m) 19.9 
5 22.8 
6 3.05-3.12 (4H, m) 45.9 
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1 12n2 
11 3 
10cN'fr;~\4 
9 NHJS 
8 7 6 
207 
1,5,10-Triazacyclopentadecane[Zn(II) ]Br2 (207) 
+2 
129 (0.013 g, 0.0163 mmol) was dissolved in D20 (0.50 ml) and titrated as described 
above. The structure was analysed in situ and the complexed product was not 
isolated. See Appendix 2 for spectra. 
Characterisation of 207 
assign. 'H shift (ppm) 13C shift (ppm) (Integ., multlp.) 
1 1.40-1.49 (2H, m) 22.9 
2 1.58-1.74 (8H, m) 24.1 
3 2.98-3.08 (6H, m) 45.9 
4 2.67-2.74 (2H, m) 47.7 
5 See 2 25.4 
6 See 2 25.5 
7 2.90-2.95 (2H, m) 46.6 
8 See 3 48.7 
9 1.74-1.80 (2H, m) 23.3 
~, 
10 2.85-2.90 (2H, m) 48.4 
11 See 3 43.3 
12 3.05-3.12 (4H, m) See 2 
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6.4. Experimental to Chapter 5 
6.4.1. Anti-cancer testing 
6.4.1.1. Cytotoxicity of free mustard ligands (Prof. Hartley) 
The cytotoxic effects of the free ligands studied were measured against the human 
chronic myeloid leukaemia cellIine K562. Cells were maintained as a suspension in 
RPMI 1640 medium supplemented with 10% fretal calf serum (PCS) and 2 mM 
glutamine (GIn) at 37°C in a humidified atmosphere containing 5% C02/ 95% air. 
The ICso values of the series of analogues following a 1 hour exposure to drug were 
deterrrlined using the MTT assay 270 as has been previously described.271 This is 
based on the ability of viable tumor cells to convert a yellow tetrazoli~m salt (3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyl-2H-tetrazolium bromide, MTT) into mauve 
formazan crystals. 
6.4.1.2. Cytotoxicity and hypoxia-selectivity of complexes (Prof. 
Stratford) 
The toxicities of the complexes were determined using the MTT proliferation 
assay.272 . All media, plates and other plastic material were placed into the anoxic 
incubator for at least 24 h prior to the hypoxic experiments. The lung-derived tumor 
cell line, A549, was exposed to each of the three drugs for 24 h under aerobic or 
hypoxic conditions. After 24 h ~xposure, the drug was removed and fresh media 
instilled into each well. After 96 h incubation at 37°C, the MTT proliferation assay 
was performed. The ICso results were expressed as the mean of at le~t three 
.. different experiments (± SEM). HCR is the hypoxic cytotoxicity ratio [ICso (air) / 
ICso (N2)] and ACR is the aerobic cytotoxicity ratio [ICso (N2) / ICso (air)]. 
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6.4.2. Anti-parasitic testing 
6.4.2.1. Cytotoxicity against Leishmania mexicana (Dr. Barrett) 
Serial dilutions of the drugs (starting at 200 ,."glrnL) in a 96-well plate were 
incubated at 37°C with a culture of L. mexicana in the logarithmic phase for 5 d. 
The ICso values were determined using the acid phosphatase assay, which assesses 
the level of active (live) phosphatase enzyme present in the culture. p-
Nitrophenylphosphate (40 mglrnL), NaOAc (1.0 M, pH 5.5) and Triton X-IOO (1%) 
were added to the plates and the culture incubated at 37°C for 1 h. The level of 
phosphatase activity was determined using UV -Vis spectroscopy (to detect p-
nitrophenolate ion at 405 nm). 
6.4.2.2. Cytotoxicity against Trypanosoma brucei (Dr. Barrett) 
Serial dilutions of the drugs (starting at 200 p,glrnL) in a 96-well plate were 
incubated at 37°C with a culture of T. brucei for 36 h. All experiments were 
performed in duplicate. The cytotoxicities were determined using the alamar blue 
assay,221 which measures the ability of viable parasite cells to convert a blue dye to a 
colorless compound. The cultures wer~ incubated at 37°C with the dye for a further 
24h. ICso values were determined from UV-Vis spectroscopy, detecting dead cells 
by the concentration of alamar blue dye left in so~ption. 
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Appendix 1 
Cyclic voltammagrams for all complexes 
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c. Cyclam[Cu(II)]CI2 (202) in phosphate buffer 
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e. 1,4,7, 10-Tetra(2-hydroxyethyl)cyclen[Cu(II)]CI2 (192) in phosphate buffer 
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g. 1,4,8,11-Tetra(2-hydroxyethyl)cyclam[Cu(II)]Cb (188) in phosphate buffer 
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h. 1,4,8,11-Tetra-N-ethyl Cyclam[Cu(II)]CI2 (204) in phosphate buffer 
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Appendix 2 
Two-dimensional NMR sp,ectra of Zn(lI) titrations 
1. 206: COSY, HMQC and HMBC 
A. COSY spectrum for 206 (refer to section 6.2.6 for assignments) 
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